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Outline 
Chromosome translocations are cytogenetically visible genetic abnormalities that are 
often associated with specific tumors. Characterization of the genes at the chromosome 
breakpoints can give insights into the processes that transform normal cells to tumor 
cells. The (6;9) translocation, associated with acute myeloid leukemia and 
myelodysplastic syndrome, fuses the DEK gene to CAN and results in the expression 
of a chimeric DEK-CAN gene. In a second chromosome rearrangement, found in one 
patient with acute undifferentiated leukemia, CAN is fused to SET. Knowledge of the 
normal functions of the proteins encoded by the fusion partners is indispensable in 
understanding the mechanisms by which DEK-CAN and SET-CAN contribute to 
leukemogenesis. The aim of the research described here is to define the functions of 
CAN, which was identified as a nuclear pore complex component (nucleoporin), and of 
the CAN-derived fusion proteins. 
This thesis starts out with an introduction about chromosome aberrations in 
hematopoietic malignancies, that result in the generation of fusion genes. The DEK, 
SET, and CAN proteins are introduced, and a number of molecular mechanisms in 
oncogenic transformation by fusion proteins are highlighted with examples (Chapter 1). 
The chapters that follow describe our experimental work concerning the functions of 
CAN and DEK-CAN. First, we studied the consequences of loss of CAN function after 
disruption of the mouse CAN gene by homologous recombination (Chapter 2). Second, 
the effects of CAN and DEK-CAN expression on the growth, differentiation and survival 
of myeloid precursor cells were investigated (Chapter 3). Third, we studied the 
localization of the CAN protein within the nuclear pore complex using immunoelectron 
microscopy (Chapter 4). An additional approach to unravel the function of CAN was to 
identify CAN-interacting proteins by coimmunoprecipitation (Chapter 5). Lastly, sensitive 
molecular detection of the (6;9) translocation was applied towards the diagnosis and 
follow-up of an acute myeloid leukemia patient (Chapter 6). CAN emerges from these 
studies as an essential factor involved in both nuclear protein import and mRNA export 
through the nuclear pore. These findings have implications for the possible molecular 
mechanism of leukemogenic transformation by the CAN-derived fusion proteins 
(Chapter 7). 
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1 Introduction 
Cancer is the result of the accumulation of multiple genetic changes. Some of these 
alterations, that can either be initiating or progression-associated events, involve gross 
chromosomal abnormalities, that can be either structural or numerical. Structural 
alterations include translocations, inversions, deletions, insertions, and amplifications, 
whereas numerical abnormalities result in losses or duplications of whole 
chromosomes. Genes implicated in cancer can be subdivided into two classes, the 
proto-oncogenes and the tumor suppressor genes. Proto-oncogenes are activated by 
dominant gain of function mutations, whereas tumor suppressor genes contribute to 
oncogenicity through loss of function. 
For proper growth and differentiation cells depend on regulatory signals from 
their environment. The cell membrane contains receptors that enable cells to respond 
to specific soluble factors or extracellular matrix proteins. Upon ligand binding, 
intracellular second messenger molecules are activated, often resulting in the 
phosphorylation of target proteins. Some ligands, such as steroid hormones, do not 
need a membrane receptor but pass the lipid bilayer directly and bind to intracellular 
receptors. Molecules transmitting the signal to the nucleus, enter via an active import 
mechanism through the nuclear pore complex. Inside the nucleus, these signals 
eventually lead to activation of transcription factors that bind to specific DNA 
sequences. These transcription factors affect the expression of responder genes that 
are crucial for the regulation of cell proliferation or differentiation. Changes in any of the 
genes encoding the proteins taking part in these cascades can deregulate proper 
growth and differentiation and contribute to the transformation of a normal cell to a 
cancer cell. 
2 Chromosome aberrations in hematopoietic malignancies 
The production of blood cells is normally regulated by a homeostatic mechanism. Acute 
leukemia is the uncontrolled proliferation or expansion of hematopoietic cells that do not 
retain the capacity to differentiate normally to mature blood cells. Some chronic 
hematologic disorders display only part of the full leukemic phenotype - either growth 
expansion (myeloproliferative syndromes) or a differentiation block (myelodysplasia) -
yet both conditions can progress to acute leukemia. These observations suggest that 
full leukemic transformation requires multiple genetic changes, resulting in defects in 
both growth and differentiation (Sawyers et aI., 1991). 
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A characteristic of many leukemias is the presence of recurring and highly 
consistent chromosome rearrangements, such as trans locations and inversions, that 
usually generate chimeric genes which are considered to be involved in tumorigenesis. 
Sometimes the chromosome breakpoints occur in the regulatory sequences of two 
genes. This can lead to activation of a proto-oncogene when it comes to lie near a 
promoter or enhancer of another gene, such as those of the T-cell receptor or 
immunoglobulin genes. Aberrant expression of the translocated proto-oncogene is often 
associated with lymphomas or lymphocytic leukemia of T- or B-cells. Mostly however, 
the chromosome breaks are such that a gene fusion is created that encodes a chimeric 
protein with protein segments of both genes at the translocation breakpoints. Fusion 
genes encoding tumor-specific proteins are associated with different types of leukemias 
and lymphomas, as well as with solid tumors (Rabbitts, 1994). 
3 Oncogenic fusion proteins 
Chimeric genes encoding fusion proteins are generated when breakpoints of 
chromosomal trans locations or inversions are located in introns flanking codogenic 
exons of two fusion partners. The breaks generally occur within specific introns to 
combine functionally essential parts of the involved genes while maintaining the reading 
frame of the two juxtaposed coding regions. Reciprocal translocations potentially give 
rise to two reciprocal gene fusions encoded by the two derivative chromosomes 
involved in the translocation event. In most cases however, only one of the fusion genes 
encodes a chimeric protein that is responsible for the oncogenic transformation. 
Chimeric proteins often deregulate cell growth or differentiation due to the combination 
of functional domains from both partners. In addition, one of the fusion partners may 
normally be silent in the hematopoietic lineage, or may only be expressed at a specific 
maturation stage, while the promoter driving the fusion gene is more ubiquitously active, 
resulting in deregulation of the fusion gene. 
Most recurrent translocations are associated with specific leukemia subtypes 
suggesting that at least one of the affected genes normally plays a role in blood cell 
development. Functional dissection of the proto-oncogene products therefore may give 
insights into the regulation of proliferation and differentiation in the hematopoietic 
system. The in vivo oncogenicity of leukemia-specific fusion proteins is apparently 
restricted to hematopoietic cells, since expression of fusion proteins under control of 
ubiquitous promoters in mice generally leads to the development of hematopoietic 
malignancies only. Also, the malignant phenotype in these mice takes several weeks 
to months to occur, indicating that tumor formation requires additional mutations to 
complement the transgene. 
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4 The DEK-CAN and SET-CAN fusion genes in acute leukemia 
The CAN gene, located on chromosome 9q34, is involved in at least two 
chromosomal rearrangements associated with acute leukemia. First, the recurrent t(6;9) 
is found with low frequency in acute myeloid leukemia (AML) and myelodysplastic 
syndrome (Rowley and Potter, 1976; Soekarman et aI., 1992). The translocation fuses 
the DEK gene, on chromosome 6p23, to CAN and results in expression of a chimeric 
DEK-CAN mRNA from the 6p- derivative (Von Lindern et aI., 1992a). DEK is a nuclear 
sequence-specific DNA-binding protein that recognizes the pets site, a DNA element 
in the human immunodeficiency virus type 2 (HIV-2) enhancer involved in upregulation 
of this promoter in response to T-cell or monocyte mitogenic stimulation. Divergent 
pets-like sites are also present in the promoters for myeloperoxidase and neutrophil 
elastase, potentially linking DEK to gene expression in immature neutrophils (Fu et aI., 
1997). Except for an N-terminal acidic region, DEK does not contain any known protein 
motifs (Figure 1). CAN is a nuclear pore complex (NPC) component, or nucleoporin, 
that contains multiple phenylalanine-glycine (FG) motifs characteristic for a group of 
NPC proteins (Fornerod et aI., 1995). CAN is also called NUP214, for nucleoporin of 
214 kDa (Kraemer et aI., 1994).The central region of CAN contains several a-helical 
protein interaction domains. Most of CAN's FG repeats and one amphipathic helix are 
retained in the DEK-CAN fusion protein, which contains almost the entire DEK protein 
and the C-terminal two-thirds of CAN (Figure 1). DEK-CAN is located in the nucleus, 
resulting in the relocation of the C-terminal, FG repeat-rich region of CAN from the 
nuclear envelope to the nucleus (Fornerod et aI., 1995). 
DEK 
DEK-CAN 
CAN 
SET-CAN 
SET 
Figure 1. Structural features of CAN-derived fusion proteins 
Fusion proteins created by 1(6;9) and ?(9;9) contain the nucleoporin-specific FG repeat-rich C-terminus 
of CAN fused to DEK or SET. The fusion proteins and their normal counterparts are aligned on their 
fusion and break pOints (vertical line). Diamonds, FXF repeats; Vertical bars, FG repeats; LZ, coiled-coil 
and leucine zipper; AH, amphipathic helix; Horizontal bars, acidic regions. 
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A second chromosome rearrangement found in one patient with acute 
undifferentiated leukemia (AUL) fuses the same part of CAN to SET, located on 
chromosome 9q34 at the centromeric side of CAN and c-ABL (Von Lindern et aI., 
1992b). SET is a nuclear protein whose only common feature with DEK is an acidic 
region, that is also retained in the SET-CAN fusion protein (Figure 1). Like DEK-CAN, 
SET-CAN is a nuclear protein (Fornerod et aI., 1995). SET, which has sequence 
similarity to nucleosome assembly protein 1 (NAP-i), was identified as a template 
activating factor (TAF-I) that is required for adenovirus DNA replication (Kellogg et aI., 
1995; Nagata et aI., 1995). Therefore, SET may interact with core proteins complexed 
to the adenovirus genome and facilitate their dissociation from DNA, thereby rendering 
the DNA accessible for binding of replication proteins (Nagata et aI., 1995). 
Furthermore, SET interacts specifically with B type cyclins (Kellogg et aI., 1995) and 
inhibits the protein serine/threonine phosphatase PP2A (Li et aI., 1996). PPA2 is 
involved in diverse cellular processes, such as cell cycle transition and DNA replication 
(Cohen, 1989; Mumby and Walter, 1993; Shenolikar and Nairn, 1991). Recently, SET 
was found to bind to MLL, a protein that is involved in many chromosome translocations 
associated with both myeloid and lymphoid acute leukemias (Adler and Tkachuk, 1996). 
MLL binds DNA in a non-sequence-specific manner and is thought to function as an 
architectural factor in transcription factor-DNA complexes (Tkach uk et aI., 1992). 
It is not clear by which mechanisms DEK-CAN and SET-CAN transform 
hematopoietic cells. Since DEK, SET and CAN are normally expressed in many cell 
types, including those of the hematopoietic system, ectopic expression of the fusion 
genes is probably not the main cause of transformation. More likely, the combination 
of functional domains of CAN with domains of SET or DEK leads to deregulation of the 
normal functions of one or both of the fusion partners. The studies described in 
Chapters 2 to 6 of this thesis aim at understanding the biological functions of CAN and 
the role of the CAN-derived fusion proteins in leukemogenic transformation. 
For a better understanding of the mechanism by which DEK-CAN and SET-CAN 
contribute to leukemogenesis, it is useful to review other fusion proteins involved in 
human leukemias for which the affected genes have been cloned and characterized in 
some detail. Given what we and others found out about the structure and function of 
DEK, SET, and CAN, the fusion proteins could interfere with several basic cellular 
processes. The identification of DEK as a sequence-specific DNA-binding protein 
suggests that DEK-CAN could function as an altered transcription factor. Therefore, 
some prominent examples of fusion proteins that deregulate transcription will be 
discussed in section 5.1. SET also seems to be involved in transcription, or in 
replication, but the available data suggest that SET plays an indirect role by affecting 
chromatin structure. Thus, SET could belong to the super family of architectural factors, 
some of which have been implicated in tumorigenic fusion proteins (section 5.2). From 
the perspective of CAN, the involvement of an NPC component in an oncogenic fusion 
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Table 1. Gene fusions encoding chimeric oncoproteins 
Translocation Malignancy Affected gene Protein domain 
Transcription factors 
I( 1; 19)(q23;p13.3) pre-B acute lymphoblastic E2A (19p13) transactivalion 
leukemia PBX-1 (1q23) homeodomain 
1(17;19)(q22;p13) pro-B acute lymphoblastic E2A (19p13) transactivation 
leukemia HLF (17q22) bZIP 
1(15;17)(q21 ;q11-22) acute promyelocytic leukemia PML (15q21) CH-rich, coiled-coil 
RARa(17q21) DNA & RA binding 
1(11;17)(q23;q21.1) acute promyelocytic leukemia PLZF (11q23) POZ, zinc finger 
RARa(17q21) DNA & RA binding 
1(5;17)(q32;q21) acute promyelocylic leukemia NPM(5q32) oligomerization 
RARa(17q21) DNA & RA binding 
1(8;21 )(q22;q22) acute myeloid leukemia AMLt (21q22) runt homology 
ETO (8q22) zinc fingers 
1(3;21)(q26;q22) chronic myeloid leukemia, acute AMLt (21q22) runt homology 
myeloid leukemia, myelodysplasia EVil (3q26) zinc fingers 
1(3;21 )(q26;q22) myelodysplasia AML 1 (21q22) runt homology 
EAP (3q26) unknown 
1(3;21)(q26;q22) acute myeloid leukemia AMLt (21q22) runt homology 
MOSI (3q26) unknown 
1(12;21)(p13;q22) pre-B acute lymphoblastic TEL (12p13) helix-loop-helix 
leukemia AMLt (21q22) runt homology 
inv(16)(p13;q22) acute myeloid leukemia CBF{J(16q22) AML1-binding 
MYH11 (16p13) coiled-coil 
Architectural factors 
1(12;15)(q15;q24) lipoma HMGI-C (12q15) AT hooks 
novel gene (15q24) ST-rich 
1(3;12)(q29;q15) lipoma HMGI-C (12q15) AT hooks 
novel gene (3q29) LIM domains 
1(4;11)(q21 ;q23) acute lymphoblastic leukemia MLL (11q23) AT hooks, MT 
AF-4 (4q21) SP-rich 
1(9;11 )(p22;q23) acute myeloid leukemia MLL (11q23) AT hooks, MT 
AF-9 (9p22) SP-rich 
t(11;19)(q23;p13) acute myeloid leukemia and MLL (11q23) AT hooks, MT 
acute lymphoblastic leukemia ENL (19p13) SP-rich 
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Table 1. Continued 
Tyrosine kinases 
1(9;22)(q34;q11 ) chronic myeloid leukemia and BCR (22q11) ST kin, multimers 
acute leukemia c-ABL (9q34) tyrosine kinase 
1(5;12)(q33;p13) chronic myelomonocytic leukemia TEL (12p13) helix-loop-helix 
PFGFRP(5q33) tyrosine kinase 
1(9;12)(q34;p13) acute undifferentiated leukemia TEL (12p13) helixwloopwhelix 
and acute myeloid leukemia ABL (9q34) tyrosine kinase 
1(1 ;7) gastric carcinomas TPR (1) coiled-coil 
MET (7) tyrosine kinase 
7(1;1) papillary thyroid carcinomas TPR (1) coiled-coil 
TRK (1q) tyrosine kinase 
Nucleoporins 
1(6;9)(p23;q34) acute myeloid leukemia and DEK(6p23) unknown 
myelodysplasia CAN (9q34) nup repeats 
7(9;9)(q34;q34) acute undifferentiated leukemia SET (9q34) unknown 
CAN (9q34) nup repeats 
1(7;11)(p15;p15) acute myeloid leukemia NUP98 (11p15) nup repeats 
HOXA9 (7p15) homeodomain 
The protein domains indicated are those likely to be important in tumor pathogenesis. Abbreviations used: 
bZIP, basic region leucine zipper; CH, cysteine/histidine; RA, retinoic acid; POZ, protein-protein interaction 
domain; AT, adenine, thymine; ST, serine/threonine; LIM, cysteine-rich motif; MT, DNA-methyltransferase; 
SP, serine/proline; ST kin, serinelthreonine protein kinase; nup, nucleoporin. 
protein is intriguing. Thusfar, two other nucleoporins have been found as part of fusion 
proteins. First, TPR, which does not contain nucleoporin-specific repeat motifs, is fused 
to several partners with protein kinase activity. These and other examples of chimeric 
genes encoding activated tyrosine kinases will be reviewed in section 5.3. Second, the 
FG repeat-containing nuclear pore complex component NUP98 is fused to HOXA9 in 
AML. This fusion protein, and a brief overview of nucleocy1oplasmic transport, will be 
described in section 5.4. Table 1 summarizes the discussed chromosome aberrations 
and the resulting fusion proteins. 
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5 Molecular themes in transformation by fusion proteins 
5.1 Fused transcription factors 
Transcription factors contain a DNA-binding motif that recognizes specific DNA 
sequences present in the regulatory regions of target genes. With their transactivation 
domains. transcription factors positively or negatively regulate RNA polymerase " 
activity by direct or indirect interaction with the basal transcription initiation complex. In 
order to allow either DNA binding or transcriptional activation. transcription factors often 
need to form homo- or heteromeric complexes. This process is mediated by protein 
interaction modules present in many transcription factors. Chromosome translocations 
often alter the structure of transcription factors, which leads to their activation. Why 
should transcription factors play such a central role in leukemogenesis? The neoplastic 
behavior of a malignant cell reflects altered patterns of transcription factor activity. One 
can speculate that mutations affecting cytoplasmic and cell surface membrane 
components of signal transduction pathways may be subject to a series of physiological 
checks and balances which tend to limit signal alterations of nuclear transcription factor 
activity. By contrast, mutations which directly affect transcription factor activity may be 
less easily regulated and hence more potently oncogenic (Green, 1992). 
E2A fusions 
In pediatric acute lymphoblastic leukemia (ALL) the translocation site is frequently 
located within the E2A gene on chromosome 19, which encodes the basic helix-Ioop-
helix (HLH) DNA-binding immunoglobulin enhancer binding proteins E12 and E47 
(Henthorn et aI., 1990; Murre et aI., 1989; Nelson et aI., 1990). In two translocations 
involving E2A, t(17;19) and t(1;19), the N-terminal portion of E2A, which contains two 
transactivation motifs, is linked to a heterologous DNA-binding domain and a 
dimerization domain. In addition to the unique structure of these chimeric transcription 
factors, the E2A promoter directs expression of the fusion partners, that are not 
normally expressed in lymphoid cells. 
In the t(1 ;19) translocation, found in a subset of childhood pre-B-cell acute 
leukemia, the 3' end of the chimeric gene contains the homeodomain and flanking 
sequences derived from PBX1 (Kamps et aI., 1991; Kamps et aI., 1990; Nourse et aI., 
1990). Homeodomain proteins, such as PBX1, are sequence-specific transcription 
factors that regulate normal differentiation and development (McGinnis et aI., 1984). By 
itself, PBX1 is incapable of transforming NIH 3T3 cells and it requires fusion with E2A 
to activate its oncogenic potential (Kamps et aI., 1991). Similarly, in reporter systems 
using the PBX 1 consensus sequence in lymphoid cells, the fusion protein strongly 
activates transcription whereas PBX1 does not (Van Dijk et aI., 1993). Surprisingly, the 
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PBX1 homeodomain was found to be dispensable for transformation (Monica et aI., 
1994). A stretch of conserved amino acids located C-terminal of the PBX1 
homeodomain is involved in cooperative DNA binding wilh a subset of HOX proteins 
(Chang et aI., 1995) and is required for transformation (Monica et aI., 1994). This region 
could contribute to oncogenesis by heterodimerization with HOX proteins which direct 
E2A-PBX1 to regulatory sequences of appropriate target genes. Alternatively, this 
region of E2A-PBX1 could mediate the formation of non-DNA-binding complexes that 
sequester tumor-suppressing factors. 
Introduction of the E2A-PBX1 gene in mice induces acute hematopoietic 
malignancies, albeit of cell types that differ from those affected in the human disease. 
Transgenic mice expressing E2A-PBX1 under control of the immunoglobulin heavy 
chain enhancer demonstrate profound disturbances in T and B cell development, 
including increased proliferation and apoptosis, and the animals die before five months 
of age with T-cell lymphomas (Dedera et aI., 1993). On the other hand, mice 
reconstituted with bone marrow cells infected with a retrovirus carrying a cDNA 
encoding E2A-PBX1 develop AML after three to eight months (Kamps and Baltimore, 
1993). Murine myeloid progenitor cells that are infected in vitro with the E2A-PBX 1 
retrovirusses are strongly retarded in their differentiation wilhout loosing their growth-
factor dependence (Kamps and Wright, 1994). These data suggest that a principal role 
for E2A-PBX 1 in leukemia is to block hematopoietic differentiation. 
In pro-B-cell ALL involving the t(17;19} translocation, the transactivation domain 
of E2A is linked to the basic leucine zipper (bliP) DNA-binding and dimerization 
domains of hepatic leukemia factor (HLF) (Hunger et aI., 1992; Inaba et aI., 1992). HLF 
belongs to the proline- and acidic amino acid-rich (PAR) subfamily of bliP proteins 
(Drolet et aI., 1991), binds DNA, and activates transcription in a tissue-specific manner. 
Blocking E2A-HLF activity in a t(17;19}-positive human leukemia cell line results in rapid 
apoptosis, suggesting that E2A-HLF affects cell survival rather than cell growth. 
Moreover, when introduced into murine pro-B lymphocytes, E2A-HLF reverses both 
interleukin-3-dependent and p53-mediated apoptosis (Inaba et aI., 1996). E2A-HLF 
forms homodimers that bind to the HLF consensus site and transactivate reporter gene 
expression in a wide variety of cell types (Hunger et aI., 1992; Inaba et aI., 1994), 
suggesting that E2A-HLF homodimers could directly regulate the expression of genes 
required for cell survival. Since mutants lacking HLF-mediated DNA-binding can also 
promote cell survival, E2A-HLF may have an additional capacity to block apoptosis by 
heterodimerizing with other bliP transcription factors that normally bind to the HLF 
consensus sequence and regulate programmed cell death in pro-B-cells (Hunger et aI., 
1994; Inukai et aI., 1996). 
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RARa fusions 
A t(15;17) occurs in virtually all cases of a subtype of AML known as acute 
promyelocytic leukemia (APL) (Rowley et aI., 1977). The translocation fuses the gene 
for the retinoic acid-a receptor (RARd) on chromosome 17 to the promyelocytic 
leukemia gene (PML) on chromosome 15 (De The et aI., 1991; Kakizuka et aI., 1991). 
Retinoic acid (RA) has significant effects on development, differentiation and 
proliferation, and RARa is a nuclear, inducible transcription factor mediating these 
effects (reviewed in Gillard and Solomon, 1993). The expression of a functionally 
altered RA receptor explains the response of t(15;17) promyelocytic blasts to all-trans 
RA as a differentiating agent in vitro and in vivo (Chomienne et aI., 1990; Huang et aI., 
1988). PML was recently discovered to suppress growth and transformation (Wang et 
aI., 1996d) and belongs to a family of nuclear proteins which share N-terminal 
cysteine/histidine-rich clusters, including the so-called RING domain (Lovering et aI., 
1993; Reddy et aI., 1992). Immediately C-terminal to the cysteine cluster, PML contains 
a coiled-coil dimerization motif, and its N-terminus contains a proline-rich putative 
transactivation domain (De TM et aI., 1991; Kakizuka et aI., 1991; Kastner et aI., 1992). 
The PML-RARa hybrid protein contains most of the native PML protein fused to the 
DNA- and hormone-binding domains of RARa. The PML-FARa fusion protein also 
retains RARa's interface of dimerization with retinoid X rece'ptors (RXRs) (reviewed in 
Kastner et aI., 1994), a family of retinoid receptors which act as co-factors for other 
nuclear receptors. 
The coiled-coil region of PML directs the formation of PML-RARa homodimers 
and PML-RARa/PML heterodimers in vitro (Kastner et aI., 1992; Perez et aI., 1993). 
PML-RARa homodimers can bind to the RA-responsive elements on the DNA, in 
contrast to RARa itself that requires the RXR dimerization partner (Jansen et aI., 1995; 
Perez et aI., 1993). Furthermore, PML-RARa demonstrates promoter and cell-type 
specific alterations in RARa-mediated transcriptional activation compared with wild-type 
RARa (De The et aI., 1991; Kakizuka et aI., 1991; Kastner et aI., 1992; Pandolfi et aI., 
1991). Importantly, PML-RARa inhibits transactivation of some RA target proteins by 
RARa-RXRa heterodimers in a dominant fashion (Jansen et aI., 1995). These 
properties of PML-RARa may contribute to the transformed phenotype of APL cells 
(Weis et aI., 1994). In addition, PML-RARa could act in a dominant-negative way to 
disruption the growth suppressing activity of PML. PML is normally localized in specific 
nuclear subdomains, so-called nuclear bodies. In APL cells, these nuclear bodies are 
disrupted and PML-RARa and PML co-localize in poorly characterized microspeckled 
nuclear structures (Dyck et aI., 1994; Kastner et aI., 1992; Koken et aI., 1994; Weis et 
aI., 1994). 
PML-RARa blocks vitamin D,-induced differentiation of myeloid precursor cell 
lines and reduces the frequency of commilment to apoptosis upon growth factor 
deprivation (Grignani et aI., 1993; Rogaia et aI., 1995). The PML coiled-coil domain is 
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indispensable for the blocking activity of PML-RARa on differentiation, whereas the 
RARa DNA-binding domain only contributes partially (Grignani et aI., 1996). Recently, 
PML-RARa transgenic mice in which the transgene is specifically expressed in 
promyelocytes were found to have altered myeloid development and an increased 
frequency of AML after a long latency period (Grisolano et aI., 1997). In conclusion, the 
capacity of PML-RARa to regulate retinoid acid target genes, to bind RXR and PML in 
vitro and to disrupt PML nuclear bodies in vivo has led to the hypothesis that PML-
RARa might interfere with the function of a variety of nuclear proteins that include 
RARa, PML, other RXR-dependent nuclear receptors and other components of the 
nuclear bodies. 
In a variant translocation t(11 ;17), found in a small subset of APL patients, RARa 
is fused to the N-terminal part of promyelocytic leukemia zinc finger (PLZF) protein 
(Chen et aI., 1993). PLZF belongs to a family of proteins with a highly conserved N-
terminal POZ domain, which mediates protein-protein interactions and nuclear 
localization, and contains a C-terminal Kruppel-like zinc finger DNA-binding domain. 
Like PML, PLZF is a growth suppressor. (Chen et aI., 1993). Moreover, PLZF and PML 
partly co-localize to the same nuclear bodies and interact with each other, suggesting 
a functional relationship between these two proteins (Koken et aI., 1996). The POZ 
domain mediates the formation of PLZF-RARa homodimers and PLZF-RARa/PLZF 
heterodimers, whereas heterodimerization of PLZF-RARa with RXRa is mediated by 
the RARa sequence. It was shown that the POZ domain is primarily responsible for the 
inhibitory activity of PLZF-RARa on transactivation by the wild-type RARa/RXRa (Chen 
et aI., 1994; Dong et aI., 1996; Licht et aI., 1996). Therefore, PLZF-RARa may playa 
role in leukemogenesis by antagonizing actions of both RA receptors and PLZF, and 
possibly other POZ-domain-containing regulators (Dong et aI., 1996). Other parallels 
with PLM-RARa are the inhibition of terminal differentiation of hematopoietic precursor 
cell lines by PLZF-RARa and localization to the characteristic microspeckled structures 
(Ruthardt et aI., 1996). 
In a third translocation found in APL with t(5;17), RARa is fused to 
nucleoplasm in (NPM), a protein involved in ribosome assembly that forms oligomers 
in vivo (Chan and Chan, 1995; Redner et aI., 1996b). Structural as well as functional 
similarities between NPM-RARa and the other two RARa fusion proteins suggests that 
the mechanisms by which they cause APL are similar. This conclusion is illustrated by 
the finding that NPM-RARa blocks differentiation of myeloid precursor U937 cells 
(Redner et aI., 1996a). The occurrence of identical RARa sequences in three different 
fusion proteins demonstrates the importance of an altered RARa receptor in the 
pathogenesis of APL. Remarkably, the sale identified common feature of at least three 
different fusion partners of RARa in APL - PML, PLZF, and NPM - is their ability to 
mediate oligomerization. 
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CBF fusions 
A frequent target of chromosome translocations in leukemia is the core-binding factor 
(CBF) transcription complex, which consists of the acute myeloid leukemia 1 (AML 1) 
protein and core-binding factor P (CBFP). AML 1 contains an N-terminal DNA-binding 
domain, which is homologous to the Drosophila segmentation gene product runt, and 
a C-terminal transactivation domain (Daga et aI., 1992; Erickson et aI., 1992; Kania et 
aI., 1990). From the AML1 gene two representative forms of proteins - AML 1a and 
AML 1 b - are generated by alternative splicing, that both have the runt homology 
domain (RHO) but, unlike the full-length AML 1 b, AML 1 a lacks the transcriptional 
activation domain (Miyoshi et aI., 1995). AML 1a antagonizes both transactivation and 
myeloid cell differentiation by AML 1 b, and may function as a regulator of the activity of 
full-length AML 1b (Tanaka et aI., 1995b). 
The DNA-binding site for AML 1, called core-enhancer motif, is present in the 
regulatory sequences of a variety of hematopoietic-specific genes, such as those for T-
cell receptor, myeloperoxidase, neutrophit elastase, interleukin-3 (IL-3), granulocyte-
macrophage colony-stimulating factor-1 (GM-CSF), and colony-stimulating factor-1 
(CSF-1) receptor (Hiebert 
et aI., 1996). Transient 
transfection studies have 
shown that AML 1 can 
activate promoter-
enhancer constructs from 
some of these genes. 
The crucial role of AML 1 
in hematopoietic 
differentiation is 
confirmed by gene-
disruption experiments, 
since mice lacking AML 1 
die during embryogenesis 
because of a defect in the 
establishment of 
definitive hematopoiesis 
of all lineages (Okuda et 
aI., 1996a; Wang et aI., 
1996b). 
At least three 
different chromosome 
translocations - t(8;21), 
t(3;21), and t(12;21) -
RHD 
AML1a .1 250aa 
AML1b 
AML1-ETO 
AML1-EVI1 
AML1-EAP 
AML1-MDS1 
TEL-AML1 
Figure 2. Fusion proteins involving transcription factor AML 1 
Structural features of two splice forms of AML 1, AML 1a (truncated 
isoform) and AML1b (full-length AML1 protein). Fusion proteins 
AML 1-ETO,AML 1-EVI1, AML 1-EAP, andAML 1-MDS1 have loslthe 
AML 1 transactivation domain. In TEL-AML 1, the TEL gene Is fused 
to the N-terminal end of the entire AML 1 gene. RHD, runt homology 
domain; TA transactivation; Z, zinc fingers; H, helix-loop-helix. 
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share a breakpoint in AML 1, at 21q22. AML 1 was first identified through its involvement 
in the AML-associated t(8;21), which juxtaposes 5' sequences of AML 1 to 3' sequences 
of ETO (for eight twenty-one) on the derivative 8 chromosome. The chimeric gene 
product contains the RHD of AML 1 fused to near full-length ETO (Figure 2), a putative 
zinc finger-containing transcription factor that can transform fibroblasts (Erickson et aI., 
1992; Miyoshi et aI., 1993; Wang et aI., 1996a). AML 1-ETO retains the ability to interact 
with the enhancer core DNA sequence, but suppresses AML 1-dependent 
trans activation (Meyers et aI., 1993; Meyers et aI., 1995). Thus, transformation by 
AML 1-ETO may result from dominant-negative activity on wild-type AML 1. Further 
evidence for this hypothesis is provided by in vivo expression of AML 1-ETO by 
homologous recombination in mice. Embryos heterozygous for the AML 1-ETO fusion 
gene die in midgestation with a phenotype very similar to that caused by homozygous 
disruption of AML 1. Culture of hematopoietic precursor cells from these embryos 
revealed an increase in dysplastic colonies of macrophage or mixed origin, indicating 
an additional gain-of-function activity of AML 1-ETO as activator of some myeloid cells 
(Okuda et aI., 1996b; Yergeau et aI., 1996). An alternative strategy, which will allow 
expression of the fusion gene only in adult hematopoietic cells, should help to belter 
address the role of the fusion protein in leukemogenesis. 
The consequence of three different t(3;21)(q26;q22) translocations is similar to 
that of t(8;21), replacement of the AML 1 transactivation domain with sequences from 
another protein (Figure 2). The RHD-encoding part of AML 1 is fused to either the EVI1 
gene, encoding a zinc finger-containing transcription factor, or to EAP, which codes for 
the abundant ribosomal protein L22, or to MOS1, a gene of unknown function (Mitani 
et aI., 1994; Nucifora et aI., 1993; Nucifora et aI., 1994). Like AML 1-ETO, AML 1-EV11, 
AML 1-EAP, and AML 1-MDS1 fusion proteins all dominantly repress trans activation by 
intact AML 1 (Meyers et aI., 1995; Zent et aI., 1996). Furthermore, AML 1-EV11, as well 
as AML 1a and EVI1, block granulocytic differentiation of 32DCL3 myeloid precursor 
cells without abrogating IL-3 requirement for growth (Morishita et aI., 1992a, 1992b; 
Tanaka et aI., 1995a; Tanaka et aI., 1995b). 
Rearranged forms of the AML 1 gene are not only associated with myeloid 
leukemias, but also with lymphoid leukemias. In t(12;21), associated with childhood pre-
B cell ALL, almost the entire AML 1 protein is fused to the N-terminal part of TEL 
(Translocation, Ets, Leukemia), a member of the Ets family of transcription factors 
(Golub et aI., 1995; Romana et aI., 1995). The N-terminus ofTEL contains a conserved 
domain, which has weak homology to the helix-loop-helix (HLH) domains of 
transcription factors such as myc and myoD, that mediates oligomerization of TEL and 
TEL-derived fusion proteins (Jousset et aI., 1997). The TEL-AML 1 fusion is unique in 
that the AML 1 RHD and transactivation domains are both preserved in the chimeric 
protein (Figure 2), and that the fusion transcript is expressed from the TEL promoter. 
Despite the presence of the AML 1 transactivation domain, TEL-AML 1 efficiently 
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interferes with AML 1-dependent transactivation and TEL's HLH domain is essential for 
this repression (Hiebert et aI., 1996). These data suggest that the inhibition of 
expression of AML 1 target genes is critical for B-cell leukemogenesis. Another intriguing 
finding is the deletion of the TEL allele from the cytogenetically normal copy of 
chromosome 12 in part of the patients with a TEL translocation (Golub et aI., 1995; 
Kobayashi et aI., 1994). Recent findings suggest that TEL may antagonize the function 
of some transcriptional activators of the Ets family (Ringold et aI., 1996). Thus, TEL-
AML 1 may also contribute to hematopoietic transformation through interference with 
wild-type TEL function. 
The binding partner of AML 1 in the CBF transcription complex, CBFIl, was found 
to be targeted by inversion (16)(p13; q22) associated with a subtype of AML (Liu et aI., 
1993). CBFIl does not contact DNA directly, but increases the DNA-binding affinity of 
AML 1 by heterodimerization through the RHD and is required for transactivation by 
AML 1 (Meyers et aI., 1993; Wang et aI., 1993). Inversion 16 results in the fusion of 
CBFP to a smooth muscle myosin heavy chain gene, MYH11. The chimeric product, 
which still interacts with AML 1, contains most of the CBFIl protein and the coiled-coil 
dimerization motif of MYH11 (Liu et aI., 1993). Depending on the promoter, CBFIl-
MYH 11 can either enhance or suppress AML 1 aclivity and it has been proposed that 
the large size of the CBFIl-MYH11/AML 1 transcription factor complex may interfere with 
adjacent co-activator or repressor proteins required for normal CBF function (Caslilla 
et aI., 1996; Liu et aI., 1994). Mouse embryos heterozygous for CBFIl-MYH11 lacked 
definitive hematopoiesis (Castilla et aI., 1996). This phenotype is strikingly similar to that 
resulting from homozygous deletions of either AML 1 (Okuda et aI., 1996a; Wang et aI., 
1996b) or CBFIl (Wang et aI., 1996c), and from in vivo AML 1-ETO expression (Okuda 
et aI., 1996b; Yergeau et aI., 1996). This observation is consistent with a dominant 
negative function of the CBFIl-MYH11 fusion oncogene on CBF. An impairment of 
primitive hematopoiesis was also observed, however, suggesling a possible additional 
function of CBFIl-MYH11 (Castilla et aI., 1996). 
In conclusion, the frequent targeling of the AML 1/CBFIl complex by leukemia-
associated chromosomal rearrangements suggests that alteration of its activity leads 
to the disruption of AML 1-mediated Signals, which are critical for normal growth or 
differentiation of hematopoielic cells. 
5.2 Architectural factors in fusion proteins 
Transcriptional regulation in eukaryotes is based on the synergislic aclion of several 
DNA-binding transcriplion factors, assembled on a given enhancer or promoter 
sequence. An additional mechanism for achieving a high level of specificity and gene 
aclivation is the assembly of a stereospecific nucleoprotein complex. Th is process 
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requires proteins that function as architectural components in the nuclear scaffold 
through protein-protein and protein-DNA interactions (for review see O'Neill et aI., 
1994). These proteins differ from classical transcription factors in that they lack 
activation domains and have little if any sequence specificity; instead they bind to the 
minor groove of DNA causing sharp bends in the double helix (Grosschedl et aI., 1994; 
Paull et aI., 1993; Pil et aI., 1993). 
The architectural proteins belonging to the high-mobility group (HMG) family of 
proteins are abundant, heterogeneous, nonhistone components of chromatin (Bustin 
et aI., 1990; Grosschedl et aI., 1994). HMG proteins are divided into three distinct 
classes, the HMG domain containing HMG1/HMG2, the active chromatin-associated 
HMG14/HMG17, and the HMGI proteins, that bind DNA sequences rich in adenine and 
thymine with domains termed AT hooks (Reeves and Nissen, 1990). Additional proteins 
carrying AT hook motifs were discovered and they form a new class of proteins that are 
involved in transcriptional regulation of genes that contain or are near AT-rich DNA. 
They are proposed to bind in the minor groove within core elements of enhancer sites, 
resulting in tortional changes of the DNA to facilitate binding of transcription factors 
within the major groove (Tkachuk et aI., 1992). HMG1/HMG2 as well as HMGI proteins 
were shown to physically and functionally interact with sequence-specific transcription 
factors by enhancing DNA binding and transcriptional activation (Du et aI., 1993; Onate 
et aI., 1994; Thanos and Maniatis, 1992; Zappavigna et aI., 1996; Zwilling et aI., 1995). 
A number of studies have revealed an association between increased expression of 
HMGI proteins and transformation (Berlingieri et aI., 1995; Giancotti et aI., 1989; Ram 
et aI., 1993). Interestingly, two genes encoding architectural factors that contain AT 
hook motifs, HMG/-C and MLL, are translocated with multiple chromosomal partners 
in mesenchymal neoplasms and leukemias, respectively. 
HMG/-C fusions 
Rearrangements of chromosome region 12q14-15 are consistently associated with a 
number of benign tumors, mainly of mesenchymal origin (Schoenberg Fejzo et aI., 
1995). The affected gene was identified as HMG/-C, coding for an HMGI protein (Patel 
et aI., 1994). A variety of chromosome translocations results in fusion of the AT hooks 
of HMGI-C to novel C-terminal sequences. In a lipoma containing a t(12;15)(q15;q24) 
a highly acidic, serine- and threonine-rich domain that could contribute a transcriptional 
activator was fused to HMGI-C (Ashar et aI., 1995). In a second lipoma carrying 
t(3;12)(q29;q15), two tandemly arrayed LIM domains, involved in protein-protein 
interactions, may recruit other transcriptional activators to the DNA sites bound by the 
AT hooks of HMGI-C (Ashar et aI., 1995; Schoenmakers et aI., 1995). These studies 
suggest that a number of transcriptional regulatory domains can be placed downstream 
of the HMGI-C AT hooks and contribute to the pathobiology of lipomas. Truncation of 
HMGI-C may also contribute to tumorigenesis, since in a leiomyoma with 
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inv(12)(q14-15;q24) only ten codons of the mitochondrial aldehyde dehydrogenase 
gene were linked to HMG/-C (Kazmierczak et aI., 1995). The association of 
chromosomal rearrangements in bands 12q14-15 with benign solid tumors of 
mesenchymal origin implicates HMG/-C as a key regulator in adipogenesis and 
mesenchyme differentiation. 
MLL fusions 
The MLL gene (also called ALL-t, HRX or HTRX), located on chromosome 11q23, is 
frequently affected by a variety of chromosomal rearrangements that occur in ALL and 
in de novo and secondary AML (Djabali et aI., 1992; Gu et aI., 1992; Tkachuk et aI., 
1992; Ziemin-van der Poe I et aI., 1991). The MLL gene encodes a very large protein 
(Figure 3) that shares three regions of similarity with the trithorax protein of Drosophila 
me/anogasler. two central zinc finger motifs and a 210-amino acid C-terminal segment 
(Gu et aI., 1992; Tkachuk et aI., 1992). The N-terminal region of MLL contains three AT 
hook motifs, a region with homology to the non-cataly1ic domain of DNA-
methyltransferase (MT), and a region similar to the 70 kDa protein of U1 small nuclear 
ribonucleoprotein particles (Domer et aI., 1993; Ma et aI., 1993; Tkachuk et aI., 1992). 
Studies of MLL knock-out embryos showed that MLL is required for normal 
hematopoiesis and for the maintenance of expression of Hox genes, which have been 
implicated in development and hematopoietic differentiation (Hess et aI., 1996). MLL's 
involvement in acute leukemias of multiple lineages suggests that it is an important 
gene in early lymphoid-myeloid differentiation. 
More than 20 different reciprocal trans locations involving the MLL gene have 
been reported, most common of which are t(4;11), t(9;11), and t(11 ;19) (Thirman et aI., 
MLL 
MLL-AF4 
MLL-AF9 
MLL-ENL 500aa 
Figure 3. Chimeric proteins containing the architectural factor MLL 
Schematic representation of three different fusion proteins composed of the N-terminal region of MLL 
and the C-terminal regions of one of three different partner proteins, AF-4, AF-9 or ENL, resulting from 
1(4;11), 1(9;11) and 1(11 ;19), respectively. The C-Ierminal regions of AF9 and ENL are homologous. The 
vertical line indicates the fusion point in e8ch chimeric protein. AT, AT hooks; MT, DNA-
methyltransferase; NLS, nuclear localization sequence. 
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1993). The fusion genes encode chimeric proteins in which a similar N-terminal part of 
MLL, including the AT hooks and MT domain, but lacking the zinc-finger motifs and C-
terminal trithorax homology, is fused to novel protein sequences (Downing et al., 1994; 
Rowley, 1992). The role of the MLL portion in the fusion proteins is not clear. On the 
one hand, AT hooks bind the minor groove of DNA and may allow other transcription 
factors to gain access (Tkachuk et aI., 1992). On the other hand, the MT domain may 
allow the MLL fusion proteins to modify the methylation status of DNA and thereby 
affect transcription. 
Several of the genes that participate in 11 q23 translocations have been cloned 
and sequenced (reviewed in Rubnitz et aI., 1996). AF4, localized on chromosome 4q21, 
encodes a serine/proline-rich protein that contains a nllclear localization sequence 
(NLS) (Gu et aI., 1992; Morrissey et aI., 1993). AF-9 (band 9p22) and ENL (band 
19p13) encode homologous proteins that also contain NLSs and are rich in serine and 
proline, suggesting that these three proteins may function in the regulation of 
transcription (Nakamura et aI., 1993; Rubnitz et aI., 1994). Not all chimeric products are 
expected to act through the same mechanism, since sequence analysis of additional 
MLL partner genes suggests that there are no common structural features shared by 
all of them. Recently, in several cases of AML that lacked 11 q23 translocations, partial 
internal duplications of MLL were found resulting in dissociation of the AT hooks and 
MT domain from the remainder of the protein (reviewed in Schichman et aI., 1995). 
Uncoupling of N-terminal domains of MLL from regulatory C-terminal regions may be 
a crucial alteration in the oncogenic transformation of MLL. 
The subtype of the leukemia correlates with specific MLL fusion proteins. For 
example, t(4;11), which generates the MLL-AF4 fusion protein, is found predominantly 
in ALL (Djabali et aI., 1992; Domer et aI., 1993; Gu et aI., 1992; Morrissey et aI., 1993; 
Nakamura et aI., 1993), whereas t(9;11) is mainly associated with AML and fuses AF9 
to MLL (Iida et aI., 1993; Nakamura et aI., 1993). However, tumors of different 
phenotype can have similar or identical MLL chimeric proteins, indicating that the tumor 
phenotype is not dictated by the type of MLL fusion product alone (Corral et aI., 1993; 
Lo Coco et aI., 1993; Thirman et aI., 1993). The timing of the MLL-associated 
chromosomal translocation compared to additional mutations, and the precise stage of 
commitment of the cell in which the translocation occurs may combine to determine 
lineage of the tumor (Corral et aI., 1996). 
To mimic t(9;11) in mice, an MLL-AF9 fusion gene was made by homologous 
recombination in embryonic stem cells, so that expression of the fusion gene occurred 
from endogenous MLL promoter elements (Corral et aI., 1996). Chimeric mice carrying 
the fusion gene develop AML closely resembling the human disease, with a latency 
period of four months. A truncation of MLL, generated in a similar way, did not lead to 
disease, indicating that at least in mice the addition of functional domains from a fusion 
partner is essential for leukemogenesis. 
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5.3 Fusion proteins with tyrosine kinase activity 
Tyrosine kinases are important in the transduction of signals regulating cell proliferation 
and differentiation. Abnormal expression of tyrosine kinases often leads to malignant 
transformation. Mutant protein tyrosine kinases include transmembrane growth factor 
receptors (e.g., the EGF receptor), membrane-associated signal transduction molecules 
(e.g., src), and soluble tyrosine kinases (e.g., fps). Truncation of protein tyrosine 
kinases often leads to mutant versions that deliver a continuous rather than a ligand-
regulated mitogenic signal. Another way to activate some proteins containing tyrosine 
kinase activity is by fusion to a protein with an oligomerization domain. 
BCR-ABL 
The chimeric BCR-ABL oncogene, formed by the t(9;22) Philadelphia chromosome 
translocation, is present in almost all cases of chronic myelogenous leukemia (CML), 
25-50% of cases of adult B-lineage ALL and about 5% of cases of AML (Kurzrock et aI., 
1988). Two different fusion proteins can be produced which differ in their BCR 
sequences. The p210BCR.ABL protein is associated with CML, and also present in about 
one-third of Philadelphia-positive ALL cases (Groffen et aI., 1984; Konopka et aI., 1984; 
Shtivelman et aI., 1985). In the other cases a smaller p190BCR.ABL is found, which has 
a higher intrinsic tyrosine kinase activity and transforming potential (Chan et aI., 1987; 
Clark et aI., 1988; Hermans et aI., 1987; Kurzrock et aI., 1987). 
c-ABL, the cellular homolog of the viral oncogene v-ABL, encodes a nuclear 
tyrosine kinase that negatively regulates growth (Sawyers et aI., 1994; Van Etten et aI., 
1989). Fusion to BCR (Figure 4) relocates almost the entire ABL protein from the 
nucleus to the cytoplasm (Van Etten et aI., 1989; Wetzler et aI., 1993), exposing a now 
constitutively active tyrosine kinase to a new range of substrates. Since the growth 
suppression by ABL requires nuclear localization, the changed cellular location of the 
activated ABL kinases may contribute to leukemogenesis (Sawyers et aI., 1994). BCR-
ABL binds and phosphorylates proteins of the RAS signalling pathway and may also 
affect proteins involved in other growth-factor signalling pathways (summarized in 
Butturini et aI., 1996). 
In normal cells, BCR is widely expressed and BCR-deficient mice have defects 
in polymorphonuclear neutrophil function (Voncken et aI., 1995b). The N-terminus of 
BCR contains a serine/threonine kinase domain (Maru and Witte, 1991) and a domain 
that binds to the SRC homology region 2 (SH2) domain of ABL (Muller et aI., 1992). Its 
C-terminal third, that is not present in the BCR-ABL fusions, contains a GTPase-
activating protein (GAP) activity for p21"'" (Diekmann et aI., 1991). Furthermore, the N-
terminal 60 amino acids of BCR, which have an a-helical coiled-coil structure, mediate 
tetramerization of BCR-ABL proteins and are important for activation of the ABL kinase 
activity and transforming potential of BCR-ABL (McWhirter et aI., 1993; Muller et aI., 
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1991). The oligomerization domain of BCR also mediates heterodimerization between 
BCR and BCR-ABL, so it is possible that interference of BCR-ABL wilh the normal 
function of BCR contributes to transformation (Campbell et aI., 1990). 
Much is known from experimental models about the growth-stimulatory 
properties of BCR-ABL that correlate with its ability to expand the myeloid compartment 
in CML. Firstly, introduction of the BCR-ABL gene into hematopoietic cell lines of many 
different lineages (myeloid, B or T lymphoid) renders them growth factor independent 
and tumorigenic in animals (Cook et aI., 1985; Daley and Baltimore, 1988; Hariharan 
et aI., 1988; Mandanas et aI., 1992; Pendergast et aI., 1993; Sirard et aI., 1994). 
Secondly, expression of p210BCR.ABLwas found to inhibit apoptosis and inappropriately 
prolong cell survival of human CML cells and transfected murine cell lines (Bedi et aI., 
1994; McGahon et aI., 1994). Thirdly, mice expressing BCR-ABL proteins, eilher by 
retroviral infection of bone marrow cells or introduction of the transgene into the 
germ line, develop diverse leukemias resembling the human disease (Daley et aI., 1990; 
Elefanty et aI., 1990; Groffen et aI., 1993; Heisterkamp et aI., 1990; Kelliher et aI., 1991; 
Kelliher et aI., 1990; Voncken et aI., 1995a). 
N-terminal TEL fusions 
Two translocations resulling in the fusion of the N-terminal HLH domain of TEL to 
protein tyrosine kinases have been described. Firstly, in t(5;12), associated wilh chronic 
myelomonocytic leukemia, TEL is fused to the transmembrane and tyrosine kinase 
domains of the platelet-derived growth factor receptor 13 (PDGFRIl) (Golub et aI., 1994). 
TEL-PDGFRIl renders a murine hematopoietic cell line IL-3 independent, presumably 
by activating PDGFRIl-dependent signaling pathways. Both the TEL HLH domain and 
the PDGFRIl tyrosine kinase aclivity are required for the transformation (Carroll et aI., 
1996). HLH-induced self-association was shown to be essential for the constitutive 
activation of the protein kinase activity and mitogenic properties of TEL-PDGFRIl 
BCR-ABL 
TEL-ABL 
TEL-PDGFR 
250aa 
Figure 4. Structure of fusion proteins involving tyrosine kinases 
Fusion proteins involving the ABL and PDGFRp tyrosine kinases are aligned on their breakpoints. 
BCR-ABL is crealed by 1(9;22), TEL-ABL by 1(9;12), and TEL-PDFGRp by 1(5;12). TK, tyrosine kinase 
domain; H, helix-loop-helix dimerization motif; TM, transmembrane domain. 
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(Jousset et aI., 1997). Apparently, oligomerization by TEL mimics ligand-dependent 
dimerization of the normal receptor, which is sufficient for tyrosine kinase activation and 
association with effector molecules. 
Secondly, t(9;12)(q34;p13) associated with AUL and AML, links TEL to ABL 
(Golub et aI., 1996; Papadopoulos et aI., 1995). Both the tyrosine kinase and 
transforming activities of TEL-ABL are impaired by deletion of the TEL oligomerization 
domain (Golub et aI., 1996). Because of the similarities to BCR-ABL, TEL-PDGFRp 
and TEL-ABL are postulated to function by activation of similar signal transduction 
pathways (Sawyers, 1997). 
TPR fusions 
The translocated promoter region (TPR) gene appears in oncogenic fusions with the 
tyrosine kinase domains of the MET and TRK proto-oncogenes in gastric carcinomas 
and thyroid cancers, respectively (Greco et aI., 1992; Soman et aI., 1991). TPR is an 
NPC protein without FG repeats. It contains an exceptionally long predicted coiled-coil 
domain and is thought to be a structural component of the cytoplasmic fibrils of the NPC 
(Byrd et aI., 1994). Fusion of the N-terminal coiled-coil of TPR to MET results in a 
constitulively active tyrosine kinase that causes malignancies in transgenic mice (Liang 
et aI., 1996). A leucine zipper motif within TPR mediates homodimerization of the TPR-
MET protein and is essential for the transforming activity of the fusion protein 
(Rodrigues and Park, 1993). It is possible that the TPR moiety of the fusion protein 
contributes more than an oligomerization domain. If TPR fusions are still able to bind 
to the NPC, they could interfere with nucleocytoplasmic transport by phosphorylating 
NPC components or transport substrates (Byrd et aI., 1994). 
5.4 Repeat-containing nucleoporins in fusion proteins 
The NPC is a supramolecular structure that spans the nuclear envelope and mediates 
bidirectional transport of proteins and ribonucleoproteins (RNPs) between the 
cytoplasm and the nucleus (recently reviewed by Gorlich and Mattaj, 1996). Multiple 
copies of an estimated 100 different proteins, named nucleoporins, are present at 
distinct positions within the NPC. A number of these proteins contain degenerated 
amino acid repeat motifs, that have an FG dipeptide core (Fabre and Hurt, 1994; Pante 
and Aebi, 1994; Rout and Wente, 1994). Studies in yeast mutants have established a 
role for several nucleoporins in mRNA export or nuclear protein import, or both, as well 
as in NPC morphology and distribution (reviewed by Doye and Hurt, 1995). Three 
vertebrate nucleoporins have been implicated in malignancies by gain-of-function 
mutations. Fusion proteins involving TPR, an NPC component that does not contain 
nucleoporin-specific FG repeat sequences, playa role in the oncogenic activation of 
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tyrosine kinases and are discussed above. To date, two repeat-containing nucleoporins 
have been implicated in leukemia by gene fusion, NUP98 and CAN. 
NUP98-HOXA9 
The translocation t(7;11)(p15;p15) is very rare, but has primarily been observed in 
AML. It creates a fusion between the HOXA9 gene on chromosome 7 and the 
nucleoporin gene NUP98 on chromosome 11. NUP98 encodes an FG repeat-containing 
nucleoporin that is located on the nucleoplasmic side of the NPC (Radu et aI., 1995b). 
The predicted fusion protein contains the repeat-rich N-terminal half of NUP98 and 
most of the coding region of the homeobox gene HOXA9, including its homeodomain 
(Borrow et aI., 1996; Nakamura et aI., 1996a). The murine Hoxa9 gene was also found 
to be activated by proviral integration in myeloid leukemias in BXH-2 mice (Nakamura 
et aI., 1996b), identifying this gene as an important myeloid leukemia gene in both man 
and mouse. 
The presence of the FG repeats of both NUP98 and CAN in the NUP98-HOXA9, 
and DEK-CAN and SET-CAN fusion proteins, respectively, argues for an important 
contribution of these sequences to the development of leukemia. The peptide repeat 
domains function as NPC binding sites for cytosol-mediated docking of import 
substrates, at least in vitro (tovine et aI., 1995; Kraemer et aI., 1995; Radu et aI., 1995a; 
Radu et aI., 1995b; Rexach and Blobel, 1995). A heterodimeric nuclear import receptor, 
consisting of importin Il (atso called p97 or karyopherin Il) and importin a (also called 
karyopherin a or NLS receptor) binds to an NLS-bearing protein in the cytoplasm via 
the NLS-binding domain of importin a (Adam and Adam, 1994; Adam and Gerace, 
1991; Giirlich et aI., 1994; Moroianu et aI., 1995a; Weis et aI., 1995). Importin Il is 
predominantly localized at the NPC where it acts as an adaptor between importin a and 
repeat-containing nucleoporins (Chi et aI., 1995; Giirlich et aI., 1995; Moroianu et aI., 
1995b). Translocation of the ligand-bound importin complex through the pore is driven 
by the GTP cycle of the small nuclear GTPase Ran (Melchior et aI., 1993; Moore and 
Blobel, 1993), and may occur by repeated docking and undocking of importin Il to an 
array of FG repeat-containing nucleoporins, including NUP98 and CAN, that line the 
NPC (Nehrbass and Blobel, 1996; Rexach and Blobel, 1995). At the nuclear side of the 
NPC, dissociation of the importin heterodimer is mediated by direct binding of RanGTP 
to importin Il (Giirlich et aI., 1996b; Rexach and Blobel, 1995). The NLS protein and 
importin a are released into the nuclear interior, whereas importin Il remains bound to 
the NPC (Giirlich et aI., 1995; Moroianu et aI., 1995b). The gradient in Ran's nucleotide 
binding state is generated by the nuclear GDP/GTP exchange factor for Ran, RCC 1, 
and cytoplasmic RanGAP, the Ran-specific GTPase activating protein (Bischoff et aI., 
1994; Bischoff and Ponstingl, 1991; Corbett et aI., 1995). Low cytoplasmic RanGTP 
levels allow importin a to bind importin Il, whereas the high nuclear RanGTP 
concentration favors importin heterodimer dissociation in the nucleus. Thus, the 
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RanGTP gradient determines from which compartment the importin heterodimer can 
transport an NLS substrate. 
The export of RNPs from the nucleus to the cytoplasm is probably directed by 
associated proteins carrying nuclear export signals (NESs; Fischer et aI., 1995; Wen 
et aI., 1995) and also requires Ran and its cofactors (for reviews see Gerace, 1995; 
Gbrlich and Mattaj, 1996; Izaurralde and Mattaj, 1995). The different classes of RNAs 
leave the nucleus via distinct routes, each with their own (set of) carrier proteins. For 
example, the best candidates to mediate export of mRNAs are hnRNP A 1 and its 
relatives (Pinol-Roma and Dreyfuss, 1993), and the cap binding complex (CBC) is 
involved in export of capped U snRNAs (Izaurralde et aI., 1995). Importin a was also 
recently found to be involved in the export of capped U snRNAs from the nucleus, and 
release of the RNA molecule into the cytoplasm is mediated by importin Il binding to the 
importin a-RNA complex (Gbrlich et aI., 1996a). 
The mechanism of oncogenic activation of the NUP98-HOXA9 fusion gene is not 
clear. Preliminary data suggest that NUP98-HOXA9 localizes to the nucleus (J. van 
Deursen, personal communication), similar to DEK-CAN and SET-CAN (Fornerod et 
aI., 1995). One possibility is that the addition of NUP98 sequences to HOXA9 affects 
the DNA-binding or transcriptional activity of HOXA9. NUP98 could for instance affect 
HOXA9-mediated transcription by either contributing a transcriptional activation or 
repression domain or providing binding sites for proteins imported from the cytosol 
carrying these functions. Homeobox proteins heterodimerize with other divergent 
homeodomain proteins, giving yet another possibility for transcriptional deregulation: 
NUP98-HOXA9 could act as a dominant-negative HOXA9 protein by sequestering co-
factors (Borrow et aI., 1996). On the other hand, NUP98-HOXA9 may interfere with 
NPC function. The fusion protein contains the majority of the FG peptide repeats and 
would therefore be expected to retain the ability to bind importin Il, potentially with an 
adverse effect on nucleocytoplasmic transport. 
6 Cellular mechanisms of hematopoietic transformation 
The cloning of translocation breakpoints associated with hematopoietic malignancies 
has identified a variety of proto-oncogenes and their molecular analyses have revealed 
some principles governing the contribution of translocations and inversions to 
leukemogenesis. The proteins activated by gene fusions in leukemia often seem to be 
involved in hematopoietic differentiation. Normal roles in the differentiation program of 
blood cells are established for AML 1, the retinoic acid receptor, and for the homeobox 
protein PBX1. Fusion proteins derived from these transcription factors block 
differentiation of hematopoietic progenitors: (i) EVI1, AML 1a and the chimeric AML 1-
EVI1 protein block G-CSF-induced differentiation of the IL-3 dependent 32DCL3 
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myeloid cell line (Morishita et aI., 1992a, 1992b; Tanaka et aI., 1995a, 1995b). 
(ii) RARa fusion proteins block differentiation of promyelocytes in patients and of U937 
monoblastic cells to macrophages in vitro (Grignani et aI., 1993; Redner et aI., 1996a; 
Rogaia et aI., 1995; Ruthardt et aI., 1996). (iii) E2A-PBX1 strongly retards the 
differentiation of myeloblasts in primary bone marrow cultures (Kamps and Wright, 
1994). It is not clear whether these altered transcription factors block differentiation 
directly, by inhibiting a programmed pattern of myeloid differentiation genes, or 
indirectly by preventing a necessary exit from the cell cycle. 
Another recurring general mechanism by which fusion proteins contribute to 
leukemogenesis is the abrogation of growth-factor dependence by inhibition of 
apoptosis, indicating that some chimeric oncoproteins affect cell survival rather than cell 
growth: (i) BCR-ABL inhibits apoptosis and renders many different hematopoietic cell 
lines growth factor independent (for references see section 5.3), and a similar 
phenotype is found with another altered protein tyrosine kinase, TEL-POGFRp, which 
transforms a murine hematopoietic cell line to IL-3 independence (Carroll et aI., 1996). 
Most likely, these chimeric kinases feed into signal transduction pathways normally 
activated by a ligand-bound growth factor receptor, thereby bypassing the requirement 
for the growth factor. (ii) PML-RARa reduces apoptosis upon serum starvation of U937 
cells (Grignani et aI., 1993; Rogaia et aI., 1995). (iii) E2A-HLF protects t(17;19)-positive 
human leukemia cells and transfected murine pro-B lymphocytes from apoptosis (lnaba 
et aI., 1996). 
Paradoxically, some fusion proteins induce apoptosis in immature cells that fail 
to initiate or complete differentiation. This leads to dysplasia, often accompanied by a 
compartment enlargement of precursor cells. The enlarged compartment may increase 
the chances for additional transforming mutations to take place that abrogate the 
apoptotic response or stimulate proliferation and lead to acute leukemia (Greenberg, 
1996; Raza et aI., 1996). For example, expression of E2A-PBX1 in transgenic mice 
induces both enhanced proliferation and apoptosis of T and B cells prior to the 
development of T-cell lymphomas (Oedera et aI., 1993). Also, 320CL3 cells expressing 
the EV/1 zinc finger gene die in the presence of G-CSF without differentiating (Lopingco 
and Perkins, 1996; Morishita et aI., 1992a). 
A possible explanation for the success of fusion proteins in transformation may 
be that the chimeras potentially deregulate functions of both partner proteins, thereby 
targeting two different pathways in the same cell. The dual functions of fusion proteins 
are reflected for instance in the combined dominant-negative and gain-of-function 
activities of AML1 fusions (section 5.1). The requirement for both partners of most 
chimeric proteins is further demonstrated by the general finding that neither truncation 
nor overexpression of one of the partners is sufficient to generate the transforming 
phenotype. 
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7 Clinical implications 
The molecular characterization of fusion transcripts has had a major impact on 
diagnosis and prognosis of leukemia. First, analysis of the chimeric DNA or RNA in 
tumors, by Southern blot or reverse transcriptase-polymerase chain reaction (RT-PCR) 
respectively, can be used for diagnosis in addition to cytogenetics. Second, the fusion 
transcript is an important target for RT-PCR-based detection of residual tumor cells 
after treatment and may also assist in early detection of tumors. Third, fusion-specific 
antibodies can be raised to the junction region which can be used in diagnosis of some 
translocation-associated diseases, potentially with a sensitivity similar to RT-PCR 
(Samoszuk et aI., 1996; Viswanatha et aI., 1996). 
The first attempts to treat leukemia using strategies that target the specific 
molecular abnormality responsible for the disease are becoming a reality. The best 
example is the widespread use of all-trans retinoic acid in the treatment of APl, in 
which the retinoic acid receptor gene is rearranged. In principle, therapeutic strategies 
could be applied to interfere with any step between transcription of the oncogene, RNA 
processing and translation, and function of the fusion protein. The chimeric mRNA can 
be inactivated either by sequence-specific cleavage of the fusion region by ribozymes 
or by introduction of antisense oligonucleotides. Both approaches are effective in 
suppressing the transformed phenotype of cell lines expressing BCR-ABl proteins or 
AMl1-ETO (James et aI., 1996 and references therein; Kozu et aI., 1996; Matsushita 
et aI., 1995; Sakakura et aI., 1994). To inhibit the transforming activity of a specific 
fusion protein directly, detailed knowledge of its function is necessary. For example, 
expression of the DNA-binding domain of AMl1 inhibited growth and induced 
differentiation of AMl-ETO positive cells (Matsushita et aI., 1995; Sakakura et aI., 
1994). Similar studies show growth inhibition of BCR-ABl positive cells upon co-
expression of the oligomerization domain of BCR, or inhibition of the tyrosine kinase 
activity of ABl (Bergen et aI., 1994; Bergen et aI., 1995). These approaches will 
invariably affect the functions of the normal counterparts of the fusion proteins and their 
usefulness in therapy awaits further investigation. 
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The wrtebratc nucleollore complex (NPC) is a 125 i'tIDa 
Illlliliprotein assembly that mediates nucleocytoplasmic 
transport. One of its cOIllPonents, CANlNup214, is an 
FXFG repeat-containing protein known to be involved 
in myeloid leukemia in humans. We hal'e devised a 
powerful genetic approach, using maternally deriyed 
protein in murine uull embryos, to show that CAN! 
Nup214 is essential for NPC fuuction ill }';I'O. We 
demonstrate that CAN-/- mOllse embryonic stem (ES) 
cells are not viable and that Cf1N-/- embryos die ill 
IItero between 4.0 and 4.5 days poStcOitlllll, following 
the depiction of their CAN from maternal sonrces. In 
3.5-day-old lIlutant embryos, cultured ill ~'itroJ pro-
gressi,'e depletion of CAN leads to cell cycle arrcst in G1 
phase, and eHntually to blastocoel collapse, impaired 
NLS-mediated protein uptake and nuclear accumula-
tion of polyadenyJated RNA. Remarkably, these defect-
h'e CAN-depleted embryos do not display any gross 
morphological abnormalities in their nuclear enHlopes 
or NPCs. Our data suggest that CAN is critical to cell 
cycle progression and rC{luired for both nuclear protein 
import and mRNA export. 
Keyn'ords: CAN(Nup214)/ceil cycle/gene targeting/ 
nUcleocytoplasmic trafficking/oncogenesis 
Introduction 
The human CAN gene was first identified as a target of 
chromosomal translocation (6;9)(p23;q34) associated with 
a SUbtype of acute myeloid leukemia (von Lindern e/ 01., 
1992). CAN. also called Nup214. is a nuclear pore complex 
(NPC) protein: it associates with the NPC and its primary 
sequence contains Illultiple copies ofNPC protein-specific 
peptide repeat motifs (Kraemer e/ 01.. 1994; Fomerod 
et 01., 1995). Some 100 different proteins (nucleoporins) 
make up the NPC, a 12511Da supramolecularstructure that 
crosses the nuclear envelope and mediates bidirectional 
transport of macromolecules between the cytoplasm and 
the nucleus (reviewed by Rout and Wente, 1994; see also 
Pante and Aebi, 1994; Davis, 1995; Doye and Hurt, 1995; 
Gorlich and Mattaj, 1996; Hurt, 1996). 
Selccth'e protein import into the nucleus is a two-step 
process. First, a heterodinleric complex composed of the 
nuclear localization signal (NLS) receptor and p97 binds 
to a karyophilic substrate in the cytosol. The NLS receptor 
of the heterodimer recognizes the substrate's NLS (Adam 
and Gerace, 1991; Adam and Adam, 1994; Gorlich et 01., 
1994), and p97 may mediate binding of the import complex 
to FXFG repeat-containing nUcleoporins associated with 
the NPC (Chi el 01., 1995; Gorlich e/ 01., 1995; Moroianu 
et 01., 1995a; Radu e/ 01., 1995a). Second, the entire 
complex moves through the central channel of the NPC. 
This process is energy-dependent and mediated by the 
small GTPase Ran (Melchior et 01., 1993; Moore and 
Blobel, 1993). The import complex components are then 
released into the nucleoplasm, except for p97, which is 
retained at the nuclear side of the NPC (Gorlich e/ 01., 
1995; Moroianu e/ al., 1995a). Export of proteins and 
ribonucleoproteins (RNPs) from the nucleus is also an 
active, energy-dependent and factor-mediated process, and 
short protein sequences that act as nuclear export signals 
(NESs) have recently been identified in some of these 
factors (Bogerd et 01., 1995; Fischer e/ 01., 1995; Fritz 
e/ 01., 1995; Gerace, 1995; Stutz et al., 1995; Wen e/ 01., 
1995; Gorlich and Matlaj, 1996). 
Owr the past few years, a number of NPC proteins 
have been identified in yeast and biochemical and genetic 
approaches have shed some light on their roles in nucleo-
cytoplasmic transport (Davis, 1995; Doye and Hurt, 1995; 
Rexach and Blobel, 1995). Yet, the lack of both accurate 
protein import assays and experiments that localize the 
proteins within the NPC, together with pleiotropic defects 
ill some nucleoporin mutants, have hampered precise 
interpretation of functional studies. In higher eukaryotes, 
most llucleoporins identified to date have been sublocalized 
to specific NPC regions (Pante and Aebi, 1994), but their 
ill vivo function(s) remain to be explored by genetic tools. 
Results 
CAN is an essential nucleoporin 
As a first step towards genetic dissection of the NPC we 
disrupted the murine C'AN gene by using gene targeting 
and ES cell technology (Figure lA). Heterozygous mutant 
mice were interbred and their offspring genotyped by 
Southern blot analysis (Figure IB). None of the 233 pups 
screened was homozygous for the disrupted CAN allele, 
demonstrating that CAN is essential for embryonic 
deyelopment. To deteonine the time at which the CAN 
gene disruption is lethal, 3.5-, 6.5-, 7.5- and 9.5-day-
old embryos were isolated and their genotypes were 
determined by polymerase chain reaction (PCR) ampli-
fication of DNA fragments diagnostic for the wild-type 
and the disrupted CAN allele (data not shown). No CAN-I..., 
embryos were found at days 6.5, 7.5 and 9.5 of gestation; 
however, at 3.5 days postcoitUIll, CAN-I- embryos were 
detected at a nonnal Mendelian frequency of 25%. These 
homozygous mutant blastocysts were morphologically 
indistinguishable from their wild-type and heterozygous 
counterparts. 
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Fig. 1. Targeted disruptions of the mouse CAN gene in ES cells. (A) Schematic diagram showing a J2 kb EcoRV frogmen! of the mouse CAN locus 
and primary targeting vector c8.51acZneo. The solid box indicates the mouse exon that corre5ponds to codons 278-429 of the human CAN gene. 
Shaded w~es mark probes used for Southern blot screening of homologous recombinants and arrowheads indicate the po,itions of the three primers 
used to peR genotype the embryos. (B) Southern blot analysis of wild-type (+1+) E14 ES ceUs and targeted ES clone 65 (+/-), EcoRV...:Iigested 
DNA h) bridized to probe n, Arrows indicate the positions of the wild·type (32 kb) and laeZneo--disrupted alleles (23 kb). (C) Schema of the wild-
type CAN allele of heteroz)'gous mutant ES cells and the three targeting welors used in [he second rounds of homologous recombination. Restriction 
sites and probes (c and d, shaded boxes) used in Southern blot analysis are indicated. Abbreviations: TK, HSV·tk gene; B, BamH!; C, Claf; E, 
£CoRI; P, P\'lI[l; R, i:"coRV; S, Sluf; X, XbaL 
To evaluate the role of CAN further, we wanted to 
inactivate the remaining functional CAN allele in hetem-
zygous ES cells. First, CAN+/- ES cells were selected in 
high concentrations of G418 (Mortensen et af., 1992), but 
none of the 34 resistant clones showed duplication of the 
mutant CAN allele. Second, CAN+/- ES cells were 
subjected to a second round of homologous recombination 
by using vector c8.5hyg (Figure IC). Twelve targeted ES 
clones were obtained; strikingly, all homologous recombin-
ation events occurred at the previously disrupted allele. A 
second double-targeting \'cctor, cl2.7hyg (Figure IC), 
yielded 105 targeted clones but, again, all recombination 
events occurred at the previously disrupted CAN allele. 
The above results strongly suggest that inactivation of 
both CAN alleles is incompatible with ES cell survival. 
To exclude the possibility that the wild-type allele in 
the CAN+/- ES clones was refractory to homologous 
recombination, we constmcted and tested a third double-
targeting vector, c8.5hygint (Figure IC). This \'ector was 
designed to insert a lielectable marker in the CAN gene 
without dismpting its coding sequence. Nine of23 doublc-
targeted CAN+/- clones showed recombination at the 
wild-type allele, thereby indicating that this allele is 
accessible to homologous recombination, and supporting 
our conclusion that CAN is essential for cell suryival. 
How can homozygous null embryos survive during the 
early steps of development, yet ES cells that lack the 
CAN protein die? To test whether maternally derived 
CAN (Kidder, 1992) could account for the normal develop-
ment of homozygous mutants during very early embryo-
genesis, we inununostained fertilized eggs (0.5 day 
postcoitum; 11=35), 2-cell embryos (1.5 days postcoitum; 
11=24), 8/16·cell embryos (2.5 days postcoitum; 11=39), 
blastocysts (3.5 days postcoHum~ 11=15) and hatched 
blastoc),sts (4.0 and 4.5 days postcoitum; 11= 15 and 11=39, 
respectively) with affinity-purified anti·CAN antibodies 
(aCNN76~2). We found that the intensity of staining of 
0.5-, 1.5- and 2.5-day-old mutant embryos was indistin-
guishable from that in wild-type and heterozygous embryos 
(Figure 2A and B). In contrast, cells of CAN-I- blastocysts 
stained very weakly for CAN (Figure 2C and D) and 
CAN-/- day 4.0 hatched blastocysts did not stain at all 
(Figure 2E and F), At 4.5 days no CAN-negative hatched 
blastocysts were observed. These results indicate that 
CAN levels appear noonal in mutant embryos up to 2.5 
days poslcoitum; howe\'er, over the next 24 h CAN levels 
drop and the embryos die between day 4.0 and 4.5 because 
of the ongoing CAN depletion. 
Growth arrest and degradation of cultured CAN-/-
embryos 
To understand the degeneration of CAN-/- embryos better, 
we isolated blastocysts from matings between hetero-
zygous mutant mice, cultured them, and examined them 
microscopically. Initially, wild-type, heterozygous and 
homozygous mutant bJastocysts, genotyped by PCR, were 
morphologically indistinguishable (Figure 3A and B). 
However, after 18-24 h, the blastocoel of homozygous 
mutant embryos (11=22) gradually became smaller until 
it had completely collapsed 2-3 h later (Figure 3D-D). 
Trypan blue staining of these collapsed embryos revealed 
no signs of cell death. In contrast, 91% of wild-type 
(n=23) and 96% of heterozygous embryos (11=44) hatched 
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Fig. 2. Indirect imlllliflofluofescencc detection of CAN in pre-implantation embryo;, fWnl CAN+I- intcrhrccrlingo;, ReprcsenlatiH: confocal inw.ges of 
2.5- to 4-day-old embryo> ~tain<"tl with affinity-puritled anli·CAN :mtiilodk, (aCNN76-1). (,\) Cells of a hClcfl',.)'goU'i mutant emhf)'o at day 25 
showing CAN·~p.;cific ~taining of the nudear membrane, imJkaled by the arrow, (Il) i'\UdNf enwlopcs of cml;lryonic cell" [rum 11 l.5-dar-old 
homozygous !Ilutunt embryo stained with similar intemity as nonna! embf)'Dnic cell" (C ,mtl E) In wild·!ypi: or heterolygous embryos (day 35 and 
4), CA.:'/" is localilcd to 1111" nuclear membrane of inner cell rna~~ cells (Iabdcd i) and of the truphecIlxlerrn cells that shap<' Ih<' blaSilX:oel (!abdcd b). 
(D) In mulant 3.5-day-old embryos, CAN.s~cific ,t~ining is bardy uNectablc; ~r[!)\\heJd, poinlto eells with weak nuckar en\"elo~ ~taining. 
{FJ A hatcheu CAN-/- hl~\!OCY~I. 4 da)s poslcoitUlll, do~, not ~1<1in fur CAN. The' SCJk \>Jr in (F) r~presents 14 ].1m. 
nomlally from the zolla peUucida and attached 10 the 
culture dish during the second day of culture. 
1'1ulaol and control blastocysts conlained similar 
numbers of cells at the sl,ut of culture {38± 10 (1/=3) 
versus 37±5 (n=26)] cells, respectively). In contrast, at 
the onset of blastocoel contraction, CAN-I- embryos 
contained considerably fewer cells than did controls [45±7 
(no=i12) versus 76±4 (11=11) cells, respectively], indical-
ing that vcry few cells of the Illutant blastocy.<.t cells had 
divided in culture. 
We then examined whether the cells of CAN-/- blasto-
cysts were arrested at a particular stage of the cell 
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propidium iodide intensity 
Hg. 3. Gro\\th anti morphology of CAl'l".depleted blastocr,ts cultured in film. ('\-0) Phase contrast images of repre,entatiw 3.5-day--old embI}'os 
euhured in film. (A) \''lld·type embI}'o cuhured [or 18 h; the morphology of the embI}'o remained unchanged owr the ne~t 5 h. (Ii-D) A CAN-I-
embI}'o at various stages of in film culture: (8) al t =18 h (-I h before the onset of its blastocoel colJapse); (C) 2 h later; (D) 4 h later. Arrows 
indicate tfophectodwlI cells; b, blastocO<'i; i, inna eel! mass, Arrowheads point to the zona p.;l!ucida. (E-H) DNA replication and DXA content of 
blaSIOC)'SIS cuhured ill film for 20 h in the preseoce of DrdU. (E and FJ Confocal inwges of a control blastocyst stained for BrdU (El and propidium 
iodide (F). (G and H) A representative CAN-I- embI}'o at the onset of it" bla,tocO<'i collapse (at -20 h of ill I'ilro cultur(') staincd for UrdU (0) and 
propidiulll iodide (H). Note that almost all mutant nuclei ~tain strongly for propidium iodide, (E and G) anti (F and II) \\'ef<~ s(anned and 
photographed under identical conditions. (I-I.) Nuclear enwlope morphology anti NI'C distribution as viewed by immunofluorescence micro,copy. 
(I and 1) Confocal images of a control bla<;\ocyst (cuhured for 24 h) stained with (I) uCNN76-2 and (J) mAb-i14 (10 pgfml). 
(K and L) A repre,entatiw CAN·depleted embryo 2 h after oruet of its blasto(od rcmi~,ion (I '" 26 h of in I'ilro culture) ~tained \,jth (K) 
uCNN76·2 and (L) mAb-i14. (i'II and N) Electron microgmphs uf the nuclear en\'dope, of control and degenerating embI}'os. Detail of (:-'1) a 
normal and (N) a collapsed blastocyst (_2 h after onset of blastocoel contraction). n, [ludcu,; c, C),lopla,m; arrows indic,lle the nud~.ar pores. The 
blr in (L) represents the length of 30 pm in (A-D), 36)1111 in (E-H), 18 11m in (Ii\'L), and 155 lllll in (~I) and (N). (0) Hhtogmm of the DNA 
contenl of control (black) and mutant embryonic cell, (gray) after 20 h of culture derived frOIll cytomctric analysi,. Propidium iodide Iluore,ceoce is 
indicated in arbitrary units. 2N. unreplkated DNA; 4N fully replical~d DXA. 
cycle. For this study, 3Sday·old embryos from CAN+/-
intercrosses were isolated and cultured ill the presence of 
bromodeoxyuridine (BrdU) until the CAN-/- embryos 
started to collapse (18-24 h). The BrdU incorporated into 
the DNA during S phase was then assessed by using 
indirect immunofluorescence with an anti~BrdU antibody. 
The embryos were also stained for DNA with a fluorescent 
marker, propidium iodide, to quantitate the total DNA 
content of their cells by image c)'toilletric measurements. 
BrdU did not affect growth and development of mouse 
embryos ill vitro. All oflhe nuclei of both control cmbryos 
(11=7; Pigure 3E) and CAN-/- embryos (11=5 embryos; 
Figure 3G) stained for BrdU, which demonstrated the 
ability of CAN-/- cells to enter and progress through S 
phase. In contrast to embryonic nuclei of controls (Figure 
3F), the vast Ill<tiority of nuclei of Ihe mutant embryos 
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stained strongly for propidium iodide (Figure 3H). Cyto-
metric quantitation of propidium iodide stained nuclei 
revealed that 75-85% of cells from CAN-/- embryos 
contained a 4N equivalent of DNA. On the other hand, 
only 10-15% of cells in CAN+/- and CAN+I+ embryos 
showed a 4N DNA contcnt: the majority of cells from the 
control embryos undergo mitosis during the 18-24 h 
culture period and therefore show a DNA content of ~2N 
(Figure 30). These results indicate thai CAN-I- cells seem 
to progress through S phase and become arrested in G2' 
As a control, we arrested cells of wild-type embryos 
(1I=16) in O2 by treating them with Hoechst 33342 
(0.15 ~Iglml, 1/=10; Tobey el 01 .• 1990), and found that 
the G1 arrest does not induce blastocyst degeneration. 
. To test whether ill vitro degeneration of murine CM'-I-
embryos is accompanied by alterations in the morphology 
of the nuclear envelope or NPCs, as has been shown in 
yeast (Doye et ai., 1994; Wente and BlobeJ, 1994; Gorsch 
et at., 1995; Li et (II., 1995), embryos from CAN+/-
intercrosses were stained with a monoclonal antibody 
(mAb414; Davis and Blobel, 1986), to O-glycosylated 
nucleoporins. Indirect immunofluorescence showed a 
punctate nuclear rim staining in all celIs of the CAN-I-
embryos for at least 6 h after the onset of blastocoel 
remission (Figure 3L). This staining pattern was indistin-
guishable from that seen in CAN+/+ and CAN+/-
embryos (Figure 3J). Moreover, there was no evidence of 
NPC clustering. We also did not observe fractionated 
nuclei, indicating that there were no apoptotic cells in 
these collapsed embryos. 
Ultrastructural examination of thin-sectioned CAN-I-
embryos (0.5 and 2 h after initiation of blastocoel remis-
sion) revealed no herniations, im'aginations (Wente and 
Blobel, 1993, 1994), or other abnormalities of either the 
nuclear envelope or the NPCs (Figure 3M and N). Together, 
these data show that CAN depletion docs not induce major 
structural changes in the nuclear envelope or the NPCs, 
and that the death of CAN-/- cells is likely caused by 
functional rather than structural deficiencies. 
Impaired NLS-mediated nuclear protein import 
We examined whether CAt\[ depletion affects nuclear 
protein import in embryonic cells by assaying the ill vitro 
import of fluorescent allophycocyanin protein (APC) 
chemically coupled to the SV40 large T NLS peptide 
(APC-NLS~ Adam e/ al., 1990). We assessed APC-NLS 
accumulation at the onset of blastocoel contraction in the 
nuclei of digitonin-permeabilized cells from CAN-I- and 
control embryos after 5 and 10 min incubations at 25°C. 
As shown in Figure 4A-D, the nuclei of both control 
and CAN-depleted embryos at the onset of blastocoel 
contraction accumulated increasing amounts of APC-NLS 
during the assay period; however, the rate of import was 
always significantly lower for the mutants (P<0.05). The 
average nuclear concentration of APC-NLS after 5 min 
incubations was 45...(j0% lower for the CAN-/- embryos 
(11=8; Figure 4B) than for the control embryos (11=8; 
Figure 4A) in the same import reaction. Import of APC-
NLS was selective because APC without an NLS did not 
accumulate in the embryonic nuclei (11=4 embryos; Figure 
41). We also analyzed nuclear import at two earlier 
stages of in \'itro culture when CMc/- embryos appeared 
morphologically indistinguishable from controls. Nuclear 
uptake of APC-NLS in mutant embryos that had been 
cultured for 12 h (1/=4) was similar to that in control 
embryos cultured for the same amount of time (data not 
shown). In contrast, after about 20 h in culture, four 
CAN-/- embryos (compare Figure 4G and H) showed 
impaired NLS-mediated protein import (24--33% less 
APC-NLS imported compared with control embryos), 
whereas seven other CAN-I- embryos still displayed 
similar import as controls (compare Figure 4E and F). 
These results show that protein import becomes defective 
shortly before the onset of blastocoel contraction. 
Recent results suggest that p97 may mediate docking 
of cytosolic import complexes to repeat-containing nucleo-
porins associated with the l\TPC (Radll e/ ul., 1995b). To 
test for abnormalities in p97 binding to CAN-depleted 
NPCs, we imlllunostained embryos derived from CAN+/-
interbreedings with a monoclonal antibody to p97 
(mAb3E9; Chi et al., 1995). We observed a strong punctate 
nuclear rim staining in the cells of tbe controls (Figure 
4J) and of the CAN-/- embryos at different stages of 
blastocoel contraction (I, 3 and 6 h after onset; Figure 
4K). It demonstrates that CAN-depleted NPCs can bind 
p97, suggesting that the p97-mediated docking of nuclear 
proteins to the .i\TPC is not solely dependent on CAN. 
We also examined the ill l'h'o localization of the nuclear 
protein DEK by using immunofluorescence with anti-
DEK antibodies (Fornerod et at., 1995). DEK localized 
to the nucleus of CAN-I- embryos stained I and 3 h after 
the onset of the blastocoel collapse (data not shown). In 
addition, we analyzed the subcellular distribution of the 
heterogeneous nuclear ribonucleoprotein AI (hnRNP AI) 
in mutant embryos at the onset of blastocoel contractioll. 
hnRNP Al plays an important role in the biogenesis of 
mRNA. It shuttles continuously between the nucleus and 
the cytosol, although it localizes predominantly to the 
nucleus (Pinol-Roma and Dreyfuss, 1992). Nuclear uptake 
of hnRNP A 1 is mediated by a 38 amino acid sequence, 
termed M9, that is distinct from classical NLS sequences, 
and also functions as an NES to mRNA export from the 
Ilucleus (Michael e/ at., 1995; Siomi and Dreyfuss, 1995). 
Using a monoclonal antibody against hnRNP AI (91-£10) 
to immunostain CAN-I- (11=5) and control embryos 
(1/=7) at the onset of blastocoel contraction, we found 
that hnRt"fP AJ localized propedy and did not accumulate 
in the cytoplasm of CAN-/- embryos (Figure 4L and NI). 
Nuclear accumulation of poly(A)+ RNA 
We next examined embryonic cells for nuclear export of 
mRNA. Subcellular localization of poly(A)+ RNA in 
mutant embryos was studied at various time points before 
and after onset of blastocoel contraction by ;11 situ hybrid-
ization with an oJigo(dT>So probe directly coupled to FITC 
(Figure 5A, C, E and G). For reference in each of the 
hybridized embryos the position of the nuclei is shown 
by double staining with propidium iodide (Figure 5B, D, 
F and H). In the cells of control embryos (11= 12), poly(A)+ 
RNA was diffusely distributed in the nucleoplasm and 
cytoplasm (Figure 5A). By contrast, in CAN-/- embryos 
(11=14) that were at the onset of blastocoel contraction or 
I to 4 h thereafter (Figure 5C), we found strong nuclear 
staining, demonstrating nuclear accumulation of poly(A) + 
RNA. As control on the speci1icity of our mRNA detection 
method, embryos pretreated with RNase were stained. 
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Fig, 4. Nuciear import of I;aryophilic substrates and subcellular distributions of p97 and hnRNP AI. (A-H) Representative nuciear protein import 
a~says on cultured blastocysts. Import of APC-r-,'LS into the nuciei of control (A and CJ and CAN-/- embI}'os at the onset of blastocoel collapse 
(after 20.5 h of culture) (0 and 0), after 5 min (A and 0), and after 10 min (C and 0) incubations in transport mixture. All four embI}'os were from 
the same import c~periment. The average nuclear concentration of APC-l\'LS was 45% lower in (8) than in (A), and 52% lower in (D) than in (CJ, 
Import of APC-NLS into the nuciei of control (E and OJ and CAN-/- embryos (F and H) cultured for 20 h (but lacking any signs of blastocoel 
collapse) incubated for 5 min in transport mixture, The average nuclear concentration of APC-NLS was similar in (E) and (F), but was 30% lower 
in (H) than in (0). (I) Repw,entative embryo incubated with APC that lacks an NLS. All embI}'os were e~amined with a com'entional 
immunofluorescence microscope and photographed under identical conditions. Not all of the fluorescent nuciei were in the $amc focal plane. Nuclei 
in the center of embryos (El, (F) and (H) that were not in focus appeared as background fluorescence. (J-K) Confoca! microscopy of embI}'os 
immunostained Ilith an antibody to p97 (mAb3E9; 2 J1gfml). p97 localized to the nuciear membrane and the c}10plasm (weak staining) of control (1) 
and CAN..J- embI}'onic cells (K; I h afler onset of bla<;tocoel remission). (1 .... ,1) Confocal images of embryos immunostained with a monoclonal 
antibody to hnRt"{P Al (mAb9HIO; 1 in 500 dilution). hnRNP Al predominantly localizC5 to the nuciei of both control (L) and CAN-/- (.\I) 
embI)'os at the onset of blastocoel contraction, UnstainC"d areas represent c)10plasmic compartments of embI)'onic cells, Abbrel'iation: b, blastocoel. 
The outline of embI}'os (8) and (I) marked by arrows, The scale bar in (M) represents 18 11m in (A-I), and 8 J1m in (J-~l). 
Typically, such embryos showed little or no cytoplasmic 
or nuclear staining (Figure 5G and H). 
We also assayed the mRNA export status at two earlier 
stages of culture, when mutants and controls were still 
microscopically indistinguishable. CAN-/- embryos 
(11=4 embryos) grown ill \'itro for 12 h, had normal 
poly(A)+ RNA distribution patterns (data not shown). Yet, 
after 20 h of culture, two out of four homozygous mutant 
embryos had begun to accumulate poly(A)+ RNA (Figure 
5E and F). This result shows that the block in RNA export 
precedes the onset of blastocoel contraction. 
Discussion 
We have demonstrated that expression of CANlNup214, 
an FXFO repeat-containing component of the NPC, is 
critical to NLS-mediated nuclear protein import and 
poly(A)+ RNA export. Radu et at, (l995b) have recently 
shown that repeat-containing nucleoporins, immobilized 
on nitrocellulose. can bind a model substrate in the 
presence of the NLS receptor and p97. This led to the 
hypothesis that bidirectional transport across the vertebrate 
NPC may require transport substrates to dock and undock 
at an array of repeat-containing nucleoporins across the 
NPC (l\'ioroianu et al., 1995a,b; Radu et at .• I 995a), 
Our finding that l\TLS-medialed nuclear protein import 
is significantly reduced in CAN-depleted embryos is 
consistent with, and provides the Hrst ill vivo support for 
this hypothesis. The residual nuclear protein uptake in 
CAN-depleted embryonic nuclei may reflect some func-
tional compensation by other repeat-containing proteins 
that are associated with the NPC. Alternatively. it may 
result from trace amounts of CAl~ in the NPCs. 
Only very few cells of the CAN-I- blastocysts divide 
during the 18-24 h of ill vitro culture. BrdU labeling 
experiments and DNA content analysis suggest that these 
cells are arrested in O2 phase of their cell cycle, Interest-
ingly, cells expressing srpl-31, a temperature-sensitive 
mutant of the Saccharomyces cerevisiae NLS receptor, 
are also defective in nuclear protein import and arrest in 
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Fig. 5. CAN depIction causes poly(A)+ RNA accumulation in 
embryonic nuclei. (A, C, E and G) Suocellular iocalila!ion of 
polyadenylated RNA in embryonic cells analYled by ill situ 
hybridization with an HTC-ra~Ied oligo(dTJ.<O probe. 
(8, D, F ;lOll H) Coincident DNA staining with propidiurn iodide. 
(A and B) W:iId·ty~ embryo (in culture for 24 h): (C and DJ embryo 
homolygous for the disrupted CAN allele, -2 h after onset of its 
blastocod remission (in culture for 24 b); (E and FJ CAN-I- embryo 
showing no signs of degeneration after 20 h in culture; (G :md H) 
wild-type embryo pretreated with RNase. Cells from this embryo 
displayed little nuclear or cytop!:>5lllk staining, BIastocods are 
denoted by h. The bar in (H) represent, 7 11m. 
the cell cycle during the 0/1\-1 phase when cultured under 
non-pemlissive conditions (Loeb et af., 1995). The Gir",! 
arrest in Slpl-3l cells presumably results from a block in 
import of nuclear protein(s) that mediate a cell cycle-
regulated wave of proteolysis that is known to trigger 
progression through 1·1 phase (Amon et af., 1994; Loeb 
et al., 1995). It is conceivable that the O2 arrest in the 
CAN~/- embryos is also induced by sensitivity of the cell 
cycle machinery to reduced nuclear protein import 
capacity. 
CAN-/- embryos not only have impaired NLS~mediated 
protein import, but their nuclei also accumulate poly(A)+ 
RNA. These hvo defects in nucleocytoplasmic transport 
coincided as CAt'/" was depleted, and may reflect a dual 
role in protein import and mRNA export, as has been 
reported for the yeast Ilucleoporin NUP49 (Doye et al., 
1994). Some temperature-sensitive NUP49 mutants are 
primarily defective in nuclear protein import, while in 
others the initial transport defect occurs at the level of 
mRNA export. A dual role for CAN in both import and 
export could be achieyed via its FXFG repeats. The FXFG 
repeats lIlay sen'e ill l'El'O as a docking site for nuclear 
import of proteins carrying a classical NLS, and they 
could also have some function in RNA export. This is 
supported by the remarkable homology between the FXFG 
repeats of CAN and those of the novel human nucleoporin-
like protein RIPIRAB (Bogerd el af., 1995; Fritz e/ al., 
1995). The FXFG repeat-containing domain of RIP/RAB 
is sufficient for binding to the'NES of HlV-I Rev in a 
yeast two-hybrid assay, which suggests that the repeats 
may function as an NBS receptor for selective export of 
viral mRNAs from the nucleus (Gerace, 1995). By the 
same token, the FXFG motif of CAN may function as an 
NBS receptor in RNA export. 
The srpl-3l mutation blocks NLS-mediated import 
without causing poly(A)+ RNA accumulation in the 
nucleus (Loeb et al., 1995). From this obsen'ation, we 
infer that a basic defect in protein uptake does not hinder 
mRNA export. It supports Ollr contention that the block 
in mRNA export may be caused by a second function of 
CAt'/" that is independent from its role in NLS-mcdiated 
protein uptake. Like a number of other nucleoporins 
(Siniossoglou et al., 1996), CAN could be part of one or 
more subcomplexes within the NPC, and its depletion 
may simultaneously lead to dissociation of one or 1Il0re 
additional nucleoporins from the NPC, for example one 
that functions directly in mRNA export or protein import. 
Just as proteins are selectively imported into the nucleus, 
RNA export must be carefully controlled. RNP particles 
nlOye from the site of transcription and assembly to 
the NPC, where they are translocated to the c)10plasm 
(Izaurralde and ivfatlaj, 1995). Nuclear accumulation of 
poly(A)+ RNA could, therefore, be an indirect con-
sequence of decreased nuclear import of proteins critical 
to mRNA export that do 110t employ the classical NLS-
mediated pathway for their transport into the nucleus. A 
prime candidate for such a protein would be hnRNP Al 
(Michael et al., 1995). We found no mislocalization of 
this protein in the cytoplasm of CAN-/- cells at a stage 
when poly(A)+ RNA was retained in the nucleus. This 
result suggests that the export defect cannot be attributed 
to the consequences of impaired hnRNP Al import. It 
remains to be seen whether Ihis observation holds twe for 
other proteins invol\'cd in the poly(A)+ RNA export 
pathway. The apparently nonnal nuclear uptake of hnRNP 
Al by cells lacking CAN suggests that the M9-mediated 
nuclear import pathway is independent of CAN. 
To conclude, CANINup214 is the first nucleoporin gene 
to be disrupted in higher eukaryotes to study its function 
in nucleocytoplasmic transport ill vim, We have shown 
that the prescnce of maternal gene products in early 
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embryogenesis permits the use of gene knockout strategies 
10 study the function of genes that arc essential for 
cell survival. 
Materials and methods 
Targeted disruption of the CAN locus In ES cells 
Vector c8.5!acZneo contained an S.5 kb Bamfll-SaR CAN !29Sv/E 
genomic fragment with an IRES-IacZneo selection cassette (Mountford 
and Smith, 1995) inserted into a unique Pl"ulI site that corresponds to 
codon 297 of the human CAN gene. Vector cS.5hyg consisted of the 
same S.5 kb genomic CAN fragment. A hyg' mmer was positioned in 
its PmII site and a herpes simplex virus thymidine kinase (HSV-tk) 
gene cassette was included for negative selection (van Deursen and 
Wieringa, 1992). VlXlor c8.5hygint is identical to cS.5hyg except that 
the hyg' marker was insertet! into an intwnic StuI site. Vixtor c12.7hyg 
consistet! of a 12.7 kb Hilldm CAN fragment (from a 129S\·/E genomic 
library) with a hyg' mmer inserted into a unique Balllfll site that 
corresponds to codon 8().1. of the human CAN gene. These targeting 
vectors were linearized and electroporated into wild.type or CAN+/-
E14 mouse ES cells, drug-resistant ES Jines isolated, and targeted clones 
identified for correct replacement events hy Southern blot analpis using 
external pro~s on EcoRV- (c8.5lacZneo: probe a), EcoRI- (cS.5hyg and 
cS.5 hygint: pro~ c) or EcoRVlCfaI-cut genomic DNA (c12_7h)'g: probe 
d) as previously descri~d (van Dem-sen and Wieringa, 1992). Mutant 
mice were generated as previously described (mn Deur;;;en et aT., 1993). 
Isolatton, culture and genotype analysis of mouse embryos 
Heterozygous mutant mice, kept on a 6 a.m. to 6 p.m_ Jight-<lark 
schedule, were mated for timet! pregnancies. The vaginal plug was 
scored at 12 p.m. which we designated 0.5 day of development (0.5 day 
postcoitum). At \·arious times of development, we collected embryos 
from the uterine horns of plugged CAN+/- female mice as described 
by Hogan el III. (1994). Blastocysts, were cultur('d in I"itra as describtd 
by Hsu (1979). 
Embryos were genotyped by PCR amplification. Individual embryos 
were transferred to Eppendorf tu~s containing I JJI sterile water, to 
which 3 JJI lysis buffer [0.05% SDS (wI\') and 0.QJ5 N NaOHJ was 
added. The samples were boiled for 3 min, and 1.5 JJI of this mLxture 
was used for PCR. Embryos at day 6.5, 7.5 and 9.5 were washed 
e.\tensiwly in PBS before being transferred to 50 JJI of PCR protK 
buffer [60 mM Tris-HC!. pH 9.0, 15 m.M INH4hS04, 2 mM MgC[l> 
0.5% 1\veen-20 ("tv) and 250 JJgfml proteinase K]. After incubation for 
5 h at 56'C, the proteinase K wa, inactivated by boHing for 10 min, 
and 3 Il[ from each sample was used for PCR. PCR cocktails containing 
primer;;; (see ~Io\\') that were diagnostic for the wild-type and lacZneo-
disrupted allele were addet!to the embryo Iysates [final concentrations, 
60 mM Tris-HCI, pH 9.0, 15 mM [[\'1I4hS04. 2 mM MgCI2, 200 JlM 
dNTPs, 250 ng of each primer, ISO ug of TaqStart antibody (ClonetlXh), 
and 0.8 unit Taq DXA pol)'merase (Perkin-Elmer Cetus)]. Samples were 
amplified for 30-35 cycles (94"C for I min, 55T for 2 min, 72'C for 
2 min), and PCR products were resolved by ekctrophoresis through 
1.5% agarose gels. The identity of the PCR fragments was confirmed 
by Southern blot analpis, using an internal CAl"" oligonucleotide (5'-
CACfCCTCGATGTAGCTGAGG-3') as a prok 
Sequences spIXifiC for the wild·type allele were amplified by using, 
anti-sense (5'-TGGAATCACTCACTGTGGITG-3': Figure lA, primer 
1) and sense (5'-GTGAACITCATGGAGCCCTG-3': Figure lA, primer 
2) primers thatllank the PI·uII site within the targeted CAN cxon (Figure 
lA). The targeted allele sequences were amplified b)' using the same 
anti-sense CAN primer in combination with a sense strand primer for 
the neo' gene (5'-TCGTGCTITACGGTATCGC-3': Flgure lA, primer 
3). These PCR fragments measure 0.\30 bp (wild-type) and 860 bp (IacZ-
disrupted), respectively_ 
Antibody purification and indirect Immunofluorescence 
Polyclonal rabbit anti-CAN antibodies directed against the N-terminal 
part of human CAN (aCr-.'N) were affinity-purifiet! hy adsorption for 
IS h at o.\"C to a bacterially produced polypooptide representing amino 
acids 363-SQ.t of human CAN (Fornerod e/ al., 1995) bound to 
Immobulon PVDF membrane (Millipore Corp., Bet!ford, MA). The 
membr.llle was washed five times with PBS containing 0.05% 1\wen-
20 (v/\'), and then washed once with PBS alone. Bound antibodies were 
eluted for 3 min at O'C in a huffer containing 100 m..\1 glycine at pH 2.5 
and 0.05% (w"') bovine serum albumin. They were then immediately 
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neutralized with 0.05 volumes of I M NaP04 at pH 7.5. The purified 
antibodies are designated aCNN76-2. 
Indirect immunofluorescence was as previously describtd (Fomerod 
et al., 1995). Antibody dilutions were 1 in 16 for aCI\'N76-2, 10 fJgfml 
for protein A-purified mAb414 (BAbCO), 2 JJgfml for mAb3E9 (Chi 
et aT., 1995), I in 1000 for aDEK {Fomerod el 01., 1995}, and I in 500 
for 9HIO (anti-hnRNP AI). Primary antibodies were visualizcd with 
FITC- or Texas red-conjugated goat anti-mousc or goat anti-rabbit 
antibodies (10 fJgfml) diluted in PBS containing 1% non-fat dry milk. 
Embryos were c.~amined by confocal laser scanning microscopy on a 
Bio-Rad ,\fRClooo. 
Electron microscopy 
Mutant and control cmbryos wue isolated from microdrop cultures and 
immediately fixed in 0.1 M phosphate buffer, pH 7.4, containing 2% 
glutaraldehyde for at Icast 12 h at 4"C. Embryo samples were then post-
fixed in 1% osmium tetroxide for I h, dehydratet!, and embedded in 
Spurr low-viscosity resin. Thin sections were cut and examined with a 
mOL JElI.I-1200EX II electron microscope_ 
BrdU Incorporation in cultured blastocysts and DNA content 
analysis 
Embryos were cultured in the presence of 20 pM BrdU for 18-20.\ h, 
and then fixed with methanol:acetone (I:\) for 10 min at room tempera-
ture (P3gano et III., 1994). After three washes with PBS, embryos were 
tre3ted with 1.5 N Hel for IO min at room temperalUre. After four 
wa,hes with PBS, embryos were inCubated with PBS containing 1% 
non-fat dry milk for 15 min, and then with anti-BrdU antibodies 
(undilutcd; Amersham, Life Science) for I h at room temperature. Anti-
BrdU antibody binding was detected with FITC-conjugated goat anti-
mouse antibodies (I in 50 dilution: Amef5ham, Life Scicnce). Embryos 
were staincd for DXA in PBS containing 100 pgfml propidium iodide 
for 60 min at room temperalUre. After three washcs in PijS, cmbryos 
were embtdded in Vectashield mounting medium, and c~amined by 
confocal laser scanning microscopy_ The DNA content of individual 
ceUs of the scanned cmbryos was detennined by cytometric quantitation 
of free-I)'ing embryonic nuclei. 
Import assay on whole mount embryos 
The ill vitro import assay was done essentiaU)' as described (Adam el al., 
1990). In brief, two (or occasionally four) embryos cultured in DMEM 
were rinsed once in tramport buffer (20 mM HEPES, pH 7.5, 110 m'\( 
potassium acetate, 5 m..\( sodium acetate, 2 m..\( magnesium acetatc, 
I mM EGTA, 2 m..\f dithiothreitol and I Ilgfml of aprotinin, 'eupeptin, 
and poopslatin), followed by permeabi1i7ation in SO ~tglml digitonin 
(Calbiochem: diluted from a 20 mgfm! stock solution in D,\[SO) in 
transport buffer on ice for 10 min. Aftcr one rinse in tramport buffer, 
the embryos were transferred to 5 JJI complete transport mixture which 
containcd 40% reticuloc)·te lysate, 250 nM APC-NI.S (Adam el al_, 
1990) or unmodified APC as negative control (Calbiochem, San Diego, 
CA), I Ul~t ATP,. 10 m:\1 creatine phosphate (Calhiochem), and 
20 units/ml creatine phosphokinase (Calbiochem) in tran'port buffer. 
Import reactions wcrc carried out in the dark for 5 or 10 min in a 
humidified chamber at room lempooralUre and tenninated hy rinsing 
briefly in tmnsport buffer. The cmbryos wefe then immediately examined 
by epilluorescence (Olympus BX50 microscopoo) and photographs were 
taken with a Kodak Royal Gold 1000 film. AI! embl)·os were photo-
graphed under identical conditions (e~po,ures of 10 s). The conl'entration 
of APC-NLS in embl)·onic nuclei was quantitated by scanning the 
photographs with a densitometer (X-Rite SIO) and deriving the \'alues 
from a standard CUf\"<,_ On average, 12-18 frce-Iying nuclei were scanned 
per cmbl)·o. We detennined the average nuclear concentration of APC-
i\'LS of each CAN-I- and control embl)·o within the same reaction and 
comparcd them. Average nuclear concentrations of APC-NLS of two 
control cmbl)'os within the same import reaction were not significantly 
different (1/== 10 reactions: P<O.05). 
In situ hybridization on whole mount embryos 
III vilm culturcd blastocysts were collected and washed with PBS. The 
embl)'os were then fixcd in 4% paraformaldehyde (in PBS) for 15 min 
at 4'C, washed thrce tillles in PBSIO.I% 1\\"een-20 (vlv; PBT), and 
permeabilized in RlPA buffer [50 m..\1 Tris-HCI, pH 8, 150 mM NaCI, 
I<::f. Nonidet P-o.\O (v/v), O.S% deoxycholate (wlv), O.I~ SDS (w/\")I. 
After three washes with PBT and one wash with 2X SSC, thc embl)·os 
wefe hybridized with an oligo(dT) pro~ directly coupled to mc as 
describtd (Ambtrg el of., (992). 
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Abstract 
The human CAN gene was first identified as a target of t(6;9)(p23;q34), associated with 
acute myeloid leukemia and myelodysplastic syndrome, which results in the expression 
of a DEK-CAN fusion gene. CAN, also called NUP214, is a nuclear pore complex 
protein that contains multiple FG-peptide sequence motifs. It exists in a subcomplex at 
the NPC with at least two other proteins, hCRM1 and NUP88. Depletion of CAN in 
knock-out mouse embryonic cells results in cell cycle arrest in G" followed by inhibition 
of nuclear protein import and a block of mRNA export. We overexpressed CAN and 
DEK-CAN in U937 myeloid precursor cells. DEK-CAN expression did not interfere with 
terminal myeloid differentiation of U937 cells, whereas CAN-overexpressing cells 
arrested in Go, accumulated mRNA in their nuclei, and died in an apoptotic manner. 
Interestingly, we found that hCRM1 and import factor p97/importin Jl colocalized with 
the ectopically expressed CAN protein, resulting in depletion of both factors from the 
NPC. Overexpression of CAN's C-terminal FG-repeat region, which contains the binding 
site for hCRM1, caused sequestering of hCRM1 in the nucleoplasm and was sufficient 
to inhibit cell growth and to induce apoptosis. These results confirm that CAN plays a. 
crucial role in nucleocytoplasmic transport and imply an essential role for hCRM1 in cell 
growth and survival. 
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Introduction 
The recurrent chromosome translocation (6;9)(p23;q34), found in acute myeloid 
leukemia (AML) and myelodysplastic syndrome, fuses together the coding regions of 
two genes, DEK and CAN (Von Lindern et aI., 1992). The resulling DEK-CAN mRNA 
encodes an in-frame chimeric protein that contains almost the entire DEK protein linked 
to the C-terminal two-thirds of CAN. DEK is a nuclear DNA-binding protein (Fu et aI., 
1997). CAN, also called NUP214, is a nuclear pore complex (NPC) component, or 
nucleoporin, and contains NPC protein-specific FG-repeat sequences (Fornerod et aI., 
1995; Kraemer et aI., 1994). Its deletion in mouse embryos results in cell cycle arrest 
in G" followed by a block in mRNA export and inhibition of nuclear protein import (van 
Deursen et aI., 1996). 
The central region of CAN contains two predicted coiled-coil domains and 
anchors the protein to the NPC. Approximately the same domain binds NUP88, a novel 
NPC component of 88 kDa (Fornerod et aI., 1996; Fornerod et aI., 1997). The 
translocation breakpoint in CAN lies in the middle of this region, and in the DEK-CAN 
fusion protein both nuclear envelope localization and NUP88 binding are disrupted 
(Fornerod et aI., 1996). DEK-CAN is nuclear and relocation of the C-terminus of CAN 
from the nuclear envelope to the nucleus may contribute to the leukemogenic potential 
of the fusion protein (Fornerod et aI., 1995).The C-terminus of CAN, consisting of 
nucleoporin-specific repeats, can direct the protein to the nucleus in the absence of the 
NPC-binding domain (Fornerod et aI., 1995). This relocation is mediated by binding of 
this part of the repeat, which is present in CAN as well as in DEK-CAN, to hCRM1, a 
recently identified human protein of 112 kDa that moves from the NPC to the nucleus 
(Fornerod et aI., 1996; Fornerod et aI., 1997). hCRM1 shows considerable homology 
to yeast CRM1, a protein required for correct chromosome structure. Its dynamic 
localization, coupled to the discovery that hCRM1 is a member of a newly identified 
family of NPC-interacting proteins, suggests that hCRM1 is a nucleocytoplasmic 
transport factor (Fornerod et aI., 1997). 
The NPC is a supra molecular structure that contains multiple copies of about 100 
different proteins. It mediates bidirectional transport of macromolecules between the 
cytoplasm and the nucleus (reviewed by Davis, 1995; Fabre and Hurt, 1994; Pant'" and 
Aebi, 1994; Rout and Wente, 1994). Karyophilic proteins contain a nuclear localization 
signal (NLS) that is recognized by the NLS-receptor, also called importin a, Srp1 p, or 
karyopherin a (Adam and Adam, 1994; Adam and Gerace, 1991; Gorlich et aI., 1994; 
Moroianu et aI., 1995a; Weis et aI., 1995). This complex docks to the cytoplasmic side 
of the NPC via p97, synonymous with importin 13 and karyopherin 13 (Chi et aI., 1995; 
Gorlich et aI., 1995; Radu et aI., 1995a). p97 binds to repeat-containing nucleoporins 
in vitro and in vivo (Iovine et aI., 1995; Kraemer et aI., 1995; Radu et aI., 1995a; Radu 
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et aI., 1995b; Rexach and Blobel, 1995). After this initial docking step, the complex is 
translocated through the pore via an energy-dependent process that is mediated by the 
small nuclear GTPase Ran and its cofactors (Melchior et aI., 1993; Moore and Blobel, 
1993). At the nuclear side of the NPC, the NLS-receptor and the substrate are released 
into the nucleoplasm, while p97 remains bound to the NPC (Gbrlich et aI., 1995; 
Moroianu et aI., 1995b). Protein and ribonucleoprotein (RNP) export from the nucleus 
also occurs via a receptor-mediated, energy-dependent mechanism and nuclear export 
signals (NESs), identified in a number of proteins, are thought to playa role in this 
process (for reviews see Gerace, 1995; Gbrlich and Mattaj, 1996; Izaurralde and Mattaj, 
1995). Importin a was recently found to be involved in the export of capped RNA 
polymerase II transcripts from the nucleus, and dissociation of the importin a-RNA 
complex into the cytoplasm is mediated by importin Jl (Gbrlich et aI., 1996). 
Depletion of nuclear pore components often leads to nucleocytoplasmic transport 
defects, grow1h inhibition and cell death. Such effects have been demonstrated for 
several yeast mutants (Doye and Hurt, 1995; Rout and Wente, 1994), and recently for 
CAN/NUP214 in the mouse (van Deursen et aI., 1996). The yeast studies have also 
shown that it is important to maintain the correct relative stoichiometry of NPC 
components, as overexpression of some components severely restricts cell grow1h 
(Davis and Fink, 1990; Wente and Blobel, 1993; Wozniak et aI., 1994). Overexpression 
of CAN and DEK-CAN in cell lines has proven to be toxic (Fornerod et aI., 1995). To 
address why overexpression of these proteins is cytotoxic and to study the effects of 
overexpression on myeloid differentiation, we introduced inducible CAN and DEK-CAN 
genes into the human myeloid precursor U937 cells. Expression of the AML-specific 
DEK-CAN protein did not affect differentiation of U937 cells, whereas overexpression 
of CAN in U937 cells arrested them in Go, caused a defect in mRNA export and 
mislocalization of hCRM1 and p97, and ultimately led to apoptosis. Overexpression of 
the hCRM1-binding domain of CAN resulted in nuclear sequestering of hCRM1 and was 
sufficient to inhibit cell grow1h and to induce cell death. 
Results 
CAN overexpression induces Go arrest and apoptosis 
To study the effects of CAN and DEK-CAN on grow1h, survival and differentiation of 
myeloid cells, we introduced inducible CAN and DEK-CAN genes into the human 
myeloid precursor U937 cells. First, we generated cell line U937T, which expressed 
tetVP16 in a tetracycline-dependent manner (Gossen and Bujard, 1992; Shackett et aI., 
1995; Vignali et aI., 1996) but maintained normal grow1h characteristics. Subsequently, 
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this clone was stably transfected with expression constructs containing HA 1-epitope 
tagged (II) CAN or DEK-CAN cDNAs under the control of the tetVP16-responsive 
promoter. Each cell line used for this study was selected from a number of clonal lines 
based on the relative expression level of the transfected gene after tetracycline 
withdrawal. 
A clone that expressed relatively high levels of IICAN upon withdrawal of 
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Figure 1. CAN-Qverexpressing ceUs are growth inhibited 
(A) Inducible expression of HA1-tagged CAN in CAN? cells grown for 24 hr in the presence of 1000, 
5, 3, 2, 1, and 0 ngfml of tetracycline, as indicated above the lanes, was assayed by Western blot 
analysis of the 6 % 80S·PAGE gel. Induced parental U937T cells serve as a negative control. Each 
lane contains lysate from 5x105 cells. The blot was probed with the anti-HA1 monoclonal 12CA5. The 
arrow indicates ttCAN protein. Lysates of cells expressing high amounts of ttCAN protein show specific 
degradation products. The sizes of molecular weight standards, run in an adjacent lane, are indicated 
on the left in kilodalton. (8) Growth curves of induced CAN? cells (e) and U937T control cells (.6.). 
Cultures were maintained in medium containing the indicated tetracycline concentrations and viability 
was measured daily by using a non*radioactive proliferation assay. The relative density was calculated 
as a percentage of the density of uninduced ceUs on day 4. Mean values of triplicates are ploUed, the 
standard deviations were below 10 %. This experiment is one of three that all gave similar results. (C) 
Cell cycle phase distribution of induced CAN? cells (upper panel) and U93?T cells (lower panel) at 1, 
2, 3, and 4 days (allowing tetracycline withdrawal was calculated from flow cytometric measurements 
of DNA content. (D) Flow cytometry profiles showing DNA fluorescence of propidium iodide*stained 
CAN? ceU nuclei at 1, 2, 3, and 4 days following withdrawal of tetracycline. This is a representative 
experiment of three, all of which gave similar results. 
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tetracycline, CAN?, was selected to study the effects on cell growth of overexpression 
of different amounts of CAN by varying the concentrations of tetracycline in the culture 
medium. tlCAN was detected by immunofluorescence staining, using the anti-HA 1 
monoclonal antibody, as early as 10 hr after induction and reached maximal levels after 
-24 hr (data not shown). Western blot analysis showed that low concentrations of 
tetracycline in the culture medium (1 and 2 ng/ml) allowed expression of intermediate 
levels of tlCAN, whereas complete absence of tetracycline caused greater amounts of 
tlCAN to accumulate (Fig. 1A). In the presence of 3 ng/ml tetracycline, tlCAN was 
barely detectable on Western blot, whereas no protein was detected in Iysates from 
cells cultured at higher tetracycline concentrations. The growth curves of induced and 
uninduced CAN? cells showed that growth inhibition was directly proportional to the 
A B c 
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Figure 2. Overexpression of CAN induces Go apoptosis in U937T cells 
(A) Agarose gel electrophoresis of DNA from CAN7 cells cultured for three days in the absence of 
tetracycline (lane 3) showed internucleosomal DNA cleavage, whereas DNA from the parent U937T 
cells grown in the presence (lane 1) or absence (lane 2) of 1 jJg/ml tetracycline remained 
unfragmented. Pst1·digested A DNA served as a molecular weight marker (lane M). (8) Electron 
micrographs showing apoptotic CAN-overexpressing CAN7 cells after three days of induction. The bar 
represents 2 ~m. (C) Northern blot analysis of 15 ~g RNA isolated from the total culture (lane 1) and 
the FACS-sorted diploid cell fraction (lane 2) of CAN? cells induced for 40 hr, compared to the total 
cultures of un induced CAN7 cells (lane 3) and induced parental U937T cells (lane 4). The amounts of 
c·myc (2.4 kb; upper panel), and cycHn D2 (6.0 kb; middle panel) mRNA were compared to the levels 
of actin mRNA (2.0 kb; lower panel). 
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amount of expressed ttCAN and inversely proportional to the tetracycline concentration 
in the medium (Fig. 1 B). Like the parental U937T cells, the uninduced CAN? cells 
continued to grow with a doubling time of about 24 hr, whereas cells expressing the 
highest levels of ttCAN (0 and 1 ng tetracycline/ml) stopped growing and their numbers 
were reduced after three days. Under conditions that gave expression of intermediate 
levels of ttCAN protein (2 ng/ml tetracycline), we observed some increase in cell 
number, albeit at a significantly lower rate than without induction. 
To examine if fully induced CAN? cells arrested at a particular phase of the cell 
cycle, we studied the DNA content of the overexpressing cells by FACS analysis of 
propidium iodide-stained nuclei (Fig. 1C and D). After two days of CAN induction, the 
percentage of cells in S phase was reduced from 13 % to 4 %, and the percentage of 
cells in G2/M from 50 % to 23 %. The percentage of cells with a diploid DNA content 
was increased from 35 % to 6? %, suggesting that the cells had arrested at G,IG, . At 
this time point very few cells were scored with a sub-G, DNA content (see below). By 
day 3, however, 18 % of the cells showed a sub-G, DNA content and this fraction 
increased to 62 % by day 4 after tetracycline withdrawal (Fig. 1 C, upper panel). The 
increase in the percentage of hypodiploid nuclei in ttCAN-overexpressing cells indicated 
that the cells became apoptotic (Nicoletti et aI., 1991). Moreover, the cells displayed 
morphologic features of apoptosis, including DNA fragmentation (Fig. 2A), nuclear 
segmentation, and chromatin condensation (Fig. 2B). Cells also stained positively with 
the terminal-deoxy1ransferase-mediated deoxyuridine triphosphate-biotin nick end-
labeling (TUNEL) method (Gavrieli et aI., 1992), which detects double strand DNA 
breaks that are indicative of apoptosis (data not shown). U937T cells grown in the 
absence of tetracycline continued to cycle normally. They reached confluency by day 
4, resulting in more cells in G,IG, and fewer cells in Sand G,IM. In contrast to ttCAN-
overexpressing cells, the percentage of cells with a sub-G, DNA content remained low, 
between 2 % and 4 % (Fig. 1C, lower panel). 
To determine if CAN-arrested CAN? cells were blocked in G, or G" we studied 
their c-myc mRNA expression levels. Cycling cells express high levels of c-myc mRNA, 
whereas cells that exit the cell cycle and arrest in G, do not transcribe c-myc (Kelly and 
Sieben list, 1986). CAN? cells were induced in the absence of tetracycline for 40 hr, and 
RNA was isolated from the total culture and from cells sorted for a diploid DNA content. 
RNA from total cultures of uninduced CAN? cells and parental U937T cells was isolated 
to serve as a control. Northern blot analysis showed a dramatic decrease in the amount 
of c-myc mRNA in the ttCAN expressing cells compared to that expressed in uninduced 
cells. The low level of c-myc mRNA in the total culture was derived from the fraction of 
cells that remained cycling, since the sorted diploid cell fraction was negative for c-myc 
mRNA (Fig. 2C, upper panel). A similar, albeit smaller, reduction was observed in the 
amounts of cyctin O2 mRNA (Fig. 2C, middle panel), which is normally present 
throughout the cell cycle (Sherr, 1996). The more rapid downregulation of c-myc could 
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be caused by the very short half-life of c-myc mRNA (Waters et aI., 1991).These data 
strongly suggest that, prior to apoptosis, the ttCAN-overexpressing cells exited the cell 
cycle and arrested in Go. 
Bcl-X, co-expression does not prevent apoptosis 
BcI-XL' a member of the Bcl-2 family, can protect cells against a variety of apoptosis 
inducers (Boise et aI., 1993; Gonzalez-Garcia et aI., 1995; Gottschalk et aI., 1996). We 
examined whether constilutive co-expression of the BcI-XL gene with t1CAN in CAN7 
cells could inhibit CAN-induced apoptosis. A representative stably transfected CAN7 
clone, CAN7 -B2, expressed high levels of Bcl-X, protein (Fig. 3A) and grew slower than 
the parental CAN7 clone (Fig. 3). This could be a direct consequence of Bcl-X, 
expression, since Bcl-2 expression has been shown to prolong the G, phase in U937 
and other cell lines (Borner, 1996). Bcl-X, expression had no influence on growth 
inhibilion or cell death after tetracycline was removed from several independent CAN7-
Bcl-X, clones (Fig. 3), indicating that BcI-X, could not inhibit the apoptotic cell death of 
induced CAN7 cells. 
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Figure 3. Bcl~XL co-expression does not rescue CAN-overexpressing cells 
Growth curves of a representative Bcl~Xl-overexpressing CAN? clone, CAN?-B2 (+), compared to 
CAN? (e), both grown in 1000, 2 and 0 ngfml tetracycline for four days. Mean relalive density values 
of triplicale cullures are plaited against time. the standard deviations were below 10 %. This experiment 
is one of three, all of which gave similar results. Inset: Western blot of a 9 % SDS-PAGE gel 
containing lysate from 5x105 cells per lane, probed with a mouse monoclonal antibody to Bel-Xl' The 
29 kDa doublet represents the BcI-XL protein. The position of the 28 kDa molecular weight standard 
is indicated on the right. 
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Transport defects in CAN-overexpressing cells 
We studied the subcellular localization of CAN in induced and uninduced cells by 
indirect immunofluorescence with the polyclonal CAN antiserum aCNC (Fornerod et aI., 
1995). In the parental U937T cells, endogenous CAN levels were low and the protein 
localized to the nuclear envelope (Fig. 4A). During the first day after tetracycline 
withdrawal, ttCAN in CAN? cells mainly localized to the nuclear envelope and 
cytoplasmic speckles. The latter structures could be annulate lamellae or simply 
aggregates of insoluble protein (Fig. 4B). However, during the second day after 
induction, an increasing percentage of cells showed nuclear localization of ttCAN and, 
by the third day, 90% of the cells had ttCAN in the nucleus (Fig. 4C). The nuclear 
staining was diffuse, with a few strong dots. These results demonstrate that the loss of 
cell viability upon 
ttCAN overexpression 
coincides with the 
accumulation of 
ttCAN in the 
nucleoplasm. 
Because CAN 
is a nucleoporin, we 
asked whether the 
cytotoxity of its 
overexpression 
coincided with 
perturbations in its 
NPC transport 
function. We 
measured the nuclear 
export capacity of the 
ttCAN-overexpressing 
cells by monitoring 
the localization of 
polyadenylated RNA 
by in situ 
hybridization with an 
oligo(dT)" probe 
directly coupled to 
FITC (Amberg et aI., 
1992). Forty-eight 
hours after 
Figure 4. Polyadenylated RNA export defect in CAN-overexpressing cells 
Confocal images of endogenous CAN expression in U937T cells (A) and 
overexpressed CAN in CAN7 cells 20 hr (8) and 48 hr (C) after induclion, 
stained with the anti-CAN antiserum aCNe. Subcellular localization of 
polyadenylaled RNA in conlrol U937T cells (0) and CAN7 cells afler 
48 hr (E) and 60 hr (F) of induclion analyzed by in situ hybridizalion wilh 
an FITC-conjugated oligo (dT)" probe. 
Chapter 3 CANINUP214 overexpression interferes with nuclear transport 69 
tetracycline withdrawal, poly(A), RNA in both U937T cells (Fig. 4D) and in CAN? cells 
(Fig. 4E) appeared to be diffusely distributed throughout the nucleoplasm and 
cytoplasm. In contrast, 56-60 hr after UCAN induction only CAN? cells showed strong 
nuclear staining, indicating nuclear accumulation of poly(A)' RNA (Fig. 4F). At this time 
point, most cells were still alive and arrested in Go. As a control, we induced apoptosis 
by culturing U937T cells for 48 hr in the presence of 50 Ilglml of the protein synthesis-
inhibitor cycloheximide. In this case, apoptosis was not preceded by mRNA 
accumulation in the nucleus (data not shown), suggesting that the block in mRNA 
export observed CAN? cells was specific for CAN overexpression. 
The nuclear protein import capacity of induced CAN? cells was assessed in vitro 
by examining the accumulation of an NLS-linked fluorescent substrate, APC-NLS, in the 
nuclei of digitonin-permeabilized cells (Adam et aI., 1990). After 24 hr of tetracycline 
withdrawal, UCAN-overexpressing CAN? cells showed an import capacity similar to 
U937T cells, whereas CAN? cells that had been induced for 48 hr did not appreciably 
import APC-NLS (not shown). These results indicated that the inhibition of nuclear 
protein import in CAN-overexpressing cells coincided with the cell cycle arrest. 
Therefore, we compared the import capacity of CAN? cells two days after tetracycline 
withdrawal with U937T cells that had reached their maximal density four days after 
seeding. In both cultures almost ?O % of the cells were arrested with a diploid DNA 
content (Fig. 1 C). Unexpectedly, we could not detect NLS protein import in the density-
arrested U937T cells either, which makes it impossible to distinguish between cell cycle 
arrest and CAN overexpression as the primary cause for the import defect. 
Inhibition of nucleocytoplasmic transport may be caused by gross structural 
alterations in the NPC or nuclear envelope or by functional perturbation. Thin section 
electron microscopy did not reveal structural perturbations of the NPC or nuclear 
envelope in CAN-overexpressing CAN? cells after 3 days of induction (data not shown). 
Therefore, we assessed whether the toxicity of excess CAN resulted from functional 
inactivation of CAN-interacting proteins. hCRM1, a recently identified protein that co-
immunoprecipitates with CAN, localizes to the nuclear envelope and the nucleus in 
normal cells and is thought to have a nuclear transport function (Fornerod et aI., 199?). 
We used immunopurified polyclonal antiserum to detect hCRM1 (Fornerod et aI., 199?) 
in combination with a monoclonal antibody, 12CA5, to the HA 1-epitope to detect UCAN 
in double immunostaining experiments. Strikingly, we found that hCRM1 colocalized 
with overexpressed CAN in the nuclear envelope, cytoplasm, and nucleus of CAN? cells 
(Fig. 5A and B). In cells that expressed CAN in both cytoplasmic and nuclear speckles, 
hCRM1 preferentially colocalized with the nuclear structures (cell indicated by arrow in 
Fig. 5A and B). The accumulation of ttCAN in the nucleus of CAN? cells after three 
days resulted in colocalization of hCRM1 in the nucleus and depletion of this factor from 
the nuclear envelope. We then studied the localization of the transport factor 
p9?limportin p, which binds to CAN and other FG-repeat containing nucleoporins in 
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vitro and localizes to the NPC and cytoplasm (Chi et aI., 1995; Gorlich et aI., 1995; 
Radu et aI., 1995a). We immunostained induced CAN7 cells with a monoclonal 
antibody to p97 (Chi et aI., 1995) and aCNC, and found that p97 colocalized with 
ectopically expressed CAN protein in the nuclear envelope and the cytoplasmic 
speckles. Two days after IICAN induction, colocalization also occurred in the nucleus, 
which resulted in depletion of p97 from the nuclear envelope (Fig. 6A and 8). 
Expression of DEK-CAN and CAN mutants in U937 cells 
To map the region of CAN that mediated cycle arrest and apoptosis, we studied the 
response of U937T cells to induced expression of CAN mutants and the leukemia-
specific DEK-CAN fusion protein (Fig. 7). Clones were selected for high expression after 
induction, however, some mutants, including DEK-CAN, did not reach the expression 
levels of IICAN (Fig. 8A). Most of the mutants described in this study were analyzed 
previously for subcellular localization and co-immunoprecipitating proteins in transient 
transfection studies (Fornerod et aI., 1996). The N-terminus of CAN (CAN 1-1058) and 
a shorter central region (CAN 589-1058) both associate with the NPC and bind NUP88. 
Expression of these mutants did not affect cell growth or viability (Fig. 88). However, 
expression of C-terminal regions of CAN, such as CAN 816-2090, which localizes to the 
NPC, cytoplasm, and nucleus, and the nuclear mutant CAN 1140-2090, inhibited cell 
growth (Fig. 88). This effect could be attributed to overexpression of the most C-
terminal FG-repeat-containing region (CAN 1864-2090), that was sufficient for the lethal 
phenotype (Fig. 88). Importantly, this part of CAN harbors the hCRM1-binding domain. 
DNA histogram analysis (Fig. 8C and D) of induced CAN 1864-2090 cells showed that 
two days after tetracycline withdrawal the percentage of cells in S phase was reduced 
from 50 % to 25 %, and the percentage of cells in GJG, had increased from 36 % to 
58 %. The percentage of cells with a sub-G, DNA content was 27 % after three days 
of induction, and 40 % after four days (Fig. 8C). This demonstrates that overexpression 
of the hCRM1- binding region is sufficient to cause cycle arrest and cell death. The 
Figure 5. Coloealization of full-length CAN and CAN mutants with hCRM1 
Subcellular distribution of hCRM1 and CAN proteins aner two days of induction. (A, C, E, G, I, and K) 
Confocal microscopy showing immunodetection of induced CAN and mutant proteins by an anti-HA 1 
monoclonal antibody followed by a goat anti-mouse Texas Red-conjugated secondary antibody. (8, D, 
F, H, J, and L) Distribution of endogenous hCRM1 in the same cells stained with the a-hCRM1 
antiserum and a goat anti-rabbit FITC-linked antibody. hCRM1 colocalized with full-length CAN (A and 
B), with the C-terminal FG-repeat regions of CAN, CAN 1864-2090 (C and D) and CAN (1140-1340, 
1864-1912, 1984-2090) (E and F), and wilh DEK-CAN (I and J). In contrast, hCRM1 did not eoloealize 
with the more N-terminally loealed FG-repeal region of CAN, represenled by CAN 1558-1840 (G and 
H); it showed normal distribution in the nuclear membrane and the nucleoplasm, similar to that of 
induced U937T cells (K and L). 
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Figure 6. Double immunoslaining of CAN and mutants with p97/importin p 
Subcellular distribution of p97 and CAN proteins after two days of induction. (A, C, E, and G) Confocal 
images of indirect immunofluorescence with the anti-CAN polyclona! antiserum aCNe, detected with 
a Texas Red-conjugated goat anti-rabbit antibody. (8, D, F, and H) Confocal images of the same cells 
immunostained with an antibody to p97 (mAb3E9), detected with an FITC-conjugated goat anti-mouse 
antibody. Endogenous p97 colocalized with overexpressed CAN in the nuclear membrane and in the 
cytoplasmic and nucleoplasmic speckles (A and B). In cells overexpressing CAN 816-2090, only the 
nuclear membrane and the cytoplasmic speckles showed colocalizaUon of the CAN mutant with p97 
(C and D). Cells overexpressing CAN 1140-2090 showed normal p97 localization in the nuclear 
membrane (E and F), comparable to cells expressing endogenous levels of CAN (G and H). 
effect was milder than when the full-length CAN is overexpressed, possibly because of 
subtle differences in the expression levels between the two clones. CAN deletion 
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mutants that lack part of the region necessary for hCRM1 co-immunoprecipitation (CAN 
(1140-1340,1864-1912,1984-2090) and CAN 1864-2017), still localized to the nucleus, 
and exhibited the lethal phenotype albeit at considerably higher expression levels (Fig. 
8A and 8). The FG-repeat-containing region just N-terminal of the hCRM1-binding 
region (CAN 1558-1840), was cytoplasmic and did not affect cell growth (Fig. 88). The 
highest inducible DEK-CAN clone, DEK-CAN58, expressed only about 25% of the 
amount of CAN protein produced in CAN7, as estimated by Western blot analysis (Fig. 
8A). This clone was slightly growth inhibited, but did not die from apoptosis (Fig. 88). 
Double immunofluorescence staining studies of CAN mutants (Fig. 5, left panel) 
with hCRM1 (Fig. 5, right panel) showed that endogenous hCRM1 colocalized with CAN 
816-2090 in the cytoplasm and in the nucleus (not shown). The endogenous hCRM1 
also colocalized with the hCRM1-binding domain (CAN 1864-2090) in the nucleus (Fig. 
5C and D). The nuclear mutants CAN (1140-1340, 1864-1912, 1984-2090) (Fig.5E and 
F) and CAN 1864-2017 (not shown), which both lack part of the hCRM1-binding domain 
that is required to co-immunoprecipitation hCRM1 (Fornerod et aI., 1996), still caused 
redistribution of hCRM1 to the nucleus. In contrast, CAN 1558-1840, which also does 
not coprecipitate hCRM1 (Fornerod et aI., 1996), did not colocalize with hCRM1 (Fig. 
5G and H) nor did it influence cell growth. Although DEK-CAN levels were not high 
enough to induce cell death, the staining patterns of DEK-CAN and hCRM1 were 
overlapping in high-expressing cells (Fig. 51 and J). Taken together, all (partly) nuclear 
CAN mutants colocalize with hCRM1, suggesting that the region of CAN needed for in 
vivo interaction with hCRM1 is smaller than the hCRM1-binding domain identified by co-
immunoprecipitation. High expression levels of these mutants resulted in depletion of 
hCRM1 from the nuclear envelope, which coincided with growth inhibition and cell 
death. These data suggest that nuclear sequestration inhibits an essential transport 
function of hCRM1. 
We studied the distribution of endogenous p97 (Fig. 6, right panel) in cells 
expressing CAN mutants (Fig. 6, left panel) and found colocalization of p97 with CAN 
816-2090 in the nuclear envelope and the cytoplasmic speckles. Cells expressing this 
CAN mutant in nuclear speckles showed a normal p97 distribution (Fig. 6C and D). 
Expression of DEK-CAN (not shown) or CAN 1040-2090 (Fig. 6E and F) did not affect 
p97 localization, indicating that sequences in CAN's central region mediate this effect. 
Poly(A)' RNA in clones expressing DEK-CAN or the C-terminus of CAN was 
diffusely distributed in the nucleoplasm and cytoplasm, indicating that there was no 
defect in mRNA export in these cells (not shown). Thus, it is unlikely that hCRM1 is 
involved in export of mRNA. Digitonin-permeabilized cells overexpressing the hCRM1-
binding domain were severely inhibited in APC-NLS import, comparable to CAN-
overexpressing cells and density-arrested U937T cells (not shown). Therefore, a 
possible additional effect on import of hCRM1 sequestering in the nucleus could not be 
determined. 
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Figure 7. Overview of CAN deletion mutants 
Black bars represent CAN and CAN mutant proteins, numbers on the left represent amino acid 
boundaries. Predicted structural motifs are represented as follows: Vertical lines, FG repeats; 
Diamonds, FXF repeats; LZ, leucine zipper; AH, amphipathic helix. Horizontal stripes indicate an acidic 
region in the DEK sequence (white bar). 
DEK-CAN does not inhibit differentiation of U937 cells 
To study the effect of OEK-CAN on myeloid maturation we induced clone OEK-CAN58 
to differentiate by using a combination of transforming growth factor 131 (TGFf31) and 
1,25 dihydroxy vitamin 0, (03) (Testa et ai., 1993) after three days of withdrawal from 
tetracycline. Surprisingly, the cells died rapidly (Fig. 9A). Immunofluorescence staining 
showed elevated levels of OEK-CAN in these cells compared to undifferentiated cells 
(not shown). We consistently found this effect, even when differentiation was induced 
by other chemicals, such as dimethyl sulfoxide (OMSO) and phorbol12-myristate 13-
acetate (PMA). We, therefore, tried partially releasing the OEK-CAN58 cells for three 
days in the presence of 5 and 10 ng/ml tetracycline prior to inducing differentiation. Both 
partially induced and uninduced cells ceased to proliferate upon exposure to TGFf31 
and 03 (Fig. 8A). Compared to uninduced cells (1000 ng/ml tetracycline), viability was 
not affected in cells cultured with differentiation agents in 10 ng/ml tetracycline, whereas 
about 50 % of the cells grown in 5 ng/ml tetracycline died. The remaining cells in these 
cultures expressed high levels of OEK-CAN. 
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Figure 8. The C-terminus of CAN is sufficient to inhibit cell growth 
(A) Western blot analysis of 6 % (left panel) and 10 % (right panel) SDS-PAGE gels with Iysates from 
5x10' induced cells expressing the indicated CAN mutants and DEK-CAN. CAN (1140-1340,1864-
1912,1984-2090) is abbreviated to CAN 1864-1912+1984-290. Blots were probed as described for Fig. 
1A. (8) Gro'Nth curves of cells overexpressing selected CAN mutants and DEK-CAN grown in the 
absence of tetracycline for four days. Data shown are the mean values of triplicate cultures from 
one experiment of at least three independent experiments that gave similar results. (C) Cell cycle phase 
distribution of induced CAN 1864-2090 cells. (D) DNA content was quantitated by flow cytometric 
analysis in CAN 1864-2090 cells, overexpressing the hCRM1-binding domain, at day 1, 2, 3, and 4 after 
withdrawal of tetracycline. 
DEK-CAN58 cells grown in 5 and 1000 ng/ml tetracycline were induced to 
differentiate by a 5-day exposure to TGFp1 and D3. As a measure for induction of 
differentiation, we monitored the increased expression of the cell surface antigens 
CD11a, CD11b, CD14, and CD18. The enhanced expression of these markers 
indicated that DEK-CAN-expressing DEK-CAN58 cells (Fig. 88, right panel) 
differentiated normally to mature monocy1es in a manner indistinguishable from 
tetracycline-repressed DEK-CAN58 cells (Fig. 88, left panel). Moreover, Giemsa-
staining of the two differentiated cell populations showed the same morphology (not 
shown), confirming that DEK-CAN expression did not inhibit the myeloid differentiation 
of U937 cells. 
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Discussion 
We examined the biologic properties of the CAN protein and the leukemia-specific 
DEK-CAN fusion protein by overexpressing these proteins in U937 myeloid precursor 
cells. We found that ectopic expression of CAN caused a cell cycle arrest in Go, 
followed by a block in mRNA export and apoptotic cell death. Overexpression of the 
most C-terminal FG-repeat-containing region of CAN, which binds hCRM1, was 
sufficient to reproduce most of these effects: it induced growth arrest and apoptosis. 
Thus, overexpression of CAN and the hCRM1-binding domain of CAN interfered with 
some of CAN's normal functions in a dominant-negative way. Moderate DEK-CAN 
expression slightly inhibited cell growth and did not interfere with the differentiation of 
U937 cells to mature monocytes. Because U937 cells represent an intermediate stage 
of monocytic development (Hilfinger et aI., 1993), it is possible that their terminal 
differentiation is not affected because DEK-CAN may only inhibit differentiation of 
earlier myeloid precursors. Myeloid cells from patients with t(6;9) acute myeloid 
leukemia are partially inhibited in their differentiation pathways but are not totally 
blocked. Therefore, it is also possible that DEK-CAN has no effect on differentiation but 
affects proliferation of early precursor cells in t(6;9) patients. 
CAN overexpression induces cell cycle arrest and apoptosis 
CAN-overexpressing cells, and to a lesser extent cells overexpressing the hCRM 1-
interaction domain of CAN, accumulated with a diploid DNA content. Arrested CAN-
overexpressing cells no longer express c-myc, a proto-oncogene that is continuously 
expressed in proliferating cells but is downregulated when cells exit the cell cycle 
(Freytag, 1988; Waters et aI., 1991). U937T cells that were mostly arrested in G,JG, 
after reaching their maximal density, did not import detectable levels of import 
substrate. Therefore, additional effects of the overexpression of CAN and the hCRM 1-
binding domain on nuclear protein import could not be measured. It is possible that 
CAN overexpression interferes with the nuclear transport of factors critical to cell growth 
or survival. Alternatively, proper stoichiometry of the components that make up the NPC 
could be necessary for the formation of new NPCs, a process that is presumably 
essential for growth. CAN depletion leads to cell cycle arrest in G, (van Deursen et aI., 
1996), whereas overexpression of CAN arrested cells in Go, suggesting that CAN is 
essential to proper cell cycle progression. Furthermore, CAN-depleted cells still have 
hCRM1 in their nuclear envelope (Fornerod et aI., 1997), whereas the nuclear envelope 
of CAN-overexpressing cells is depleted of hCRM1 (see below). It will be interesting to 
see how the transport function of hCRM1 could be linked to cell cycle progression. 
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Cells overexpressing full-length CAN or CAN mutants containing the hCRM1-
binding domain die after 72 to 96 hr of induction, and show morphologic features of 
apoptosis. Co-expression of the potent survival factor Bcl-XL did not protect CAN-
overexpressing cells from apoptosis, suggesting that a non-Bcl-XL-controlled pathway 
is activated. 
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Figure 9. Differentiation antigen expression in U93?T ceUs expressing DEK-CAN 
(A) Growth CUNes of DEK-CAN58 cells cultured in medium containing 1000 (II), 10 (Ao), 5 (V) or 0 (e) 
ng/ml tetracycline, seeded at 1x105 cells/ml in the presence (differentiated) or absence 
(undifferentiated) of 1 ngfml TGFp1 and 250 ngfml 03. The cells were cultured in normal medium 
containing the indicated tetracycline concentrations for three days prior to the induction of 
differentia!ian. (B) DEK-CAN58 cells cultured in 1000 ng/ml tetracycline (no DEK-CAN expression) and 
5 ng/ml tetracycline (partial DEK-CAN induction) were differentiated in medium containing TGFp1 and 
03 for five days (differentiated; black bars). Undifferentiated cells cultured in 1000 and 5 ng/ml 
tetracycline are also shown (undifferentiated; gray bars). Expression of the indicated differentatian 
antigens (CD11a, CD11b, CD14, CD15, CD18) was evaluated by cytofluarimetry using specific 
monoclonal antibodies. Results are expressed as the percentage of antigen-positive cells. 
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hCRM1 function is essential 
hCRM1, recently identified as a CAN-associating protein, is a putative transport factor 
that normally localizes to the nucleus and the NPC, and is regularly released from the 
NPC into the nucleoplasm (Fornerod et aI., 1997). CAN mutants containing the hCRM1-
binding region were, at least in part, nuclear and caused nuclear accumulation of 
hCRM1. Overexpression of these mutants at levels that were lethal, resulted in a 
complete depletion of hCRM1 from the nuclear envelope. This result suggests that the 
excess of nuclear hCRM1-binding domain competes with NPC-associated CAN for 
binding to hCRM1 and inhibits a function of hCRM1 that is essential for cell growth or 
survival. 
The localization of overexpressed full-length CAN changed from mainly nuclear 
membrane and cytoplasm after the first day of induction, to mainly nuclear during the 
second and third day of expression. Hela cells, transiently transfected to highly 
overexpress CAN, showed a similar nuclear localization in 5-10 % of the cells (Fornerod 
et aI., 1995). It may be that overexpressed CAN spills over into the cytoplasm and 
nucleus when all of the NPC binding sites are saturated. Transport of CAN into the 
nucleus could be mediated by its association with hCRM1 (Fornerod et aI., 1996). The 
colocalization of CAN and hCRM1 in cytoplasmic structures suggests that complex 
formation already occurs in the cytoplasm. Since hCRM1 has a half-life of 
approximately 24 hours (Fornerod et aI., 1997), it is unlikely that the hCRM1 observed 
in the cytoplasm of CAN-overexpressing cells is only newly synthesized hCRM1. 
Instead, these data suggest that hCRM1 travels from the nucleus to the cytoplasm, in 
addition to its release from the NPC into the nucleoplasm. In normal Hela cells, only 
a small amount of hCRM1 is present in cytoplasmic annulate lame Ilea (Fornerod et aI., 
1997). 
The region of CAN required for its colocalization with hCRM1 in the nucleus was 
smaller than the hCRM1-binding domain identified by coimmunoprecipitation (Fornerod 
et aI., 1996), suggesting that the in vivo interaction of mutants that lack part of the 
binding domain is too weak to be detected by immunoprecipitation. This finding is 
consistent with the idea that nuclear localization of the C-terminal repeat region of CAN, 
which does not contain a known NlS, is mediated by hCRM1 (Fornerod et aI., 1996). 
As yet, we do not have clues regarding the transport substrate of hCRM1. All we can 
say with certainty is that it is not essential for mRNA export. The hCRM1-binding 
domain overexpressing U937 cells should provide a good model to investigate potential 
substrates. 
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CAN overexpression induces defects in p97 localization and mRNA export 
Overexpressed CAN colocalized with the nuclear import factor p97/importin p, initially 
in the nuclear membrane and cytoplasmic structures, and subsequently in nuclear 
structures. p97 binds to CAN in vitro (Radu et aI., 1995a), but this interaction is not 
strong enough to mediate co-immunoprecipitation with CAN from ceillysates of CAN-
overexpressing cells (Fornerod et aI., 1997). Based on binding studies to NUP98 
mutants and other nucleoporins, the FG-repeat-regions are thought to harbor the p97-
binding domain (Moroianu et aI., 1995b; Radu et aI., 1995b). Our results with CAN 
1558-1840 and CAN 1864-2090 show that p97 does not bind to the overexpressed C-
terminal CAN repeat regions alone. Instead, p97 colocalizes with full-length CAN and 
partly with CAN 817-2090, both of which bind to the NPC and form structures of 
unknown composition upon overexpression. It is possible that p97 associates in vivo 
also with the central region of CAN, either directly or via another protein, and that 
binding of p97 to CAN requires both additive interactions. 
Only cells overexpressing full-length CAN demonstrated a defect in 
polyadenylated RNA export after 55-60 hr of induction. These were also the only cells 
to sequester p97 in their nuclei. These observations may be directly linked because 
depletion of p97 from the cytoplasm may lead to a block in importin a import into the 
nucleus, thereby inhibiting its function in the export of capped RNAs (Gorlich et aI., 
1996). Studies in yeast cells overexpressing the nucleoporin gene NUP116 also 
suggest that p97 plays a role in mRNA export. Overexpression of the GLFG-repeat 
region of Nup116p severely inhibits cell growth and blocks polyadenylated RNA export 
(Iovine et aI., 1995). This region interacts with Kap95p, an essential yeast homolog of 
the vertebrate import factor p97, suggesting that sequestering of this factor is at least 
partly responsible for the phenotype (Iovine et aI., 1995). 
In summary, our results show that the cytotoxicity of CAN overexpression is 
caused by depletion of hCRM1 from the nuclear envelope, thereby inhibiting an 
essential function of hCRM1. Furthermore, only full-length CAN, which contains the 
central protein-protein interaction domain in addition to the C-terminal FG-repeats 
colocalizes with p97 in the nucleus and causes nuclear accumulation of polyadenylated 
RNA. 
The mechanism by which DEK-CAN contributes to leukemogenesis remains 
unknown. DEK is a sequence-specific DNA-binding protein, and DEK binding sites were 
recently identified in the regulatory regions of several early myeloid genes (Fu et aI., 
1997). DEK-CAN could exhibit altered transcriptional regulation compared with DEK, 
due to the presence of CAN sequences or proteins that associate with this portion of 
CAN, such as hCRM1. Alternatively, the redistibution of hCRM1 towards the 
nucleoplasm by DEK-CAN could interfere with the transport function of CAN and 
hCRM1. DEK-CAN is expressed at such a low level in leukemic cells, that a total 
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depletion of hCRM1 from the NPC is not to be expected, but a shift in the balance of 
nuclear hCRM1 may have an effect on hematopoietic cell growth or differentiation. 
Materials and Methods 
Expression constructs 
All expression plasmids used in this study carry sequences encoding two copies of the influenza virus 
hemagglutinin (HA1) tag at the 5' end of their open reading frames (Fornerod et aI., 1995) and are driven 
by the tetVP16·responsive promoter (Gossen and Bujard, 1992). Expression of CAN, DEK·CAN, CAN 1-
1058, CAN 586-1058, CAN 816-2090, CAN 1864-2090, and CAN 1558-1840 was directed by plasm ids 
described previously (Fornerod et aI., 1995; Fornerod et aI., 1996). CAN 1140-2090 expression was 
directed by plasmid pHA 1-Can lI1-1139 (Fornerod et aI., 1995). Construct pHA1-CAN (1140-1340, 1864-
1912, 1984-2090) was derived from pHA1-CAN (1140-1340, 1864-2090) by an in-frame deletion using 
the BamHI sites at positions 5825 and 6044 of the can cDNA. Plasmid pHA1·CAN 1864-2017 was derived 
by subcloning the region that encodes amino acids 1864·2090 from pHA1-CAN (lI1-1139, lI1341-1863) 
and inserting an oligonucleotide containing translational stops in the Pst! site at position 6145 of the can 
eDNA. A plasmid containing the murine BcI-XL eDNA driven by the SFFV L TR was kindly provided by Dr 
G. Nunez. 
Inducible gene expression in U937T cells 
The human monoblast cell line U937 (Sundstr6m and Nifsson, 1976) and its derivatives were routinely 
cultured in RPMI1640 medium supplemented with 10 % fetal bovine serum in a 37°e incubator with 5 % 
CO2 , Transfections were performed by electroporation at 0.17 kV, 960 !-IF on a Biorad Gene pulser. To 
generate cell lines inducibly expressing the proteins of interest, we used a two-step procedure. First, U937 
cells were transfected with pUHDITetVP16Puro (Vignali et al.. 1996), encoding tetVP16 under the control 
of the tetVP16-responsive promoter (Gossen and Bujard, 1992), thereby making tetVP16 expression 
tetracycline-repressible and autoregulatory (Shackett et aI., 1995). Transfected cells were selected in 
0.5 I1gfml puromycin in the presence of 1 I1g/ml tetracycline. Single clones were examined for tetVP16 
expression by RNA dot blot of cells grown in the presence or absence of tetracycline. Of the 18 clones 
examined seven showed tetracycline-controlled expression of tetVP16. Second, clone U937T was 
selected for subsequent stable transfeclion with expression constructs containing HA1-epitope tagged (tt) 
cONAs under control of the tetVP16-responsive promoter. pHA1-CAN was colransfected with the 
neomycin-selectable pMC1NeoPolyA plasmid (Stratagene), whereas all other expression plasmids were 
cotransfected with the hygromycin-selectable pGEMHyg plasmid (van Deursen et aI., 1991). Clones were 
selected and maintained in the presence of 1 I1gfml tetracycline. Independent single clones were 
examined for tetracycline-dependent expression by Western blot analysis (Sambrook et al., 1989) using 
the anti-HA 1 epitope monoclonal antibody 12CA5 (Boehringer) at 2 ~g/ml. Bound antibody was visualized 
with a peroxidase-conjugated goat anti-mouse antibody (Jackson) and chemiluminescence reagent 
(NEN) used according to the manufacturer's instructions. 
Cell growth, DNA conlenl analysis, and apoplosis 
For induction of tetracycline-controlled gene expression, cells were washed four times with 10 ml PBS and 
seeded at 105 cells/ml in complete medium containing the desired tetracycline concentration. Cell 
proliferation was measured using a non-radioactive celJ proliferation assay (Promega) according to the 
manufacturer's instructions. DNA content and cell cycle distribution were evaluated by flow cytometric 
analysis of propidium iodide-stained nuclei as described previously (Nicoletti et aI., 1991). Fragmented 
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DNA was isolated as previously described (Martin et aI., 1990) and separated on 1 % agarose gels 
containing ethidium bromide. 
Differentiation of U937 cells 
Induced DEK-CANS8 cells were cultured for five days in the presence of 1 nglml TGFpl (Promega) and 
250 ng/ml 03 (Biomol). The percentages of monocyte surface antigen~positive cells were evaluated by 
FACS analysis five days after induction of differentiation. The following mouse monoclonal antibodies were 
used: anti-CDlla, anti-CDllb (MOl), anti-CD14 (MY4), anti-CD15, and anti-CD18. 
Indirect immunofluorescence 
Cytospins of U937 cells were fixed, permeabilized, and immunostained as described (Fornerod et aI., 
1995). Primary antibodies were diluted 1 in 400 for aCNC (Fornerod et al., 1995), 2 ~glml for 12CAS, 
2 ~glml for mAb3E9 (Chi et aI., 1995), and 1 in 90 for affinity-purified a-hCRMl (Fornerod et aI., 1997). 
Bound primary antibodies were visualized with goat secondary antibodies conjugated to FITC (Sigma) or 
Texas Red (USB). Images were obtained by confocal laser scanning microscopy on a BioRad MRC1000 
using a 60x oil objective. 
Transporl assays 
In vitro nuclear protein import assays were performed essentially as described (Adam et aI., 1990), with 
MDBK lysate instead of reticulocyte lysate as a source of essential cytosolic factors. Import was allowed 
to proceed for 20 min at 2JOC, with parallel reactions on ice as controls. Immediately following import, cells 
were washed and fixed in 3 % formaldehyde for 15 min on ice. The mean fluorescence of the accumulated 
APC~NLS substrate in these cells was determined by FACS analysis. To determine the intracellular 
distribution of polyadenylated RNA, we hybridized cells on sterile cytospins with an oligo(dT)", probe 
directly coupled to FITC as described (van Deursen et al., 1996). Images were obtained by confocal laser 
scanning microscopy on a BioRad MRC1000 using a 60x oil objective. 
Electron Microscopy 
CAN7 cells were induced for 60 hr and then fixed for 2 hr in 0.1 M phosphate buffer, pH 7.4, containing 
2 % glutaraldehyde. Cells were then post~fixed in 1 % osmium tetroxide for 1 hr, dehydrated, and 
embedded in Spurr low~viscosity resin (EMS). Thin sections were cut, stained with uranyl acetate and 
lead, and examined with a JEOL JEM-1200EX II electron microscope. 
Acknowledgements 
We are grateful to Dr Dario Vignali for pUHDITetVP16Puro, Dr Gabriel Nunez for the SFFV-BcI~XL 
plasmid, Dr Jan van Deursen for the pGEMHyg plasmid, Dr John Cleveland for a c~myc probe, Dr Charles 
Sherr for a cyclin D2 probe, Dr Stephen Adam for monoclonal antibody mAB318, and Dr Maarten 
Fornerod for affinity~purjfied hCRM1 antibodies. We thank Sharon Frase and Dr Andrea Elberger for use 
of the Confocal Laser Scanning Facility, UT Memphis (funded by PHS Grant CLSM lS10RR0838S), 
Donna Davis and Dr Gopal Murti for electron microscopic studies, Dr Richard Ashmun for FACS analyses, 
Charlette Hill for secretarial assistance, and Dr. Sue Vallance for scientific editing. These studies were 
supported in part by Cancer Center CORE Grant CA~21765 and by the Associated Lebanese Syrian 
American Charities (ALSAC) of SI. Jude Children's Research Hospital. 
82 
References 
Adam, E. J. H" and Adam, S. A. (1994). Identification of cytosolic factors required for nuclear location 
sequence-mediated binding to the nuclear envelope. J Cell Bioi 125, 547-555. 
Adam, S. A, and Gerace, L. (1991). Cylosolic proteins that specifically bind nuclear tocalization signals 
are receptors for nuclear import. Cell 66, 837-847. 
Adam, S. A, Marr, R. 8., and Gerace, L. (1990). Nuclear protein import in permeabiJized mammalian cells 
requires soluble cytoplasmic factors. J Cell Bioi 111, 807-816. 
Amberg, D. C., Goldstein, A L., and Cole, C. N. (1992). Isolation and characterization of RATI: An 
essential gene of Saccharomyces cerevisiae required for the efficient nucleocytoplasmic trafficking 
of mRNA Genes & Dev 6, 1173-1189. 
Boise, l. H" Gonzalez-Garcfa, M., Postema, C. E., Ding, L. r Lindsten, T., Turka, l. A, Mao, X" Nunez, 
G., and Thompson, C. B. (1993). be/-x, a bcl-2-related gene that functions as a dominant regulator 
of apoptotic cell death. Cell 74, 597-608. 
Borner, C. (1996). Diminished cell proliferation associated with the death-protective activity of Bcl-2. J Bioi 
Chern 271, 12695-12698. 
Chi, N. C., Adam, E. J. H., and Adam, S. A. (1995). Sequence and characterization of cytoplasmic nuclear 
protein import factor p97. J Cell Bioi 130, 265-274. 
Davis, L. I. (1995). The nuclear pore complex. Annu Rev Biochem 64, 865-896. 
Davis, l. L, and Fink, G. R. (1990). The NUP1 gene encodes an essential component of the yeast nuclear 
pore complex. Cell 61, 965-978. 
Doye, V., and Hurt, E. C. (1995). Genetic approaches to nuclear pore structure and function. Trends 
Genet 11, 235-241. 
Fabre, E., and Hurt, E. C. (1994). Nuclear transport. Curr Opin Cell Bioi 6, 335-342. 
Fornerod, M., Boer, J., van Baal, S., Jaegle, M., Von lindern, M., Murti, K G., Davis, D., Bonten, J., Buijs, 
A., and Grosveld, G. (1995). Relocation of the carboxyterminal part of CAN from the nuclear 
envelope to the nucleus as a result of leukemia~specific chromosome rearrangements. Oncogene 
10,1739-1748. 
Fornerod, M., Boer, J., van Baal, S., Morreau, H., and Grosveld, G. (1996). Interaction of cellular proteins 
with the leukemia specific fusion proteins DEK~CAN and SET~CAN and their normal counterpart, 
the nucleoporin CAN. Oncogene 13, 1801-1808. 
Fornerod, M., van Deursen, J., van Baal, S., Reynolds, A, Davis, D., Murti, K G., and Grosveld, G. 
(1997). The human homologue of yeast CRM1 is in a dynamic subcomplex with CAN/Nup214 and 
a novel nuclear pore component Nup88. EMBO J 16,807-816. 
Freytag, S. O. (1988). Enforced expression of the c~myc oncogene inhibits cell differentiation by precluding 
entry into a distinct predifferentiation state in GO/G1. Mol Cell Bioi 8, 1614-1624. 
Fu, G., Grosveld, G., and Markovitz, o. (1997). OEK, an autoantigen involved in a chromosomal 
translocation in acute myelogenous leukemia, binds to the HIV~2 enhancer. Proc Nat! Acad Sci USA 
94,1811-1815. 
GavrieH, Y., Sherman, Y., and Ben~Sasson, S. A (1992). Identification of programmed cell death in situ 
via specific labeling of nuclear DNA fragmentation. J Cell Bioi 119, 493-501. 
Gerace, L. (1995). Nuclear export signals and the fast track to the cytoplasm. Cell 82, 341-344. 
Gonzalez-Garcia, M., Garcia, I., Ding, l., O'Shea, S., Boise, L. H., Thompson, C. B., and Nunez, G. 
(1995). bcl~x is expressed in embryonic and postnatal neural tissues and functions to prevent 
neuronal cell death. Proc Nail Acad Sci USA 92, 4304-4308. 
GOrlich, D., Kraft, R., Kostka, S., Vogel, F., Hartmann, E., Laskey, R. A, Mattaj, I. W., and Izaurralde, E. 
(1996).lmportin provides a link between nuclear protein import and U snRNA export. Cell 87, 21-32. 
GOrlich, D., and Mattaj, I. (1996). Nucleocytoplasmic transport. Science 271,1513-1518. 
Chapter 3 CANINUP214 overexpression interferes with nuclear transport 83 
GOrlich, D., Prehn, S., Laskey, R. A, and Hartmann, E. (1994). Isolation of a protein that is essential for 
the first step of nuclear protein import. Cell 79, 767-778. 
GOrlich, D., Vogel, F., Mills, A D., Hartmann, E., and Laskey, R. A (1995). Distinct functions for the two 
importin subunits in nuclear protein import. Nature 377, 246-248. 
Gossen, M., and Bujard, H. (1992). Tight control of gene expression in mammelian cells by tetracyclin-
responsive promoters. Proc Nat! Aced Sci USA 89, 5547-5551. 
Gottschalk, A R., Boise, l. H" Oltvai, Z. N., Accavitti, M. A., Korsmeyer, S. J., Quintans, J., and 
Thompson, C. B. (1996). The ability of bcl-x, and bcl-2 to prevent apoptosis can be differentially 
regulated. Cell Death Diff 3,113-118. 
Hilfinger, J. M., Clark, N., Smith, M., Robinson, K, and Markovitz, D. M. (1993). Differential regulation of 
the human immunodeficiency virus type 2 enhancer in monocytes at various stages of 
differentiation. J Viral 67, 4448-53. 
Iovine, M. K., Watkins, J. L., and Wente, S. R. (1995). The GLFG repetitive region of the nucleoporin 
Nup116p interacts with Kap95p, an essential yeast nuclear import factor. J Cell Bioi 131, 1699-
1713. 
Izaurralde, E., and Mattaj, I. W. (1995). RNA export. Cell 81, 153-159. 
Kelly, K., and Siebenlist, U. (1986). The regulation and expression of c-myc in normal and malignant cells. 
Annu Rev Immunol4, 317-338. 
Kraemer, D., Wozniak, R. W., Blobel, G., and Radu, A (1994). The human can protein, a putative 
oncogene product associated with myeloId leukemogenesis, is a nuclear pore complex protein that 
faces the cytoplasm. Proc Nat! Acad Sci USA 91, 1519-1523. 
Kraemer, D. M., Strambio-de-Castillia, C., Blobel, G., and Rout, M. P. (1995). The essential yeast 
nucleoporin NUP159 is located on the cytoplasmic side of the nuclear pore complex and serves in 
karyopherin-mediated binding of transport substrate. J Bioi Chem 270,19017-19021. 
Martin, S. J., Lennon, S. V., Bonham, A M., and Cotter, T. G. (1990). Induction of apoptosis (programmed 
cell death) in human leukemic HL-60 cells by inhibition of RNA or protein synthesis. J Immunol145, 
1859-67. 
Melchior, F., Paschal, 8., Evans, J., and Gerace, L. (1993). Inhibition of nuclear protein import by 
non hydrolyzable analogues of GTP and identification of the small GTPase RanrrC4 as an essential 
transport factor [published erratum appears in J Cell Bioi 124:217, 1994]. J Cell Bioi 123, 1649-
1659. 
Moore, M. S., and Blobel, G. (1993). The GTP-binding protein RanfTC4 is required for protein import into 
the nucieus. Nature 365, 661-663. 
Moroianu, J., Blobel, G., and Radu, A (1995a). Previously identified protein of uncertain function is 
karyopherin 0 and together with karyopherin P docks import substrate at nuclear pore complexes. 
Proc Nat! Aced Sci USA 92, 2008-2011. 
Moroianu, J., Hijikata, M., Blobel, G., and Radu, A (1995b). Mammalian karyopherin a1p and a2p 
heterodimers: 01 or 02 subunit binds nuclear localization signal and p subunit interacts with 
peptide repeat-containing nucleoporins. Proc Nat! Acad Sci USA 92, 6532-6536. 
Nicoletti, I., Migliorati, G., Pagliaeei, M. C., Grignani, F., and Riccardi, C. (1991). A rapid and simple 
method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry. J 
Immunol Meth 139, 271-279. 
Pante, N., and Aebi, U. (1994). Toward the molecular details of the nuclear pore complex. J Struct Bioi 
113,179-189. 
Radu, A, Blobel, G., and Moore, M. S. (1995a). Identification of a protein complex that is required for 
nuclear protein import and mediates docking of import substrate to distinct nucleoporins. Proc Nat! 
Aead Sci USA 92,1769-1773. 
Radu, A, Moore, M. S., and Blobel, G. (1995b). The peptide repeat domain of nueleoporin Nup98 
84 
functions as a docking site in transport across the nuclear pore complex. Cell 81, 215-222. 
Rexach, M., and Blobel, G. (1995). Prolein import into nuClei: Association and dissociation reactions 
involving transport substrate, transport faclors, and nuc!eoporins. Cell 83, 683·692. 
Rout, M. P., and Wente, S. R. (1994). Pores for thought: Nuclear pore complex proteins. Trends Biochem 
Sci 4, 357-363. 
Sam brook, J., Fritsch, E. F., and Maniatis, T. (1989). Molecular Cloning: A Laboratory Manual, J. 
Sambrook, E. F. Fritsch and T. Manialis, eds. (Cold Spring Harbor Laboratory: Cold Spring Harbor, 
New York). 
Sherr, C. J. (1996). Cancer cell cycles. Science 274, 1672-1677. 
Shackett, P., Difllipantonio, M., Hellman, N., and Schatz, D. (1995). A modified tetracyclin regulated 
system provides autoregulatory inducible gene expression in cultured cells and transgenic mice. 
Proc Nail Acad Sci USA 92, 6522-6526. 
SundstrOm, C., and Nilsson, K. (1976). Establishment and characterization of a human histiocytic 
lymphoma cell line (U-937). Int J Cancer 171, 565-577. 
Testa, U., Masciulli, R, Tritarelli, E., Pustorino, R, Mariani, G., Martucci, R, Barberi, T., Camagna, A, 
ValUeri, M., and Peschle, C. (1993). Transforming growth factor-beta potentiates vitamin 03-
induced terminal monocytic differentiation of human leukemic cell lines. J Immunol150, 2418-30. 
van Deursen, J., Boer, J., Kasper, L., and Grosveld, G. (1996). G2 arrest and impa·lred nucleocytoplasmic 
transport in mouse embryos lacking the proto-oncogene CANINup214. EMBO J 15, 5574-5583. 
van Deursen, J., Lovell-Badge, R., Oerlemans, F., Schepens, J., and Wieringa, B. (1991). Modulation of 
gene activity by consecutive gene targeting of one creatine kinase M allele in mouse embryonic 
stem cells. Nucl Acids Res 19, 2637-2643. 
Vignali, D. A, Carson, R. T., Chang, B., Mitller, R. S., and Strominger, J. L. (1996). The two membrane 
proximal domains of CD4 interact with the T cell receptor. J Exp Med 183, 2097-2107. 
Von Lindern, M., Fornerod, M., van Baal, S., Jaegle, M., de Wit, T., Buijs, A, and Grosveld, G. (1992). The 
translocation (6;9), associated with a specific subtype of acute myeloid leukemia, results in the 
fusion of two genes, dek and can, and the expression of a chimeric, leukemia-specific dek-can 
mRNA Mol Cell Bioi 12, 1687-1697. 
Waters, C., littlewood, T, Hancock, D., Moore, J., and Evan, G. (1991). c-myc protein expression in 
untransformed fibroblasts. Oncogene 6,101-109. 
Weis, K., Mattaj, I. w., and Lamond, A I. (1995). Identification of hSRPI alpha as a functional receptor 
for nuclear localization sequences. Science 268, 1049-1053. 
Wente, S. R., and Blobel, G. (1993). A temperature-sensative NUP116 null mutant forms a nuclear 
envelope seal over the yeast nuclear pore complex thereby blocking nucleocytoplasmic traffic. J Cell 
Bioi 123, 275-284. 
Wozniak, R. w., Blobel, G., and Rout, M. P. (1994). POM152 is an integral protein of the pore membrane 
domain of the yeast nuclear envelope. J Cell 8io1125, 31-42. 
4 The nucleoporin CAN/Nup214 binds to both the 
cytoplasmic and nucleoplasmic sides of the nuclear 
pore complex in overexpressing cells 
Judith Boer', Jan van Deursen', Huib Croes', Jack Fransen', and Gerard 
Grosveld' 
'Department of Genetics, Sf. Jude Children's Research Hospital, Memphis, 
Tennessee, USA; and 'Department of Cell Biology and Histology, Faculty of 
Medical Sciences, Nijmegen, The Netherlands 
Experimental Cell Research, in press 
Abstract 
CAN/Nup214, an essential component of the vertebrate nuclear pore complex (NPC), 
is required for proper cell cycle progression and nucleocytoplasmic transport. It is a 
member of the FG-repeat-containing family of nucleoporins and has been localized to 
the cytoplasmic face of the NPC. Indirect immunofluorescence studies with specific 
antibodies have shown that moderate overexpression of human CAN in Hela cells 
causes an increase in CAN/Nup214 levels at the nuclear envelope. Here, we 
demonstrate that in such Hela cells, CAN/Nup214 does not localize exclusively to the 
cytoplasmic side of the NPC. Cryosections, stained with CAN-specific antibodies and 
examined by electron microscopy, showed that about one-third of the gold-labeled 
NPCs were decorated at the cytoplasmic face and the remaining two-thirds at the 
nucleoplasmic face. These data indicate that both the cytoplasmic fibrils and the 
nuclear basket of the vertebrate NPC contain specific binding sites for either 
CAN/Nup214 or for its interacting proteins, Nup88 and hCRM1. Thus, it is conceivable 
that CAN/Nup214 functions in nucleocytoplasmic transport at both faces of the NPC. 
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Introduction 
The vertebrate nuclear pore complex (NPC), a -125 MDa multiprotein assembly that 
mediates bidirectipnal transport between the cytoplasm and the nucleus, is composed 
of a spoke complex embracing a central channel or transporter. A cytoplasmic ring with 
filaments emanating into the cytoplasm is attached to the spoke complex, as is a 
nuclear ring with filaments that converge to form the nuclear basket (for reviews see 
Davis, 1995; Pante and Aebi, 1993). The NPC consists of multiple copies of an 
estimated 100 different proteins (nucleoporins), including integral membrane proteins 
and peripheral proteins. A number of these nucleoporins contain multiple degenerate 
peptide motifs, that share an FG dipeptide core sequence (reviewed by Davis, 1995; 
Fabre and Hurt, 1994; Pante and Aebi, 1994; Rout and Wente, 1994). 
Protein import into the nucleus is mediated by a heterodimer comprising the 
nuclear localization signal (NlS)-receptorlimportin a, which recognizes the NlSs of 
karyophilic proteins, and nuclear import factor p97limportin p, which contacts the NPC 
(reviewed by Gorlich and Mattaj, 1996; Melchior and Gerace, 1995; Pante and Aebi, 
1996; Schlenstedt, 1996). After this first docking step, the ligand complex is imported 
via an energy-dependent process that requires the small GTPase RanfTC4 (Melchior 
et aI., 1993; Moore and Blobel, 1993). GTP hydrolysis by Ran is thought to drive the 
translocation reaction (Corbett et aI., 1995; Melchior et aI., 1995; Schlenstedt et aI., 
1995), which may involve repeated association and dissociation of import complex 
components to the NPC (Nehrbass and Blobel, 1996; Rexach and Blobel, 1995), or the 
movement of a single complex across the NPC either in discrete steps (Gorlich et aI., 
1996a), or in a sliding motion (Schlenstedt, 1996). Many FG-repeat-containing 
nucleoporins are located at distinct positions along the NPC and may form binding sites 
for transport complexes (Radu et aI., 1995a; Radu et aI., 1995b; Rexach and Blobel, 
1995). Protein and ribonucleoprotein (RNP) export from the nucleus is also a receptor-
mediated, energy-dependent process (for reviews see Gorlich and Mattaj, 1996; 
Izaurralde and Mattaj, 1995), and involves some of the same factors necessary for 
protein import (Gorlich et aI., 1996). 
The FG-repeat-containing nucleoporin CAN, also called Nup214 and p250, is 
detected exclusively at the cytoplasmic face of the NPC in Hela cells (Kraemer et aI., 
1994). In Xenopus oocytes CAN was sublocalized to the cytoplasmic filaments of the 
NPC (Pante et aI., 1994). Recently, we made a knockout mutation of the mouse CAN 
gene. Mouse embryos that lack CAN show growth arrest, followed by simultaneous 
defects in polyadenylated RNA export and protein import (van Deursen et aI., 1996). 
Further, coimmunoprecipitation experiments demonstrated that CAN is part of a 
complex with at least two other polypeptides - one of 88 kDa, and the other of 112 kDa 
(Fornerod et aI., 1996). Recently, these proteins were identified as the novel NPC 
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component Nup88 and hCRM1, a homolog of yeast CRM1 that is localized to .the NPC 
and nucleoplasm (Fornerod et aI., 1997). 
In previous studies, we found that overexpression of CAN in HeLa-derived cells 
results in an increase of this nucleoporin at the nuclear envelope (Fornerod et aI., 
1995). To examine the sublocalization of overexpressed CAN within the NPC, we have 
used ultrathin cryosections in combination with immunogold labeling techniques. 
Results 
CE490S cells can be induced to overexpress CAN because they contain the CAN 
cDNA, under the control of the tet-operator promoter (Fornerod et aI., 1995; Gossen 
and Bujard, 1992). In the presence of 1 ~g/ml tetracycline, CE490S cells express 
endogenous levels of CAN. However, if tetracycline is removed from the medium, CAN 
is moderately overexpressed, without detectably affecting cell growth or nuclear 
envelope structure. Indirect immunofluorescence studies using our polyclonal aCNN 
antiserum, which is directed against unique sequences in the N-terminus of CAN, 
Figure 1. CAN IDealizes to both sides of the NPCs of CAN-overexpressing CE490S cells 
Ultrathin cryosections were immunolabeled with polyclonal aCNN antiserum, followed by 10 nm gOld-
conjugated protein A. Selected examples of labeled NPC cross-sections are aligned with their 
cytoplasmic and nucleoplasmic sides up and down, respectively. The NPCs are indicated (np). (A) 
Localization of epitopes of N-termina[ CAN at both the cytoplasmic and nucleoplasmic sides of the 
NPC. (8) Gold decorating the nucleoplasmic side of the NPC. Magnification is 120,000 times. 
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showed that the protein is located mainly at the nuclear envelope in cells expressing 
normal CAN levels and in cells overexpressing CAN (Fornerod et aI., 1995). 
For ultrastructural localization studies, ultrathin cryosections of CE490S cells 
were first incubated with aCNN, followed by protein A complexed to 10 nm gold 
particles. In CAN overexpressing cells, gold particles decorated both cytoplasmic and 
nucleoplasmic sides of the NPCs (Fig.1). No significant label was found in the 
cytoplasm or nucleoplasm, indicating that the overexpressed protein specifically 
associated with the NPCs. Quantitation of the gold distribution in 100 nuclei showed 
that 59% of the NPCs were decorated at the nucleoplasmic side (Fig.1 B), 36% at the 
cytoplasmic side (data not shown), and 5% at both sides or in the middle (Fig.1A). The 
amount of label detected at both sides of the NPCs varied, which is probably due to the 
plane of section. Our antibo(:iy did not detect gold label in CE490S cells expressing 
endogenous levels of CAN (data not shown). 
Discussion 
Our immunoelectron microscopic studies on CAN-overexpressing HeLa cells showed 
that CAN localized to both the cytoplasmic and nucleoplasmic sides of the NPC. This 
result indicates that specific binding sites for CAN, or for its interacting proteins, exist 
on both faces of the nuclear pore. The NPCs of normal He La cells did not stain, which 
demonstrates that immunoelectron detection of CAN with our antiserum, directed 
against N-terminal CAN sequences, requires elevated levelS of the protein. In previous 
immunolocalization studies CAN is only detected at the cytoplasmic face of NPCs of 
normal HeLa cells and Xenopus oocytes (Kraemer et aI., 1994; Pante et aI., 1994). Why 
is CAN found at the nucleoplasmic side of the NPC in overexpressing HeLa cells? 
Studies on normal He La cells employed a specific antibody against C-terminal 
CAN sequences, that localized CAN to the cytoplasmic face of NPCs (Kraemer et aI., 
1994). It is conceivable that epitopes in the C-terminal part of CAN are masked 
specifically at the nucleoplasmic side of the NPC. This region may for instance interact 
with certain proteins or protein complexes in the nucleus, thereby preventing antibody 
binding. On the other hand, the levels of endogenous CAN at the nucleoplasmic side 
may be too low to detect with the C-terminal CAN antiserum. 
CAN has also been detected at the cytoplasmic fibrils of Xenopus oocyte NPCs 
with antibodies directed against the entire protein (Pante et aI., 1994). Interestingly, the 
FG-repeat-containing nucleoporin p62 is found exclusively at the nucleoplasmic face 
of NPCs of Xenopus oocyte nuclear envelopes (Cordes et aI., 1991; Pante and Aebi, 
1993); however, in mammalian liver cells, this protein localizes to both sides of the NPC 
(Cordes et aI., 1991; Guan et aI., 1995). Consequently, the sublocalization of 
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nucleoporins at the NPC may vary with cell-type or with the expression level of the 
nucleoporin. 
Altered expression levels of nucleoporins may potentially disrupt the normal 
distribution or architecture of the NPCs. However, our electron micrographs showed no 
gross alterations of nuclear envelope structure, such as herniations or NPC clustering 
(see, e.g., Wente and Blobel, 1994; Wente and Blobel, 1993). Moreover, the growth rate 
of CE490S cells was not affected, suggesting that moderately elevated CAN levels do 
not disrupt nucleocy1oplasmic transport (Iovine et aI., 1995). Finally, it cannot be 
absolutely excluded that even mild overexpression of CAN induces an artificial 
localization of the protein at the nuclear side of the NPC, without any relevance to the 
mechanism of nucleocy1oplasmic trafficking. However, the specificity of the localization 
of overexpressed CAN protein is striking: CAN is exclusively detected at the NPCs, and 
not in any other cellular compartment or structure. This argues that CAN has the ability 
to bind specifically to nucleoplasmic components of the nuclear pore complex, in 
addition to its established association with the cytoplasmic fibrils, and that mildly 
overexpressing cells could very well reinforce a normal biological situation. 
Repeat-containing NPC proteins, such as CAN, are believed to play an important 
role in transport across the NPC, but the precise function of the repeats in this process 
is unknown (Fabre and Hurt, 1994; Rout and Wente, 1994). To date, in vitro studies 
have shown that FG peptide motifs may serve as binding sites along the pore for specific 
factors carrying transport substrates (Iovine et aI., 1995; Moroianu et aI., 1995; Radu et 
aI., 1995a; Radu et aI., 1995b). Each NPC protein that has been localized to a specific 
subregion of the NPC, with the exception of p62, is confined to a specific niche either 
on the cy10plasmic or the nucleoplasmic side. Immunoelectron microscopy has 
demonstrated that RanBP2/Nup358 localizes to the cytoplasmic fibrils (Kraemer et aI., 
1994; Pant'" et aI., 1994; Wilken et aI., 1995; Wu et aI., 1995; Yokoyama et aI., 1995), 
whereas Nup153 and Nup98 are constituents of the nuclear basket (Cordes et aI., 1993; 
Pant'" et aI., 1994; Radu et aI., 1995b; Sukegawa and Blobel, 1993). These findings 
have provided the basis for several transport models in which FG-repeat-containing 
nucleoporins form a static array of docking sites that transiently interact with transport 
complexes (Gorlich and Mattaj, 1996; Radu et aI., 1995b; Schlenstedt, 1996). 
Based on our subcellular localization data it appears that CAN could interact with 
transport complexes at both sides of the NPC. CAN depletion in mouse embryos results 
in defects in both nuclear protein import and mRNA export. Therefore, a symmetric 
distribution of CAN may be important for bidirectional transport of different substrates 
through the nuclear pore. Like CAN, other nucleoporins could also localize to multiple 
sites within the NPC. In this respect, it is interesting that Cordes et al (1993) found a 
small but significant amount of Nup153 at the cy10plasmic side of the NPC of mouse 
liver cells and Xenopus nuclei that was not detected in studies where harsher fixation 
conditions were used (Cordes et aI., 1993). Alternatively, the presence of CAN at the 
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cytoplasmic and nucleoplasmic fibrils could reflect CAN's ability to move through the 
pore with the transport complex. 
It will be interesting to assess whether overexpressing other NPC proteins affects 
their sublocalizalion. The finding that some nucleoporins are present in different 
subregions of the NPC at distinct concentrations may be relevant to our understanding 
of the role of nucleoporins in nucleocytoplasmic transport. 
Materials and Methods 
Immunoelectron Microscopy. HeLa-derived cell line CE490S has been described 
previously (Fornerod et aI., 1995). Cells were grown in the presence or absence of 
1 Ilg/ml tetracycline, fixed with 2% paraformaldehyde in bicarbonate buffer (pH 7.4) for 
90 min at room temperature, and stored in 1 % paraformaldehyde in phosphate buffer 
(pH 7.3) at 4'C. Cells were scraped from the dish and pelleted in 10% gelatin. Ultrathin 
cryosectioning and immunolabeling were performed as described before (Fransen et aI., 
1991). Sections (- 100 nm) were incubated with polyclonal aCNN antiserum (Fornerod 
et aI., 1995), followed by protein A complexed to 10 nm gold particles, before being 
examined and photographed by using a JEOL JEM1010 electron microscope, operating 
at 80 kV. 
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D EK -CAN amI SET -CAN and their normal counterpart, the nucleoporin 
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The recurrent chromosomal translocation (6;9) is 
associated \\ith aClile myeloid leukemia and results in 
expression of the DEK-CAN fusion protein. This 
oncoprotcin consists of almost the entire DEK protein 
fused to the C-terminal two-thirds of the CAL'J protein. 
In milch the same way, CAN is fused to SET in a paliellt 
uith acute undifferentiated leukemia, producing a SET-
CAN fusion protein. Interestingly, CAN is associated 
\\ith the nuclear pore complex (NPC) and we recently 
established its crucial role in nllclcoc~'toplaslllic transport 
processes and cell cycle progression. As a first step in the 
biochemical analysis of the oncogenic mechanism 
associated with translocation (6j9), we set out to identify 
proteins that interact \lith CAN and its fusion proteins. 
We fonnd that hm proteins specifically co-imnlllnoprc-
cipitate \lith CAN. One had a molecular mass of 88 kDa 
protein (Ce8S) and was determined to associate \lith the 
central region of CAN that contains seyeral protein 
interaction motifs. A second protein of 112 kDa (CC1l2) 
was found to interact \lith the C-terminal nuclcoporin-
specific repeat of CAN, a region that is supposed to 
function in nucleocytoplasmic transport. CC1I2 also 
interacts nith the DEK-CAN and SET-CAN fusion 
proteins. This finding suggests that CCI12 may 
contribute an essential function to the leukemogenic 
effect of DEK-CAN and SET-CAN. 
Keywords: DEK-CAN; SET-CAN; ('(111 proto-onco-
gene; nucleoporins; acute leukemia 
Introduction 
The recurrent translocation (6;9)(p23;q34) is associated 
with human myeloid leukemia of diverse phenotype 
(Rowley and Potter, 1976; Soekarman et al., 1992). It 
is often the sole karyotypic abnormality found in the 
leukemic cells, which suggests a causative role for this 
translocation in the disease. The translocation creates a 
dek-call fusion gene on the 6p- chromosome (von 
Lindern el al., 1990, 1992a), that is predicted to encode 
a struclurally identical 165 kDa DEK-CAN chimeric 
protein in all patients analysed. This protein contains 
all but the 26 C-tenninal amino acids of DEK linked 
to the C-terminal two-thirds of CAN. In addition, we 
found that a cryptic translocation or inversion of 
chromosome 9 in a patient with acute undifferentiated 
leukemia, created a chimeric protein comprising the 
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same sequences of CAN but linked to N-terminal 
sequences of SET (von Lindern et a/., 1992b). 
The CAN protein was found to belong to a family 
of nuclear pore complex associated proteins called 
nucleoporins (Fornerod el al., 1995; Kraemer et al., 
1994). This group of proteins is thought to play an 
important role in transport of RNA and protein across 
the nuclear membrane (for review see Gorlich and 
Mattaj, 1996; Rout and Wente, 1994). In HeLa celis, 
CAN is found generally at the fibrillar, cytoplasmic 
extrusions of the nuclear pore complex (NPC) 
(Kraemer et al., 1994; Pante et al., 1994), but is also 
detected at the nuclear face upon over·expression 
(Fornerod et al., 1995, Jll and GG, unpublished 
results). CAN is also referred to as NUP214 
(Kraemer et al., 1994) or p250 (Pante el al., 1994). 
Recently, we created a CAN knockout mutation in 
the mouse (van Deursen et al., 1996) and found that 
CAN-I- embryos survive until day 4 of gestation by 
using maternal, oocyte-derived protein. At this point in 
development, the dwindling amounts of CAN become 
critical, resulting first in a G2 arrest of embryonic cells, 
followed by a detectable dccrease in nuclear localiza-
tion signal (NLS)-mediated protein import that 
coincides with a block in mRNA export. Although 
these data firmly establish a role for CAN in 
nucleocytoplasmic transport across the nuclear pore 
complex, they shed little light on CAN's contribution 
to leukemogenic transformation. 
Presently the cellular function of the DEK protein is 
not known. It is a nuclear protein that may be 
associated with chromatin (Fornerod el al., 1995). 
The SET protein is also a nuclear protein and was 
recently identified as a replication factor TAF·l 
(Nagata et al., 1995). It appears to be part of a 
growing superfamily of proteins, including the yeast 
nucleosomc assembly factor NAP! (Nagata et al., 
1995; von Lindern et al., 1992b), that specifically 
interact with B-type cyclins (Kellogg et al., 1995). How 
these features should be interpreted in the context of 
leukemogenesis remains to be established. DEK has no 
sequence homology with SET, apart from highly acidic 
regions that arc present in both proteins. 
The primary amino acid sequence of CAN contains 
several distinct motifs including 11 FXF-sequence 
repeats scattered throughout the molecule, and a 35x 
repeated FG sequence that is confined to the C-
temlinus (von Lindern et al., 1992a). Similar repeat 
sequences appear in several vertebrate and yeast 
nucleoporins (for review see Rout and Wente, 1994), 
and it has been suggested that these repeats are 
involved in protein-protein interactions that mediate 
substrate transport through the NPC (Chi et al., 1995; 
Gorlich et al., 1995; Moroianu et al., 1995; Radu et al., 
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1995a). In fact, ill w'tro studies have shown that the 
97 kDa import factor p97/importin*,8 subunit of the 
nuclear protein import complex binds to the repeat* 
containing nucleoporins NUP98, NUP153, NUP358/ 
RanBP2, and CAN (Moroianu et al., 1995; Radu et 
al., 1995b). CAN also contains a coiled-coil region and 
a leucine zipper, situated at the N-tenninal side of the 
translocation breakpoint, and a second coiled-coil 
region that flanks the breakpoint at the C-terminal 
side. These two domains are part of the central region 
of CAN that is responsible for nuclear envelope 
association (Fornerod et al., 1995), and therefore 
could mediate NPC interaction. Surprisingly, mutants 
of CAN lacking these domains are directed to the 
nucleus. The sequences mediating this relocation are 
contained within the C-terminal 227 amino acids of the 
molecule (Fornerod et al., 1995). 
The DEK-CAN and SET-CAN fusion proteins 
retain one of the central coiled-coil domains and the 
FO repeat sequences. In contrast to CAN, these fusion 
proteins are permanently located in the nucleus and 
therefore we hypothesized that permanent relocation of 
CAN sequences to the nucleus could contribute an 
essential component to their leukemogenic activity. 
Hence, proteins that would physically interact with this 
portion of CAN may conveyor contribute to the 
transforming potential of the fusion proteins. 
Recently. a second nucleoporin was found to be 
targeted by a recurrent translocation in acute myeloid 
leukemia. This translocation (7;11) creates a fusion 
between the FXFG-repeat containing part of nucleo-
porin NUP98 and the homeobox-containing C-
terminal part of HoxA9 (Borrow et al., 1996; 
Nakamllfa et al., 1996). This discovery suggests that 
the mode of action of the CAN and NUP98 derived 
fusion proteins could be related, and emphasizes the 
need for detailed molecular analyses of leukemia-
associated nucleoporins. 
Here, as a further step to addressing the contribu-
tion of CAN to leukemogenesis, we define proteins that 
co-immunoprecipitate with CAN. We also identify the 
domains in CAN that interact \vith these proteins. 
Only one of the proteins appears to bind to DEK-
CAN and SET-CAN and we believe this protein may 
be involved in the transformation process of myeloid 
precursor cells. 
Results 
Co-immWlOprecipitatioll of CAN interacting proteills 
We performed co-immunoprecipitatioll studies to 
identify CAN, DEK-CAN or SET-CAN interacting 
proteins, that could be important for their function. 
Our polyclonal CAN antisera (Fornerod et al., 1995) 
only effectively immunoprecipitated the protein in the 
presence of SDS (data not shown), thereby dissociating 
pre-existing protein complexes. We overcame this 
problem by using previously generated expression 
plasmids encoding influenza virus hemagglutinin 
(HAJ)-tagged versions of CAN and DEK-CAN 
(HAl-CAN and HAI-DEK-CAN) (Fornerod et al., 
1995). HAl-CAN and HAI-DEK-CAN were transi-
ently expressed in the HeLa derived cell-line HtTA-l 
(Gossen and Bujard, 1992) and the proteins were 
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subsequently immunoprecipitated with anti-HAl 
monoclonal 12CA5 (Wilson et al., 1984). As shown 
in Figure 1, two major proteins are co-prccipitated 
with HAl*CAN from JH-Ieucine labeled cells; one of 
112 and one of 88 kDa. A weaker band representing a 
protein of 66 kDa can also be observcd. We named 
these proteins CC112, CC88 and CC66 (for £AN £0-
precipitating protein) and found that only CCl12 co-
precipitated with HAI-DEK-CAN (Figure I) and 
HAI-SET-CAN (not shown). These data suggest that 
CCI12 interacts with the C-tcrminal part of CAN, 
\vhereas CCS8 and CC66 require sequences that are 
either disrupted by the fusion or are no longer present 
in DEK-CAN and SET*CAN. To confirm this 
interpretation, we separately expressed HA I-tagged 
versions of the N-terminal half of CAN (amino acids 
1-1058), and the C-terminal half (amino acids 1059-
2090). Indeed, the N-terminal half of CAN co-
precipitated CC8S and CC66, while the C-terminal 
part of CAN co-precipitated only CC1l2 (Figure I). 
No smaller co-precipitating proteins were detected in 
HITA-I cells (not shown). 
To ensure that expression of these co-precipitating 
proteins was not limited to HtTA-J cells, we performed 
a similar co-inununoprccipitalion experiment using 
human U937 lllonoblastic cells, engineered to express 
HAl-CAN in a tetracycline dependent manner (cell 
line U937T-C7). We cultured these cells in the presence 
of different concentrations of tetracycline to establish 
distinct expression levels of HAJ-CAN. As shown in 
Figure 2, CCI 12 and CC88 were also co-precipitated 
with HAl-CAN expressed in U937T-C7, indicating 
that, similar to CAN (von Lindern et al., J 992a), these 
proteins are expressed in multiple human cell types. 
The signal of JJS-Iabeled CC88 was relatively weak, 
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Figure I CAN co·immunopredpitating proteins in HeLa deriwd 
HtTA-1 cells. Cells were transfe<;ted with e:o;prcssion plasm ids 
encoding HAl tagged wrsions of the CAN and DEK·CAN 
proteins or CAN deletion mutants as indicated above the lane,. 
Untransfected cells arc represented in the right lane (-), 
Following metabolic labeling with eH}leucine, proteins were 
immunoprecipitated using monoclonal antibody 12CAS and 
analysed on a 6% polyacrylamide gel. Co_pre<;ipitating proteins 
arc indicated by arrows on the left. Molecular masses of standard 
proteins are indicated on the right (kDa) 
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which we found is typical for 3.1S-methionine labeling of 
this protein. Remarkably, the amount of co-precipitat-
ing cess remained morc or less constant irrespective 
of the cellular HAl-CAN concentration. In contrast, 
the amount of co-precipitated CCl12 increased 
proportionally to the amounts of HAl-CAN expw,-
sian. These data suggest that there is a fixed amount of 
cess in the cell available for co-precipitation, whereas 
there is a surplus of CC1l2 of which normally only a 
portion is bound to CAN. A co-precipitating protein 
corresponding in size to CC66 in HeLa cells was also 
seen in U937T-C7 cells. Like CC1l2, tbe amount of 
CC66 increased proportionally with the amount of 
HAl-CAN. 
Since CCl12 and cess appeared to be cellular 
proteins tbat specifically interact with nucleoporin 
CAN, they could provide important new insights into 
thc function of CAN, DEK-CAN and SET-CAN. We 
studied their interaction with CAN in detail and 
generated a collection of plasmids encoding HAl-
-220 
-107 
-69 
-46 
Figure 2 CAN co-imnlUnopredpitating proteins in human 
myeloid cell line U937T. HAl-CAN expression is tetracycline 
repressible in the stably transfected ccliline U937T-C7. Cells were 
grown in 4,6 or 10 ng/m! tetracycline (from left to right). Parental 
cell line U937T that does not express HA I-CAN is represented in 
the right lane. Follo\\ing metabolic labeling \\ith eSSjmethionine, 
proteins were immunopredpitated using monoclonal antibody 
12eAS and analysed on a 6% polyac!)'lamide gel. HAI·CAN and 
the co-precipitating proteins are indicated by arrows on the left. 
Molecular masses of standard proteins are indicated on the right 
(kDa) 
CAN deletion mutants (see Materials and mcthods). 
After transient transfection into RtTA-I cells, 3H_ 
labeled proteins wcre immunoprecipitated with 12CA5, 
and analysed on 6% 5DS-PAGE gels, Figure 3 
summarizes thc results of this analysis, 
eel12 co-precipitation 
Thc deletion analysis shows that the smallest region in 
the C-tenninal half of CAN that could mediate co-
imlllunoprecipitation of CC1l2 consisted of the C-
terminal 227 amino acids (Figure 3; CAN 1864-2090), 
This represents the C-terminal portion of the FG 
repeat of CAN. Interestingly, the N·tenninal half of 
this repeat, represented by CAN 1558-1839, was not 
able to co-precipitate CC1l2. This indicated that the 
FG repeat region of CAN is heterogenous in nature, 
an observation not made before for nucleoporin repeat 
regions. To map the CCl12 binding region within the 
last 227 amino acids, we tested additional N-terminal 
(CAN 1957-2090), C-terminal (CAN 1864-2052) and 
internal (CAN 1864-1912, 1984-2090) deletion 
mutants (Figure 3). None of these proteins was able 
to co-precipitate CC1l2, suggesting that strong CAN/ 
CC1l2 interaction requires the entire C-terminal FG 
repeat region, 
Since association with CCIl2 could represent an 
important function of CAN, DEK-CAN and SET-
CAN, we investigated naturally occurring alternative 
forms of its binding region, Screcning for alternatively 
spliced call mRNAs by RT-PCR,led us to idcntify a 
eDNA that represents a minor transcript in KG-l and 
HeLa cells that lacks the exon representing nuc1eo-
tides 5687-5843 of the call mRNA, encoding amino 
acids 1865-1916 (data not shown). At codon 1917, 
translation of the alternatively spliced ll1RNA changes 
to a difrerent reading frame that remains open until 
position 6519, 154 nucleotides downstream of the 
normal stop codon, The 224 amino acid sequence 
encoded by the alternative reading frame shows no 
significant homology to known proteins, and does not 
contain any nucleoporin repeats. When this alterna-
tively spliced form was introduced into the normal 
call eDNA, the expressed protein (CAN FSl865, sec 
Figure 3) was unable to co.precipitate CC112, 
whereas CC88 precipitation was unaffected, 
eC88 co-precipitation 
Unlike CC112, co-precipitation of Ce88 required thc 
N-terminal half of CAN (Figure I). CAN mutant 
586-1058 was still able to co-precipitate CC88, 
whereas the mutant lacking 709-1094 (CANI-708, 
1095-2090) did not, further delineating CC88 inter-
acting sequences to CAN's central region, The same 
region was previously identified to be important for 
association of CAN with the nuclear envelopc and, by 
implication, the nuclear pore (Fornerod et 01" 1995). 
We therefore wished to map this region of interaction 
in more detail. The central domain of CAN contains 
three potential protein-protein interaction domains 
(Fornerod et al., 1995; von Lindcrn et al., 1992a). A 
predicted N-terminal coiled-coil region and an adjacent 
leucine zipper are contained within amino acids 702-
774, flanked by a second, more C-tenninally located 
coiled-coil region formed by amino acids 860-887. 
Chapter 5 Analysis of CAN co-precipitating proteins 
CAN deletion Illutants that lack the N-terminal coiled-
coil and leucine zipper region, such as CAN 1-708, 
816-2090 and CAN 804-1085 failed to co-precipitate 
CC88, establishing the importance of this region for 
CC88 interaction. The same was found for mutants 
that lack (CAN 1-832) or truncate (CAN 1-877, 
Figure I) the second coiled-coil region. These data 
indicate that multiple putative interaction domains 
contribute to CC88 binding and are needed for co-
precipitation. 
To further investigate whether the N-terminal 
coiled-coil, the leucine zipper and/or the C-terminal 
coiled-coil are involved in CC88 interaction, we 
introduced point mutations in these motifs using the 
CAN Illutant 586-1085 background. In all cases, 
aliphatic amino acids in heptad repeat motifs of 
predicted a-helices were exchanged for helix-breaking 
prolincs (Figure 4a). Since proteins had been 
metabolically labeled with ;lSS-mcthionine and the 
number of methionines remained constant in these 
CAN mutants, quantitation of the ratio of radio-
activity incorporated in immunoprecipitated CAN and 
CC88 directly reflected their binding affinity. As 
shown in Figure 4b, mutation of Im-JoP strongly 
diminished co-precipitation of CC88, suggesting that 
the leucine zipper of CAN is important for CC88 
binding. By contrast, no change in the amount of co~ 
immunoprecipitating CC88 could be detected when 
prolines were introduced into the N-temlinal (l1!O-4P) 
or C-terminal (Vm-4 P) coiled-coil regions. The double 
mutation I7IO -4P+ Vm-JoP did cause a marked 
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decrease in CC88 co-precipitation. This finding IS III 
agreement with our deletion analysis; CC88 binding 
involves both the N- and C-terminal a-helical protein 
interaction regions of CAN's central domain. 
Subcellular 10calizatioJl of CAN mutallts 
The C-terminal FG-repeat region of CAN required for 
CCl12 co-immunoprecipitation (amino acids 1864-
2090) coincides \vith the region previously identified to 
confer nuclear localization of CAN mutants that do 
not associate with the nuclear pore (Fornerod et al., 
1995). Similarly, amino acids 586-1058 of CAN 
required for CC88 co-immulloprecipitation coincide 
with a region shown to be necessary and sufficient for 
nuclear pore association. To further investigate these 
apparent relations, we determined the subcellular 
localization of the CAN mutants described above by 
indirect immunofluorescence. 
Expression of the N-terminal half of the C-terminal 
FG repeat (amino acids 1558-1839; Figure 3), that did 
not eo-immunoprecipitate CC112, showed that this 
protein is located exclusively in the cytoplasm. This 
result identified the C-terminal 227 amino acids of 
CAN as both necessary and sufl1cient for nuclear 
localization, and further sustained the correlation 
between nuclear localization and CCI12 co-precipita-
tion. However, deletion mutants within the C-terminal, 
CCI 12-binding half of the FG repeat (Figure 3) were 
either completely or partially located to the nucleus, 
but did not co-precipitate CCIl2. 
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Figure 3 Mapping of domains in CAN mediating co.pnxipitation ofCCSS and cel 12 and suocellular localization. Bars represent 
CAN and CAN mutant proteins; numbers on the left represent amino acid boundaries; FS, frame-shift. The ability of mutants to 
co-immunoprecipitale cess or CCI12 is indicated by pluses and minuses on the right hand side. Suocellular localization: NE, 
nuclear envelope; C, cytoplasm; N, nucleus. Multiple localizations appear in order of prominence. Predicted structural motifs are 
represented as follows: FG repeats as vertical bars, FXF repe.lts as diamonds, ((·helical protein interaction domains as white boxes: 
(I) coiled-coil#! and adjacent leucine zipper; (2) coiled-coil#2. The cross·hatched box represents the altemati\'c reading frame in 
CAN FS1865. Horizontal stripes indicate acidic regions in the DEK and SET proteins 
98 
a 
,o. """'=~'"-'"'V.,.:r'UY.i'n.on.rn!>J.l!'Tr~'l.'''''''':,1=''' ". 
. 
710 1~ 
_Co1I«IoQiIU __ 
U~ 7L&1I'<LI'''~JiI..5:i[J;Yl)n«1..U .n 
. 
'" 
b 
m 
ro 
0 
:b 
i8 
z ~ \l; () f ~ 
+ 
"-~ 
f-CC88 
_CAN 586-1085 
84 76 86 12 2 xO.OOl 
HgUle 4 Effect of point mutations in predicted a-helical protein 
interaction domains of CAN on cess co-immunopr«:ipilation. 
(a) Amino acid sequence of the two predicted (X-helical protein 
interaction domains flanking the 1(6;9) breakpoint. Arrows are 
placed abo\'e coiled..;oil#l. the leucine zipper and coiled-coil#2. 
(Iso)leucines that form the leucine zipper are underlined. Point 
mutations introduced are indicated underneath the sequence. (b) 
HtTA·' cells were transfttled with expression plasmids encoding 
HAI·CAN 586-1085 derivative;;, carrying point mutations as 
indicated above the lanes. Untransfected cells are represented 
in the left lane (-). Fol1o\\ing metabolic labeling ..... ith 
eSjmethionine, proteins were immunopredpitated using mono-
donal antibody 12CA5 and analysed on a 6% polyacrylamide gel. 
HAl-CAN 586-1085 and CC88 are indicated by arrows on the 
right. The ratio of radioacti ... ity present in CC88 (x 1000) over 
that of CAN 586-1085 as detemlined by phosphorimager 
analysiS is shown below each lane 
Immunofluorescence analysis of the central domain 
of CAN showed that mutants that have either the N~ 
or the C~terminal predicted protein interaction 
domains intact, such as CAN 804-1085 and CAN 
1- 832, can be detected at the nuclear envelope, even if 
they do not co-precipitate ce88. Nuclear envelope 
association of mutants missing the C~terminal coiled~ 
coil (CAN 1-832) was decreased. Similarly, coiled-coil 
point mutant Vm ..... P displayed a marked decrease in 
nuclear envelope localization, and double mutant 
I1lO ..... P+ Vm ..... P hardly showed any association at all 
(data !lot shown). In contrast, the single coiled-coil 
point mutation I7lO ..... P did not noticeably decrease the 
protein's ability to associate with the nuclear envelope, 
nor did leucine zipper point mutation IJ5.j ..... P. These 
data show that localization of CAN at the nuclear 
envelope does not correlate with CC88 co-precipita-
tion, and they identify the C-terminal coiled-coil as the 
most important motif for nuclear pore association. 
DEK-CAN and SET-CAN are nuclear proteins, in 
effect relocating the C-terminal part of CAN from the 
nuclear pore to the nucleoplasm (Fornerod et al., 
1995). Thus, we suspected that other sequences in the 
fusion proteins override the nuclear envelope interac-
lion mediated by amino acids 813-1058. To test 
whether this is dependent on nuclear localization 
signals in DEK and SET, we expressed the CAN part 
(CAN 816-2090) of the two fusion proteins alone. 
Tills mutant predominantly located to the nuclear 
envelope (Figure 3), demonstrating that DEK-CAN 
and SET-CAN depend on their DEK and SET 
moieties for relocation to the nucleus . 
Discussion 
As a first step to biochemically analyse the contribu-
tion of CAN sequences to the transforming capacity of 
the DEK-CAN and SET-CAN fusion proteins, we 
identified a 112 kDa protein (CCIl2) that associates 
with the C-terminal nucleoporin-repeat of CAN, DEK-
CAN and SET-CAN. In addition, we found that the 
central region of CAN binds to an 88 kDa protein 
(CC88), that does not co-imnnmopredpitate with the 
fusion proteins. 
Using CAN mutants, we were able to locate regions 
in the CAN protein responsible for interaction with 
CCI12 and CC8S. Since these regions operate 
independently and CC1l2 and CC88 are by far the 
most prominent co-precipitating proteins, binding is 
likely to be direct. However, we cannot exclude that 
association of either of the two proteins is mediated by 
other proteins that escaped our attention, for instance 
due to their small size. We noticed less consistent co-
immunoprecipitation of a 66 kDa protein (CC66) in 
both HeLa and U937 derived cells. Because of this 
inconsistency, most likely caused by weaker binding to 
CAN andlor CC88, we decided to focus our analysis 
on the 88 and 112 kDa proteins. 
eCI121cAN interaction 
The region of CAN necessary and sufficient for CC1l2 
co-precipitation consists of the C·terminal 227 amino 
acids. This region represents the distal half of CAN's 
420 amino acid nucleoporin specific FG-repeat. We 
cannot identify significant differences in either FG 
density or inter-FG amino acid composition between 
these two halves of the FG repeat. It is therefore 
unclear what structural features of the distal part 
constitute the CCl12 binding specificity. Identification 
of the FG repeat as a protein interaction domain per se 
suggests that its N-terminal part could specifically 
interact with other cellular proteins that may bind 
weaker than CC1l2, or that are less abundant in HeLa 
and U937 cells. In this respect, it is noteworthy that we 
isolated a cDNA for an alternatively spliced call 
mRNA encoding a C-terminally truncated FG-repeat. 
A CAN protein carrying this shortened repeat region 
could be functionally distinct since it displays a 
different specificity for associating factors, illustrated 
by the fact that it does not co-precipitate CCI12. 
The N-terminal half of the FG repeat alone localizes 
to the cytoplasm, whereas the C-terminal half localizes 
to the nucleus. This C-termillal domain of CAN bears 
no homology to known nuclear localization signals, 
such as a standard (Kalderon et al., 1984) or bipartite 
NLS (Robbins et al., 1988) or the M9 sequence of 
hnRNPAI (Siomi and Dreyfuss, 1995). Thus, unless 
the C-ternlinal repeat of CAN carries an as yet 
unrecognized NLS-type sequence, transport to the 
nucleus must be mediated by an associating nucleo-
philic protein. An obvious candidate for this would be 
CCll2, except for the apparently conflicting observa-
tion that additional N-terminal, C-terminal and 
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internal deletion mutants of the C-tenrunal FG repeat 
still localize to the nucleus, but do not co-precipitate 
CCI12. However, in these mutants, CCl12 binding ill 
l'ivo may be strong enough to mediate nuclear 
transport but too weak to withstand our co-
iml111lnOprecipitation conditions. Thus, resolving the 
question whether CCl12 mediates the nuclear localiza-
tion of C-terminal CAN awaits the molecular cloning 
of CC112. This would allow us to use more sensitive 
methods to probe for interaction between these 
proteins, such as a two-hybrid analysis in yeast. 
Since CC112 interacts with CAN, which is part of 
the nuclear pore complex, CCI12 is likely to be present 
at the nuclear pore as well. Our data strongly indicate 
that there is a molar excess of CCI12 as compared to 
CAN in the cell. This additional CCI12 may be bound 
to other nuclear pore components, in particular to 
those containing FG repeat sequences, or it may be 
located at additional sites in the cell. Since DEK-CAN 
and SET-CAN are nuclear proteins, we expect that 
CC1l2 is also located in the nucleus. 
CC88/CAN illteraction 
A second co-immunoprecipitating protein, CC88, 
interacts with the central region of CAN containing 
three potential protein interaction domains: two coiled-
coil regions and a leucine zipper (Fornerod et al., 1995; 
von Lindern et al., 1992a). Coiled-coil domains are 
common motifs in nuclear pore components, such as 
NUP82 (Grandi el al., 1995), Trp (Byrd el al., 1994), 
NSP49 (Hurl, 1989), p62 (Slarr el al., 1990) and Nspl 
(Wimmer et aI" 1992). Their coiled-coil domains appear 
to be involved in association of these proteins in nuclear 
pore subcomplexes (Grandi et aI" 1995) and could also 
be required for anchoring to structural components of 
the nuclear pore (Byrd e/ al., 1994; Hurt, 1989). Our data 
show that the coiled-coil regions of CAN are prime 
candidates to mediate bindinKofthis nucleoporin to the 
NPC, since point mutations in these motifs negatively 
influence CAN's nuclear envelope localization. 
CC88 co-precipitation is drastically decreased by a 
single point mutation in the leucine zipper as well as by 
combined point mutations in both coiled-coils. These 
data indicate that strong interaction required for co-
immunoprecipitation is mediated by all three a-helical 
interaction domains. This notion is also in agreement 
with our deletion analysis that shows that mutants that 
lack any of these domains are unable to co-precipitate 
CC88. We cannot exclude. however, the possibility that 
the point mutations affect normal folding of a larger 
region that could include other CC88 binding domains. 
All CAN mutants that interact with CC88 are 
predominantly located at the nuclear envelope, and 
by implication at the nuclear pore. It is therefore likely 
that CC88 is part of the nuclear pore complex. Because 
over-expression of CAN does not increase the amount 
of co-precipitating CC88, the NPC may be its only 
location. This raises the question as to whether the 
apparent lack of CC88 interaction with DEK-CAN 
and SET-CAN could be the result of differential 
cellular compartmentalization. We find this explana-
tion unlikely since CAN mutants that are located at 
the nuclear envelope (such as CAN 804-1058 or CAN 
816-2090), and contain the same part of CAN's 
central region as DEK-CAN or SET-CAN, do not co-
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precipitate CC88 either. Thus, at present we have no 
indications that CC88 could contribute to the DEK-
CAN or SET-CAN mediated leukemic process. 
Concluding remarks 
We have shown that CC112 interacts with DEK-CAN 
and SET-CAN. Insights into the functional significance 
of this 112 kDa protein for the leukemic process, is 
obviously hindered by our lack of understanding of the 
function of DEK-CAN and SET-CAN themselves. 
However, we would like to present two hypothetical 
scenarios. 
(i) The gene fusion between NUP98 and HoxA9 has 
recently been described in leukemic patients carrying 
translocation (7;11) (Borrow e/ al .• 1996; Nakamura et 
al., 1996). Intere-stingly, the part of NUP98 that is 
predicted to be present in the NUP98/HoxA9 fusion 
protein consists of its nucleoporin-specific FXFG 
repeat, whereas sequences contributed by the transcrip-
tion factor HoxA9 include its DNA binding domain. If 
NUP98-HoxA9 and DEK-CAN/SET-CAN work in a 
similar fashion, DEK and SET may contribute a DNA 
binding property to our fusion proteins. The observa-
tions that DEK co-localizes with metaphase chromo-
somes in mitotic cells (Fornerod et aI" 1995) and binds 
to double-stranded DNA ill \,/'/ro (Titia de Lange, 
personal communication) could support this idea. SET 
has been shown to stimulate adenovirus replication ill 
vitro (Nagata e/ al., 1995) and thus could also be 
involved in DNA binding. Therefore, in analogy to 
many other oncogenic nuclear fusion proteins (for 
review see Rabbitts, 1994), these nucleoporin fusions 
may act as mutant transcription factors, where DEK, 
SET or HoxA9 would mediate DNA binding to 
regulatory sequences of target genes, whereas CAN 
or NUP98 provide sequences essential for transcrip-
tional disregulation. Thus proteins that associate with 
the nucleoporin portions of these fusion proteins, such 
as CC112, may provide an essential contribution. 
(ii) Another, but not mutually exclusive possibility 
is, that nucleoporin related fusion proteins deregulate 
cellular growth through changes in nucleocytoplasmic 
transport. A protein was recently described, that is 
involved in Rev-mediated export of HIV RNA from 
the nucleus (Bogard et al .• 1995; Friz el al., 1995; Stutz 
et aI" 1995). This protein, called Rab or RIP, shows 
significant homology to the CCl12·interaction domain 
of CAN. We find this homology fascinating, particu· 
larly in view of our observation that CAN is essential 
for nucleocytoplasmic transport of protein and mRNA 
(van Dellfsen et al., J996). In addition to the viral Rev 
protein, one cellular protein has previously been shown 
to interact with nudeoporin-specific repeats: import 
factor p97/importinp. This protein is part of a 
cytoplasmic complex that mediates transport of NLS 
containing proteins from the cytoplasm to the nuclear 
pore (see for instance Gorlich and Mattaj, 1996). In 
analogy to Rev and p97/importinp, CC112 may be 
involved in transport processes between the nuclear 
pore and the nucleoplasm and/or cytoplasm, that may 
be disturbed by fusion proteins such as DEK-CAN and 
SET-CAN. 
We hypothesize, that further analysis of the CCI12 
protein may provide crucial information to improve 
our understanding of how DEK-CAN and SET-CAN 
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deregulate growth of early hematopoietic progenitor 
cells. Further analysis of CC1l2 and ce88 may also 
shed more light on CAN's function in nucleocytoplas-
mic transport. 
Materials and methods 
Expression COliS/filets 
All expression plasm ids used in this study carry sequences 
encoding two copies of the influenza virus hemagglutinin 
(HAl) tag at the 5' end of their open reading frames 
(Fornerod et 0/., 1995). All constructs with the exception of 
pSCTOP-HAI-Sct-Can, make use of the Tet-VPJ6 respon-
sive promoter (Gossen and Bujard, 1992). SET-CAN 
expression was directed by plasmid pSCTOP-HAI-Set-
~an. This plasmid was constructed by replacing the set 
IOsert of pSCTOP-HAl-Sel (Forncrod et ai., 1995) by a 
Sad set-call fragment from anti-sense pCDXX-Set-Can 
(Fornerod et of., 1995). DEK-CAN expression was directed 
by plasmid pHAI-Dek-Can (Fornerod el 01.,1995). pHAI-
Can is similar to pCDXX-HAI-Can (Fornerod et 01., 
1995), with the exception that the EcoRI cDNA insert is 
present in the pUHDIOS vector (Fornerod et al., 1995). 
Expression of deletion mutants CAN 1- 1058 and CAN 
586-1058 was directed by plasmids pHAI-CANA 1059-
2090 and pHAI-CANA J -585, and A 1059-2090 
respectively (Fornerod et al., 1995). pHAI-CAN 1-832 
was created by filling in the XbaI site of pHAI-CANA 
1059-2090 at position 2587 of the call cDNA (von Lindern 
et at., 1992a), creating a stop after codon 832. pHAI-CAN 
1864-2090 was derived from pHAI-CANA I-Il39, A 
1341-1863 (Fornerod el al., 1995) by deleting sequences 
encoding amino acids 1140-1340 using the NlleI site 
flanking the HAl encoding region and the MscI site at 
position 5680 of the call eDNA. pHAI-CAN 1864-2052 is 
a truncation derivative of this plasmid using XemI sites at 
position 6244 of the can eDNA and in pUHDIOS. pHAI-
CAN 1957-2090 was also derived from pHAI-CAN 
1864-2090 by deleting sequences between the NcoI site 
flanking the HAl tag coding region and the StyI site at 
position 5758 of the call eDNA. pHAI-CAN 1864-1912, 
1984-2090 was created by an in frame deletion using the 
BamHI sites at positions 5825 and 6044 of the call eDNA. 
pHAI-CAN 1556-1839 was derived from pHAI-Can by 
ligation of the filled-in NdeI site flanking the HA I tag 
coding region onto the SpeI site at position 4766 of the call 
eDNA and subsequent filling in of the HindIII site at 
position 5607. This creates a slop 5 codons downstream of 
codon 1839. pHAI-CAN 816·-2090 was derived from 
pHAJ-Can by deleting sequences upstream of the KosI 
site at position 2538 of the call eDNA. Deletions in 
expression plasmids pHAI-CAN 1-877, pHAI-CAN 1-
1085, pHAI-CAN 804-2090 and pHAI-CAN 1059-2090 
were creatcd using partial E. coli exonucicaseIII digestion 
using the Erase-a-base system (Promega, Madison, WI 
Henikolf, 1984) and was performed according to manu-
facturers' directions. For this purpose, two modifications 
of pHAI-Can were constructed. For N-terminal deletions, 
a NOlI-Spill linker was placed between sequences 
encoding the HAl tag and the NtieI site at amino acid I 
of the call open reading frame. Removal of nucleotides 
originated from thc Ndel site, while the 3' overhanging 
SphJ end protectcd upstream sequences from exo III 
digestion. Reading frames could be corrected by introdu-
cing adapters into the unique NotI site. For C-terminal 
deletions, a SalI-SphI-NoII linker was introduced 3' of 
the call eDNA, and rcmoval of nucleotides started at the 
Saii site, whereas the Spill 3' overhanging end prevented 
downstream deletions. N- and C-terminal deletions could 
be linked llsing Noll sites, giving rise to internal CAN 
deletion mutants such as pHAI-CAN 1-708, 1095-2090. 
pHAI-CAN 586-1085 was created by an N·terminal 
truncation of pHAI-CAN 1- 1085 using a HillelI site as 
described (Fornerod et 01., 1995). pHAI-CAN 804-1058 
was constructed by combining pHAI-CAN 804-2090 and 
pHAI-CANA 1059-2090. In a similar way, pHAI-CAN 
1-708, 816-2090 is the combination of pHAI-CAN 1-
708 and pHAI-CAN 816-2090. Point mutations in pHAI-
CAN 586-1085 were generated in bacteriophage M13, 
using a commercial kit (MUla-Gene, BioRad, Hercules, 
CAl based on the Kunkel method (Kunkel, 1985). The 
following proline codons were introduced: amino acid 
7JO(I~P), CCG, 754(1~P)' CCT, 825(V~n CCC. 
Cell clliture alld transjectioll 
HtTA-I culture and transfeclion was performed as 
previously described (Fornerod el al., 1995). Cell line 
U937T is a derivative of the human monoblast cell line 
U937 (Sundstrom and Nilsson, 1976) that expresses the 
tetracycline responsivc chimeric transactivator Tel-VPI6 
(Gossen and Bujard, 1992). U937T-C7 is stably transfected 
with pHAI-Can. A complete description and analysis of 
this ccll line will be published elsewhere (JB and GG, 
manuscript in preparation). 
bmmmoprecipiialioll and imlllllllojiuoresccnce 
2 x IO l cells grown in 6 em dishes were metabolically 
labeled for 6-16 h using 100 JlCi [JH]leucine (Amcrsham 
Corp., Arlington Heights, IL) or [lsSJmcthionine/cysteine ill 
),j}·o labeling mix (DuPont NEN, Wilmington, DE) in 
1.4 ml of leucine or methionine free DMEM, supplemented 
with 8% dialyzed fetal calf scrum. Metabolic labeling was 
carried out in a closed container, in order to avoid 
radioactive contamination of the environment (Fornerod, 
1996). Forty to fifty hours after transfection, cells were 
cooled on ice, rinsed twice with icc cold PBS, scraped from 
the dishes and transferred to a microfuge tube. Cells were 
briefly spun down and lysed by pipet resuspension in 500 III 
of NP40 lysis buffer (1 % NP40; 50 mM Tris-HCI, pH 8.0; 
150 mM NaCl; 5 mM EGTA; 5 mM EDTA; 15 mM MgCl l ; 
60 mM p-glycerolphosphate; 1 mM DTT; 0.1 mM NaV04; 
0.1 mM NaF; 15 mM p-nitrophenylphosphate; 1.8 Jlg/ml 
aprotinin; I Jlglml leupeptin; 10 Ilg/ml soybean trypsin 
inhibitor; 0.1 mM benzamidine). Lysates were kept on ice 
for 10 min, gently vortexed, and centrifuged for 10 min in 
a microfuge at 4°C. The supernatant was then filtered 
through a 0.45 Jim low-protein binding syringe filter (Supor 
Acrodisc, Gelman Sciences, Ann Arbor, MI), and 
prec1eared with 15 ,Ii protein A sepharose. Precleared 
Iysates were immunoprecipitated using 2 Jig of monoclonal 
12CA5 (BAbeo, Richmond, CAl bound 10 7.5 ,Ii protein A 
sepharose for I h at 4°C. Beads were washed four times 
with 500 JII ice cold NP40 lysis buffer. Indirect immuno-
fluorescence of transfected cells using anti-HAl antibodies 
(12CA5) was carried out as previously describcd (Fornerod 
et af., 1995). 
peR amplification 
First strand eDNA was prepared from total RNA of the 
myeloid leukemia cell line KG·I (Koeffier and Golde, 1978), 
using anti-sense primer CAN 6237A (5'-AACCA-
GAAGTCTGTTGGGACAGTG-3') representing position 
6237-6260 of the can eDNA (von Lindern et 01., 1992a). 
DNA was subsequently PCR amplified using sensc primer 
CAN 5586SE (5'-CTTCTGGGTTCAGCTTTTGCCAAG-
3') representing positions 5586-5609 and anti-sense primer 
CAN 6209A (5'-AAGTGGGGGCATTCTGACTCGC-3') 
representing positions 6209-6230 of the call eDNA, 
anncaling was at 60°C. Amplified DNA derived from 
alternative transcripts was sequenced and cloned into 
Chapter 5 Analysis of CAN co-precipitating proteins 
pHAI-Can using the Hil/dIIJ and Nrl/I sites at positions 5607 
and 6207 of the call eDNA, creating pHAI-CAN-FSI865, 
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The recurrent t(6;9)(p23;q34), found with low frequency in 
acute myeloid leukemia (A!v\l) and myelodysplastic syn-
drome,1.2 creates a fusion between 1\\'0 genes, DEK and CAN,3 
The resulting chimeric DEK-CAN mRNA can be detected with 
the reverse transcription-polymerase chain reaction (RT-peRJ.' 
This technique allowed sensitive detection of residualleukernic 
cells after treatment in a 1(6;9) patient.4 Here, we describe for 
the first time the complete absence of DEK-CAN transcripts in 
post-transplantation samples from a patient who has been in 
continuous complete remission for more than 2 years. 
In November 1993, a 5-year-old boy presented with mal-
aise, bone pain and weight loss. Other than mild pallor, physi-
cal examination was normal, Abnormal white cells were evi-
dent on a blood smear, and complete blood counts revealed 
hemoglobin 4.5 gfdl, platelet count 48000/mm3, and white 
blood cell count 8300/mml, with 30% blasts. Other studies 
showed normal cerebrospinal fluid, normal coagulation 
values, and lDH 1363 IU (normal 420--920 IU). The bone 
marrow was replaced by FAB type M2 blast ce!ls, which 
stained positively for myeloperoxidase and Sudan black, and 
negatively for a-naphthyl butyrate and chloroacetate esterase. 
Auer rods were not noted. Chromosome analysis revealed a 
clonal abnormality in 19 of 20 metaphases: 46,XY, 
t(6;9)(p23;q34). Immunophenotype studies of blasts were con-
sistent with myeloid lineage: CD3J+ (97%), CD13+ (92%.) and 
CDI5+ (52%). The patient was enrolled on the AML91 proto-
col.s Hematologic remission, including normal karyotype, 
was achieved after two courses of 2-CDA followed by dauno-
mydn, Ara-C, and etoposide. The patient underwent allo-
geneic bone marrow transplantation (BMT) from his HLA-
identical brother in April 1994. The BMT conditioning regi-
men included total body irradiation and high-dose chemo-
therapy, and cyclosporin and pentoxifylline were adminis-
tered to prevent graft-versus-host disease (GVHD). The patient 
required a short course of prednisone for probable intestinal 
GVHD. 
Collection of bone marrow cells, cDNA preparation and 
PCR conditions for the evaluation of OEK-CAN transcripts 
were essentially as described,l using primer set 2, with the 
following modifications: first-strand eDNA was synthesized 
from 2 Jig instead of 5 Jig total RNA. In the PCR a new CAN 
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antisense primer CEAH2 (5'-CCAGATGCTGATCCCACTCC) 
was used. First-round PCR was performed for 34 cycles (94°C, 
1 min; 4rC, 2 min; 72°C, 2 min), the product was diluted 
(1 :500) and 1 Jil was amplified in a second round of PCR (30 
cycles). Using the CEAH2 primer for t\vo rounds of PCR some-
times resulted in background amplification of CAN. In sub-
sequent studies on bone marrow samples from another t(6;9) 
patient, we found that performing a semi-nested PCR with the 
CAN antisense primer CEAHl for the first-round, followed by 
CEAH2 for the second-round, gave more consistent results. 
One-eighth of the PCR product was resolved by electro-
phoresis through 1.5% agarose gels, The' identity of the PCR 
fragments was confirmed by hybridization of Southern blots 
with specific oligonucleotide probes,l allowing the detection 
of one t(6;9) positive cell in 5 x 104 normal cells (not shown). 
RT-PCR readily detected the DEK-CAN fusion transcript in 
the patient's bone marrow at diagnosis after 34 (not shown) 
and 64 cycles (Figure 1, Jane 1). During chemotherapy-
induced remission chimeric mRNA was only detectable after 
64 cycles (Figure I, lane 2), whereas samples taken 4 months 
(Figure 1, lane 3) and 25 months (Figure 1, lane 4) afler BMT 
were negative for DEK-CAN, Due to low RNA yield, the sam-
ple taken 4 months after GMT had to be amplified for four 
additional cycles in Ihe second-round of PCR, resulting in 
about a lO-fold decrease in sensitivity. 
The DEK-CAN RT-PCR assay detects one patient cell in 
5 x 104 normal cells, which is 2-20 times less sensitive than 
similar assays (or other fusion transcripts, such as BCR-ABL 
and AML l_ETO.6--8 This degree of sensitivity probably reflects 
low levels of DEK-CAN mRNA in leukemic cells. 3 
Our PCR results show that samples from a patient who has 
achieved complete remission following allogeneic BMT do 
not contain detectable amounts of DEK-CAN transcript. The 
chemotherapy alone decreased but did not completely eradi-
cate the leukemic cells. These data support the clinical obser-
vation that 1(6;9) patients respond poorly to chemotherapy, 
with a median survival of less than 1 year from diagnosis/ 
and thattranspfantation may be the most effective therapy for 
t(6;9) AMl (our unpublished observation). 
In other translocation-refated leukemias, such as t(9;22) 
chronic myeloid leukemia and t(15;17) acute promyelocytic 
leukemia, the presence of fusion transcripts after treatment 
can be predictive of relapse, while serially negative PCR tests 
are associated with prolonged disease-free survival (Ref. 9 and 
references therein).,,·lO-ll However, persistence of fusion tran-
scripts in AML with t{8;21), APt with t{t5;1?} and CMl with 
1(9;22) in prolonged complete remission has also been 
described, and the issue is still controversial. 14--17 In the only 
other 1(6;9) patient who has been monitored for minimal 
residual disease by RT-PCR, the DEK-CAN mRNA was 
detected during and after autologous peripheral blood stem 
cell transplantation and the patient relapsed within 4 months.4 
Our data show that in a child with t(6;9) AML long-term 
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CAN DEK·CAN 
258bp-. 
~135bp 
234567 234567 
Figure 1 RT·PCR analysis of t(6;9) patient bone marrow. CAN and OEK·CAN RT-PCR products from bone marrow cells at diagnosis (lane 
1), in chemotherapy-induced remission (lane 2), 4 months (lane 3) and 25 months (lane 4) after subsequent allogeneil:: BMT, are shown on 
agarosc gels (A and B) and Southern blots (e and 0), Cultured cells expressing normal CAN (HIlA-1 ;lR lane 5) Of transfected wilh a DEK·CAN 
eDNA (C4322;'9 lane 6) served as controls as did reactions to which no RNA was added (lane 7), A 258-bp CAN fragment was amplified in 
all samples containing RNA (A) and h}·bridized to an internal CAN probe (e). Primers specific for DEK-CAN amplified a 135-bp frdgment (B) 
in patient samples at diagnosis (lane 1) and remission (lane 2), and in the positi\'e control (Jane 6). This band h}'bridized to a breakpoint-specific 
probe (lanes I, 2 and 6; 0). 
remission after allogeneic bone marrow transplantation corre-
lates with a negative RT-PCR for DEK-CAN. We believe that RT-
PCR-based monitoring for residual 1(6;9) ceUs is essential for the 
timel}' identification of patients who are at high risk of relapse. 
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Summary 
The molecular cloning of recurring chromosomal translocation breakpoints has provided 
a starting point from which the pathogenesis of human leukemias can be studied. 
Translocation (6;9)(p23;q34) is found wilh low frequency in acute myeloid leukemia and 
myelodysplastic syndrome. The translocation breakpoints occur in the DEK gene on 
chromosome 6 and in the CAN gene on chromosome 9, generating a DEK-CAN fusion 
gene. In one case of acute undifferentiated leukemia, the same part of CAN is fused 
to SET, on chromosome 9q34. The CAN gene encodes a nucleoporin, a component of 
the nuclear pore complex (NPC). NPCs are composed of multiple copies of about 100 
different proteins and form pores in the nuclear membrane through which active 
transport of macromolecules between the cytoplasm and the nucleus occurs. A number 
of these proteins, including CAN, contains nucleoporin-specific FG peptide repeat 
motifs (Fornerod et aI., 1995; Kraemer et aI., 1994). DEK and SET are both nuclear, 
and so are the two fusion proteins (Fornerod et aI., 1995). The aim of these studies was 
to gain insight into the functions of CAN and the role of CAN-derived fusion proteins in 
leukemogenesis. 
To study the normal functions of CAN, we first disrupted the CAN gene by 
homologous recombination in mouse embryonic stem (ES) cells. ES cells lacking CAN 
were not viable, suggesting that CAN is essential for cell growth or survival. Accordingly, 
embryos homozygous for the disrupted CAN allele died in utero between 4.0 and 4.5 
days postcoitum, following the depletion of their maternal CAN. The CAN-depleted 
embryo cells arrested in the G, phase of the cell cycle. We examined if transport of 
substrates through the nuclear pore was affected by CAN depletion and found that the 
import of nuclear localization sequence (NLS)-containing proteins into the nucleus was 
impaired. Moreover, the export of polyadenylated RNA from the nucleus to the 
cytoplasm was blocked. Therefore, we conclude that CAN is essential for cell cycle 
progression and NPC function in vivo (Chapter 2). 
In the search for clues about the function of CAN in nucleocytoplasmic transport 
and the CAN-derived fusion proteins in leukemia, our group identified proteins that 
interact with CAN. Two proteins were found that specifically coimmunoprecipitated with 
CAN, one of 88 kDa and the other of 112 kDa. Mutational analysis of CAN 
demonstrated that the 88 kDa protein associated with the central region of CAN, which 
contains several protein-protein interaction domains. Almost the same region of CAN 
was responsible for its localization at the NPC. The fusion of CAN to DEK or SET 
occurs in this region, disrupting both NPC association and binding of the 88 kDa 
protein. The 112 kDa co-precipitating protein bound to the C-terminal FG repeat region 
of CAN and also interacted with DEK-CAN and SET-CAN. An overlapping region 
caused nuclear localization of CAN mutants that had lost the NPC binding region 
Chapter 7 Summary and Discussion 109 
(Chapter 5). Recently, the 88 kDa protein was cloned and characterized as a novel NPC 
component and therefore named NUP88. The 112 kDa CAN-interacting protein was 
identified as the human homolog of yeast CRM1, a protein known to be required for 
maintenance of correct chromosome structure. This human CRM1 (hCRM1) localizes 
to the nucleus and to the NPC, and has characteristics of a transport factor (Fornerod 
et aI., 1997). 
Next, we investigated the effect of CAN and DEK-CAN expression on the growth 
and differentiation of myeloid precursor U937 cells. Since CAN and DEK-CAN had 
proven to be cytotoxic upon overexpression, we used an inducible expression system. 
We found that DEK-CAN expression did not affect terminal myeloid differentiation of 
U937 cells. Possibly, DEK-CAN affects a differentiation step of earlier myeloid precursor 
cells in t(6;9) acute myeloid leukemia patients. Alternatively, since myeloid cells from 
t(6;9) patients are partially inhibited in their differentiation pathways but are not totally 
blocked, DEK-CAN could affect proliferation rather than differentiation. CAN-
overexpressing U937 cells exited the cell cycle and arrested in Go, developed a block 
in mRNA export, and ultimately died byapoptosis. Interestingly, the overexpressed CAN 
protein accumulated in the nucleus where it colocalized with importin p and hCRM1, 
depleting both factors from the nuclear envelope. Expression of CAN's C-terminal FG 
repeat region alone, comprising the binding region for hCRM1, also resulted in 
colocalization with hCRM1 in the nucleoplasm and was sufficient to inhibit proliferation 
and to induce cell death. These data suggest that sequestering of hCRM1 by an excess 
of CAN inhibits an essential transport function of hCRM1 (Chapter 3). 
Immunoelectron microscopic studies designed to study the localization of CAN 
within the NPC, showed that in moderately overexpressing HeLa cells both the 
cytoplasmic and nucleoplasmic fibrils of the NPC contain specific binding sites for CAN, 
or for its interacting proteins. This finding makes it conceivable that CAN functions in 
nucleocytoplasmic transport at both faces of the NPC (Chapter 4). 
The chimeric DEK-CAN messenger RNA is a target for diagnosis via 
complementary DNA preparation followed by amplification of the breakpoint region in 
a polymerase chain reaction. We extended this method to the sensitive detection of 
minimal amounts of leukemic cells after treatment of a t(6;9) acute myeloid leukemia 
patient. The absence of the chimeric mRNA in the bone marrow after allogeneic bone 
marrow transplantation correlated with disease-free survival, suggesting that this 
parameter can be used as a prognostic factor (Chapter 6). 
These studies show that CAN is essential for nucleocytoplasmic transport. 
Moreover, CAN could play an indirect role in the progression of the cell cycle. It is less 
clear how an NPC component could contribute to the development of leukemia upon 
fusion to a nuclear protein. Possibly, the CAN-derived fusion proteins interfere with the 
transport function of CAN. Alternatively, the addition of CAN sequences to DEK or SET 
could deregulate the functions of these proteins in transcription or replication of DNA. 
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CAN is essential for nucleocytoplasmic transport and cell cycle 
progression 
CAN is a nuclear pore complex (NPC) component and studies described in this thesis 
demonstrate that CAN has an essential role in nucleocytoplasmic trafficking. Both 
absence and overexpression of CAN inhibit transport without causing structural 
perturbations of the nuclear envelope or NPC. CAN-depleted mouse embryo cells 
accumulate polyadenylated RNA in their nuclei and concomitantly show decreased 
protein import. A similar block in mRNA export is detected in U937 cells that 
overexpress CAN. Thus, overexpression of CAN interferes with some of CAN's normal 
functions in a dominant-negative way. CAN function is also important for the 
progression of the cell cycle, since knock-out embryo cells arrest in G, and 
overexpressing myeloid cells in Go (Chapters 2 and 3). 
Both CAN overexpression and depletion have consequences for the subcellular 
localization of a number of CAN-interacting proteins, which could in part be responsible 
for the phenotypes. NUP88 and hCRM1 are CAN-interacting proteins that were 
identified by coimmunoprecipitation techniques (Chapter 5 and Fornerod et aI., 1997). 
Importin p, also called p97, is a transport factor that shares a region of homology with 
hCRM 1 and other putative NPC-interacting transport factors that belong to the newly 
identified CRIME family (Fornerod et aI., 1997). Importin p interacts with CAN and 
several other peptide repeat-containing nucleoporins in an in vitro ligand blot assay 
(Moroianu et aI., 1995; Radu et aI., 1995a). In embryonic cells that lack CAN, NUP88 
is no longer detectable at the NPC, thus CAN depletion indirectly causes a defect in 
NUP88 function. hCRM1 localizes very prominently to the nucleoli of CAN-depleted 
embryos, which is not observed in wild-type embryos. This suggests that the nucleolus 
is part of normal hCRM1 routing, which may be disturbed in cells lacking CAN. 
However, hCRM1 remains present at the NPC in CAN knock-out cells, indicating that 
hCRM1 binds to other nucleoporins in addition to CAN (Fornerod et aI., 1997). Similarly, 
importin P still interacts with NPCs that lack CAN, presumably contacting other repeat-
containing nucleoporins (Chapter 2). Bidirectional transport through the NPC may 
require ligand-bound transport receptors to dock and undock along an array of repeat-
containing nucleoporins across the NPC (Moroianu et aI., 1995). CAN depletion could 
disrupt this process, thereby partly or completely blocking transport of certain 
substrates. 
CAN-overexpressing U937 cells accumulate overexpressed CAN protein in the 
nucleus. Here, it colocalizes with hCRM1 and importin p, causing depletion of both 
these factors from the NPC and potentially disturbing their transport functions. The cell 
cycle arrest in Go coincides with cessation of nuclear protein import. Unfortunately, 
U937 control cells arrested in G,/Go after reaching their maximal cell density do not 
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import detectable amounts of import substrate either. Therefore, an additional effect on 
import of importin 13 or hCRM1 sequestering in the nucleus could not be determined. A 
similar growth arrest is detected in U937 cells that only overexpress the hCRM1 ·binding 
domain of CAN. This nuclear mutant colocalizes with endogenous hCRM1 but does not 
disturb importin 13 localization. Only cells overexpressing full·length CAN develop a 
defect in polyadenylated RNA export. These were also the only cells to sequester 
importin 13 in their nuclei. The nuclear RNA accumulation could be secondary to 
importin 13 inactivation, since the partner of importin 13 in the heteodimeric import 
receptor complex, importin a, also functions in the export of capped RNA polymerase" 
transcripts (Gorlich et aI., 1996). In addition to hCRM1 and importin 13, other CRIME 
family proteins could also be inhibited in their function upon CAN depletion or 
overexpression. The discovery of this family suggests a differentiation among transport 
receptors for specific types of substrates. 
Moderate overexpression of CAN in HeLa cells resulted in an increase of CAN 
at the nuclear envelope, where it localized to both the cytoplasmic and nucleoplasmic 
aspects of the NPC (Chapter 4). In previous immunolocalization stUdies CAN is 
detected only at the cytoplasmic face of NPCs of normal He La cells and Xenopus 
oocytes (Kraemer et aI., 1994; Pants et aI., 1994). Our data indicate that not only the 
cytoplasmic fibrils, but also the nucleoplasmic structures of the NPC contain specific 
binding sites for either CAN or for its interacting proteins, NUP88 and hCRM1. Thus, 
it is conceivable that CAN functions in nucleocytoplasmic transport at both faces of the 
NPC. Clearly, at endogenous expression levels in HeLa cells not all NPC·binding sites 
for CAN are occupied. Although all examined cell types express CAN, the level of 
expression varies. Relatively high levels of CAN are expressed in HeLa epithelial cells, 
NIH 3T3 fibroblasts, and embryonal trophectoderm cells, whereas CAN levels are low 
in U937 myeloid precursors, ES cells and inner cell mass cells of 4.5·day·old mouse 
embryos (Chapter 2 and unpublished observations). Possibly, the expression level of 
CAN may reflect the nucleocytoplasmic transport activity of specific CAN substrates. 
hCRM1 binding 
Colocalization proved to be a powerful technique to further map the interaction between 
the hCRM1·binding domain of CAN and hCRM1. CAN mutants with a C·terminal or 
internal deletion of the hCRM1·binding domain no longer coimmunoprecipitated 
hCRM1, but still localized mainly to the nucleoplasm (Chapter 5). These mutants 
colocalized with endogenous hCRM1 in overexpressing U937 cells, thus it seems likely 
that they bind hCRM1, albeit with a lower affinity, and are transported to the nucleus in 
a complex with hCRM1 (Chapter 3). The nuclear accumulation of full·length CAN upon 
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overexpression in U937 cells could also be explained by binding to hCRM1 (Chapter 
3). Colocalization of CAN and hCRM1 in cytoplasmic structures suggests that complex 
formation already occurs in the cytoplasm. When all NPC binding sites for CAN are 
occupied, the complex could spill over to the nucleus. Since hCRM1 has a half-life of 
approximately 24 hours (Fornerod et aI., 1997), it is unlikely that the hCRM1 observed 
in the cytoplasm of CAN-overexpressing cells is only newly synthesized hCRM1. 
Instead, these data suggest that hCRM1 travels from the nucleus to the cytoplasm, in 
addition to its release from the NPC into the nucleoplasm. In normal Hela cells, a small 
amount of hCRM1 is present in cytoplasmic annulate lamellea (Fornerod et aI., 1997). 
To ensure directed transport across the nuclear pore complex, transport factors 
must somehow "sense" a cytoplasmic or nucleoplasmic environment. lt is possible that 
the conditions in the nucleoplasm are not favorable for dissociation of hCRM1 and 
CAN, resulting in the nuclear accumulation of hCRM1/CAN complexes. Depletion of 
hCRM1 from the NPC correlates with lethality, indicating that hCRM1 function is 
essential for cell survival. The localization of hCRM1 is the mirror image of that of 
importin p, suggesting that the direction of transport is from the nucleus to the 
cytoplasm (Fornerod et aI., 1997). As yet, we do not have clues regarding the transport 
substrate of hCRM1. All we can say with certainty is that it is not essential for mRNA 
export. The hCRM1-binding domain overexpressing U937 cells should provide a good 
model to investigate potential substrates. 
Importin ~ interaction 
The colocalization of overexpressed CAN with endogenous importin p suggests that 
these two proteins interact in vivo. Notably, importin p did not colocalize with mutants 
expressing only the C-terminal repeat-region of CAN, whereas corresponding repeat-
rich regions in both the vertebrate NUP98 and yeast NUP159 were mapped to bind 
importin p (Kraemer et aI., 1995; Radu et aI., 1995b). A CAN mutant extending from the 
t(6;9) breakpoint to the C-terminus colocalized with importin p in cytoplasmic speckles. 
This mutant contains part of the central NPC-association region of CAN, suggesting that 
CAN's central region is required for importin P interaction, either directly or via binding 
of another protein. We could not determine if this region is also sufficient for importin P 
binding, since the central region of CAN localizes only to the nuclear envelope, which 
is a natural location of importin p. Although it has been speculated that importin p 
directly binds to FG repeat regions, our data do not support this model. It is possible 
that, in contrast to in vitro binding, the in vivo interaction between importin p and CAN's 
nucleoporin-specific repeats requires the NPC-binding domain of CAN. Recent binding 
studies show that importin P has at least two non-overlapping sites of interaction with 
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the NPC. One of these sites is located at the N-terminus and includes the CRIME 
domain. The N-terminus of importin fl is also involved in RanGTP binding (Kutay et aI., 
1997). 
CAN-derived fusion proteins 
What is the role of DEK-CAN and SET-CAN in acute leukemia? The transformation 
potential of these fusion proteins is not easily demonstrated in in vitro or in vivo 
experimental systems (unpublished data), therefore we have not been able to map 
functional domains within the fusion proteins. However, comparing the CAN-derived 
fusion proteins to the structurally similar NUP98-HOXA9 fusion protein could give useful 
insights into their function (Figure 1). DEK-CAN, SET-CAN (Fornerod et aI., 1995) and 
NUP98-HOXA9 (J. van Deursen, personal communication) are all nuclear proteins. I 
will discuss the possibililies of these fusion proteins to interfere with nucleocytoplasmic 
transport or transcription and suggest some future directions. 
Nucleoporin repeat-containing fusion proteins in nucleocytoplasmic transport 
The intriguing finding of two FG repeat-containing nucleoporins, CAN and NUP98, as 
part of leukemia-associated fusion proteins, opens a new field of research into the role 
of nucleocytoplasmic trafficking in oncogenesis. Abnormal nuclear pore function could 
result from the haploinsufficiency of NUP98 and CAN. Alternatively, NUP98-HOXA9 
DEK-CAN 
SET-CAN 
NUP98-HOXA9 
Figure 1. Nucleoporin-derived oncoproteins 
Structural similarities betvJeen three leukemia-associated fusion proteins that contain nucleoporin-
specific peptide repeats, DEK-CAN, SET-CAN, and NUP9S·HOXA9. Diamonds, FXF repeats; Vertical 
bars, FG repeats; AH, amphipathic helix; Horizontal bars, acidic regions; HO, homeodomain. 
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and the CAN-derived fusion proteins could interfere with the transport functions of their 
wild-type nucleoporin counterparts. The nucleoporin-derived fusion proteins are nuclear 
and could cause a redistribution of transport factors towards the nucleoplasm. DEK-
CAN and SET -CAN tightly bind hCRM 1, and could relocate part of the endogenous 
hCRM1 to the nucleus. These fusion proteins are expressed at such low levels in 
leukemic cells (Chapter 6 and Von Lindern et aI., 1992), that a total depletion of hCRM1 
from the NPC is not to be expected. NUP98-HOXA9 contains the majority of NUP98's 
FG peptide repeats and would therefore be expected to retain the ability to bind 
importin p, potentially with an adverse effect on nucleocytoplasmic transport (Borrow 
et aI., 1996). Other, as yet unidentified transport factors may also bind to the 
nucleoporin moieties of these fusion proteins, resulting in altered transport that could 
interfere with the growth or differentiation of hematopoietic precursor cells. 
Fused transcription factors containing nuc/eoporin repeats 
Another possibility is that the nucleoporin-derived fusion proteins function as altered 
DNA-binding factors. In this respect several parallels between the HOXA9, DEK and 
SET proteins are interesting. All these proteins are nuclear and interact with DNA. 
HOXA9 is a sequence-specific transcription factor that belongs to the family of 
homeodomain proteins, which has been implicated in normal differentiation and 
development as well as in cancer (Chapter 1). Its DNA-binding homeodomain and 
flanking sequences that could be important for interactions with related proteins are 
present in the NUP98-HOXA9 fusion protein (Borrow et aI., 1996; Nakamura et aI., 
1996). 
DEK was recently discovered to be a sequence-specific DNA-binding protein, 
and DEK binding sites were identified in the myeloperoxidase promoter and the HIV-2 
long terminal repeat (Fu et aI., 1997). Since DEK has no significant homology to other 
proteins, it is not clear which domain interacts with DNA. Earlier stUdies into the 
transactivation potential of DEK, fused to the DNA-binding domain of OCT6, revealed 
that DEK has very low transactivation activity on a chloramphenicol acetyl transferase 
(CAT) reporter gene preceded by six OCT6 consensus binding sites (unpublished data). 
However, it is possible that DEK needs to interact with other transcription factors bound 
to a promoter or enhancer to reach its full transactivation potential. 
Finally, SET has been implicated in several nuclear processes (Chapter 1). The 
most exciting finding is that SET binds to MLL, a large AT hook-containing protein that 
is frequently translocated in acute leukemias. The SET interaction domain within MLL 
is located between the AT hooks (Adler and Tkachuk, 1996). A complex of MLL, SET, 
and possibly other factors, could bind to AT-rich sequences in the minor groove of DNA 
via the AT hooks of MLL and facilitate transcription by altering chromatin structure. In 
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this scenario, SET would be an architectural factor, rather than a classical transcription 
factor. The homology between SET and NAP-1, and SET's TAF-I activity are in 
agreement with a regulatory role in chromatin structure (Kellogg et aI., 1995; Nagata et 
aI., 1995). Both SET-CAN and MLL-derived fusion proteins may interfere with critical 
growth or differentiation pathways in early pluripotential hematopoietic cells. Since 
almost the entire DEK and SET polypeptides are present in DEK-CAN and SET-CAN, 
respectively, domains that directly (DEK), or indirectly (SET) interact with DNA may very 
well be present in the fusion proteins. 
Several ways can be envisioned by which nucleoporin-derived sequences could 
interfere with the transcriptional regulation of DNA-binding factors. First, the nucleoporin 
repeats could harbor a transcriptional activation domain. In the OCT6-fusion reporter 
system described above, a transcriptional activation domain similar in strength to wild-
type OCT6 was mapped to the repeat-containing region of CAN (unpublished results). 
In respect to SET-CAN, it is of interest that several of the fusion partners of MLL may 
be transcriptional regulators (Chapter 1). It is also possible that not CAN itself, but a 
protein interacting with its repeat sequence, has transactivation activity. 
Second, the addition of nucleoporin repeats could alter the DNA binding activity 
or specificity of sequence-specific DNA-binding factors. The identification of the DNA 
binding site for DEK opens the way to investigate the effects of DEK-CAN on DNA-
binding and transcriptional activation of DEK target genes. 
A third mechanism by which these fusion proteins could interfere with 
transcription, is through binding of other factors to their transcription factor moiety. In 
order to understand NUP98-HOXA9 function, a comparison with E2A-PBX1 could be 
useful: the domain of PBX 1, involved in cooperative DNA binding with a subset of HOX 
proteins, is required for transformation by E2A-PBX 1 (Chapter 1). This region, and 
possibly a similar protein-protein interaction domain in HOXA9, could heterodimerize 
with other transcription factors which direct the fusion proteins to appropriate target 
genes. It is also possible that this region of the fusion proteins mediates the formation 
of non-DNA-binding complexes that sequester tumor-suppressing factors. A search for 
DEK-interacting proteins could identify factors that cooperate with DEK in the 
transcriptional regulation of target genes, which could be deregulated in t(6;9) leukemic 
cells. SET interacts with MLL and could by required for MLL function, for instance by 
facilitating its binding to DNA. All MLL-derived fusion proteins contain the N-terminal AT 
hooks, which makes it likely that they still interact with SET. The compelling question 
arises whether SET-CAN also interacts with MLL, and how that would alter the 
transcriptional activity of MLL. The first part of this question could be answered by 
coimmunoprecipitation studies employing cells that co-express an epitope-tagged 
version of MLL (Caslini et aI., 1996) and SET-CAN. 
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Concluding remarks 
The overview of leukemia-specific fusion proteins in Chapter 1 suggests that in most 
cases both fusion partners contribute to the development of leukemia, and the available 
data suggest that the effectiveness of oncogenic fusion proteins depends on this dual 
action. Therefore, probably more than one of the mechanisms described above is at 
work in leukemic cells expressing DEK-CAN or SET-CAN. New insights into the 
functions of these fusion proteins can be expected from the study of DEK and SET. In 
addition, further characterization of the CAN-interacting proteins may link CAN to 
cellular pathways that could be deregulated in leukemic cells and improve our 
understanding of the mechanism of nucleocytoplasmic transport. 
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Functionele karakterisatie van de nucleoporine CAN en CAN-afgeleide 
leukemie-specifieke fusie-eiwitten 
Chromosomale translokaties zijn microscopisch zichtbare genetische afwijkingen die 
vaak geassocieerd zijn met specifieke tumoren. De karakterisatie van de genen op de 
chromosomale breukpunten kan inzicht geven in de processen die een normale cel 
transformeren tot een tumorcel. Translokatie (6;9) komt met lage frequentie voor bij 
acute myelOide leukemie en myelodysplastisch syndroom. De translokatie-breukpunten 
treden op in het DEK gen op chromosoom 6 en het CAN gen op ehromosoom 9, en 
leiden tot de vorming van een DEK-CAN fusie-gen, dat codeert voor een DEK-CAN 
fusie-eiwit. In een geval van acute ongedifferentieerde leukemie is hetzelfde dee I van 
CAN gefuseerd met SET, op chromosoom 9, en wordt waarschijnlijk een SET-CAN 
eiwit geproduceerd. Het CAN gen eodeert voor een nucleoporine, een component van 
het nucleaire porie com lex (NPC). NPC's zijn opgebouwd uit ongeveer 100 
verschillende eiwitten en vormen porien in de kernmembraan waardoor actief transport 
van macromoleculen tussen het cytoplasma en de kern plaatsvindt. Een aantal van 
deze eiwitten, waaronder CAN, bevat een gerepeteerd aminozuurmotief en spee/t 
waarschijnlijk een ral in het transport van substraten door de kernporie. De DEK en SET 
eiwitten zijn gelokaliseerd in de kern, net als de DEK-CAN en SET-CAN fusie-eiwitten. 
Het doe I van dit onderzoek was om inzicht te verkrijgen in de functies van CAN en de 
ral van de CAN-afgeleide fusie-eiwitten in het ontstaan van leukemie. 
Om de normale functies van CAN te onderzoeken, inactiveerden we het CAN 
gen in embryonale stamcellen (ES cellen) van de muis met behulp van homologe 
reeombinatie. ES eellen zonder CAN waren niet levensvatbaar. Dit wijst erop dat CAN 
van essentieel belang is voor celgraei of overleving. Muizenembryo's die homozygoot 
waren voor het verstoorde CAN gen stierven tussen 4,0 en 4,5 dag na de bevruchting, 
wanneer hun materna Ie CAN voorraad was uitgeput. De CAN-gedepleteerde 
embryocellen stop ten met groeien en blokkeerden in de G, fase van de celcyclus. We 
bestudeerden of het transport van sUbstraten door de kernporie werd bernvloed door 
CAN-depletie, en vonden dat de import van kerneiwitten was verminderd. Bovendien 
lag de export van gepolyadenyleerde RNA moleculen van de kern naar het cytoplasma 
stil. Onze conclusie uit deze experimenten is dat CAN essentieel is voor de voortgang 
van de celcyclus en de functie van het NPC in vivo. 
Op zoek naar aanknopingspunten voor de functies van CAN, identificeerde onze 
graep eiwitten die een interactie aangaan met CAN in de cel. We vonden twee eiwitten 
die specifiek binden aan CAN, een van 88 kDa en een van 112 kDa. Mutatie-analyse 
van CAN liet zien dat het 88 kDa eiwit associeerde met het middelste gedeelte van 
CAN, dat een aantal eiwit-eiwit interactiemotieven bevat. Bijna hetzelfde gedee/te was 
verantwoordelijk voor de lokalisatie van CAN aan het NPC. De fusie van CAN aan DEK 
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of SET treedt op in dit gebied, waarbij zowel de binding aan het NPC als de interactie 
met het 88 kDa eiwit veri oren gaa!. Het 112 kDa eiwit bond aan het C-terminale 
gerepeteerde gedeelte van CAN en associeerde ook met DEK-CAN en SET-CAN. Een 
overlappend gebied veroorzaakte nucleaire lokalisatie van CAN mutanten die de NPC 
bindingsplaats misten. Recentelijk is het 88 kDa eiwit ge'isoleerd en gekarakteriseerd 
als een nieuwe component van het NPC, NUP88 genaamd. Het CAN-bindende eiwit 
van 112 kDa werd ge'identificeerd als de humane homoloog van gist CRM1, een eiwit 
dat nodig is voor instandhouding van een correcte chromosomale structuur. Dit humane 
CRM1 (hCRM1) lokaliseert in de kern en aan het NPC, en heel! eigenschappen van 
een transportfactor. 
Vervolgens bestudeerden we de gevolgen van CAN en DEK-CAN expressie op 
de groei en differentiatie van U937 myelo'ide voorlopercellen. Aangezien gebleken was 
dat overexpressie van d,eze eiwitten cy1otoxisch is, gebruikten we een induceerbaar 
expressiesysteem. We vonden dat DEK-CAN expressie geen invloed heel! op de 
terminale myelo'ide differentiatie van U937 cellen. Het is mogelijk dat DEK-CAN een 
differentiatiestap van vroegere myelo'ide voorlopercellen be'invloedt in t(6;9) patianten. 
Aangezien de patiantencellen gedeeltelijk in hun differentiatie geremd zijn, maar niet 
volledig geblokkeerd, zou DEK-CAN ook de proliferatie kunnen be'invloeden in plaats 
van de differentiatie. De overexpressie van CAN remde de groei van U937 cellen, ze 
verlieten de celcyclus en accumuleerden in Go. CAN-overexpresserende cellen 
ontwikkelden een defect in mRNA export en stierven uiteindelijk apoptotisch. Het 
overgeaxpresseerde CAN eiwit hoopte zich op in de kern waar het colokaliseerde met 
hCRM1 en importin p, een cy10plasmatische transportfactor die bindt aan het NPC via 
de gerepeteerde gebieden in nucleoporines. Beide factoren werden hierdoor 
weggevangen uit het NPC. Expressie van CAN's gerepeteerde C-terminus aileen, de 
bindingsplaats voor hCRM1, resuiteerde ook in de accumulatie van hCRM1 in het 
nucleoplasma en was voldoende om de celgroei te remmen en celdood te induceren. 
Deze resultaten suggereren dat de binding van hCRM1 door een overmaat CAN een 
essentiale transportfunctie van hCRM1 rem!. 
Om de lokalisatie van CAN binnen het NPC in kaart te brengen, maakten we 
gebruik van immuno-elektronenmicroscopische technieken. Bestudering van Hela 
cellen die een gematigde hoeveelheid CAN overexpresseerden, liet zien dat zowel de 
cytoplasmatische als de nucleoplasmatische fibrillen van het NPC specifieke 
bindingsplaatsen bevatten voor CAN, ofvoor CAN-bindende eiwitten. Deze waarneming 
maakt het voorstelbaar dat CAN functioneert in nucleocytoplasmatisch transport aan 
beide zijden van het NPC. 
Het chimere DEK-CAN mRNA vormt een aangrijpingspunt voor de diagnostiek 
van t(6;9), aangezien het breukpuntgebied geamplificeerd kan worden met behulp van 
de polymerase kettingreactie. Wij breidden deze methode uit voor de gevoelige detectie 
van minimale hoeveelheden leukemische cellen na behandeling van t(6;9) acute 
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myelofde leukemiepatienten. De afwezigheid van het chimere mRNA in het beenmerg 
van een t(6;9) patient na allogene beenmergtransplantatie correleerde met ziekte-vrije 
overleving. Dit wijst erop dat de polymerase kettingreactie gebruikt kan worden als 
prognostische factor in de behandeling van t(6;9) patienten. 
De beschreven studies hebben ons geleerd dat CAN van cruciaal be lang is voor 
de import van kerneiwitten en de export van mRNA door de kernporie. Indirect zou CAN 
door regulatie van nucleocytoplasmatisch transport de voortgang van de celcyclus 
kunnen befnvloeden. Minder duidelijk is hoe een component van het NPC kan bijdragen 
aan het ontstaan van leukemie, wanneer het gefuseerd is aan een nucleair eiwit. Het 
is mogelijk dat de CAN-afgeleide fusie-eiwitten de transportfunctie van CAN ontregelen. 
Ook zou de toevoeging van CAN sequenties aan DEK en SET gevolgen kunnen 
hebben voor functies van deze eiwitten in de transcriptie of replicatie van DNA. 
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Abbreviations 
ALL 
AML 
APC 
APL 
AUL 
C 
CML 
ES 
FG 
kDa 
MDS 
N 
NLS 
NPC 
NUP 
NUP214 
RA 
RNP 
RT-PCR 
It 
acute lymphoblastic leukemia 
acute myeloid leukemia 
allophycocyanin 
acute pro myelocytic leukemia 
acute undifferentiated leukemia 
carboxy 
chronic myeloid leukemia 
embryonic stem 
phenylalanine-glycine (one leiter abbreviation of amino acids) 
kilodalton 
myelodysplastic syndrome 
amino 
nuclear localization sequence 
nuclear pore complex 
nuclear pore complex component or nucleoporin 
nucleoporin of 214 kDa, also called CAN 
retinoic acid 
ribonucleoprotein 
reverse transcription-polymerase chain reaction 
HA 1-epitope tagged 
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